2. Search Result
Search Result
Results for "

<i>Gardenia jasminoides<_i> Ellis

" in MCE Product Catalog:

1193

Inhibitors & Agonists

8

Screening Libraries

17

Fluorescent Dye

36

Biochemical Assay Reagents

150

Peptides

21

MCE Kits

14

Inhibitory Antibodies

202

Natural
Products

291

Recombinant Proteins

53

Isotope-Labeled Compounds

25

Antibodies

Cat. No. Product Name Target Research Areas
  • HY-147986
    hCA I-IN-2

    		Carbonic Anhydrase Cancer
    hCA I-IN-2 (Compound 6d) is a selective human carbonic anhydrase I (hCA I) inhibitor with Ki values of 18.8, 375.1, 1721 and 283.9 nM against hCA I, hCA II, hCAIX and hCAXII, respectively.
  • HY-147985
    hCA I-IN-1

    		Carbonic Anhydrase Cancer
    hCA I-IN-1 (Compound 6q) is a human carbonic anhydrase I (hCA I) inhibitor with Ki values of 38.3, 716.4, 940.1 and 192.8 nM against hCA I, hCA II, hCAIX and hCAXII, respectively.
  • HY-N2094
    Genipin 1-β-D-gentiobioside

    Genipin 1-gentiobioside; Genipin 1-β-gentiobioside; Genipin gentiobioside

    		 Others Inflammation/Immunology
    Genipin 1-β-D-gentiobioside (Genipin 1-gentiobioside) is one of the most abundant and bioactive iridoid glycosides in Gardenia jasminoides Ellis, which possesses hepatoprotective, anti-inflammatory, antioxidant, and antithrombotic activities.
  • HY-146437
    Topoisomerase I inhibitor 6

    		Topoisomerase Cancer
    Topoisomerase I inhibitor 6 (Compound 3) is a potent inhibitor of Topoisomerase I. Topoisomerase I inhibitor 6 is able to trap DNA-Top1 cleavage complex and found to be less cytotoxic in non-cancerous cell line. Topoisomerase I inhibitor 6 has the potential for the research of cancer diseases.
  • HY-149002
    Topoisomerase I/II inhibitor 4

    		Topoisomerase Apoptosis Cancer
    Topoisomerase I/II inhibitor 4 (compound F16) is a potent topoisomerase I (Topo I) and II (Topo II) dual inhibitor. Topoisomerase I/II inhibitor 4 inhibits cell proliferation, invasion and migration and induces apoptosis. Topoisomerase I/II inhibitor 4 can be used for liver cancer research.
  • HY-146497
    Topoisomerase I inhibitor 7

    		Topoisomerase Cancer
    Topoisomerase I inhibitor 7 (Compound 8) is a potent inhibitor of Topoisomerase I. Topoisomerase I inhibitor 7 significantly inhibits tumor growth (up to 79%) and increases the lifespan (153%) of mice bearing P388 lymphoma transplants. Topoisomerase I inhibitor 7 indicates prospects for further search of new antitumor agent candidates among the heteroarene-fused anthraquinones.
  • HY-150685
    Topo I/COX-2-IN-1

    		Topoisomerase Prostaglandin Receptor Apoptosis Cancer Inflammation/Immunology
    Topo I/COX-2-IN-1 (1H-30) is a potential Topo I/COX-2 inhibitor. Topo I/COX-2-IN-1 inhibits COX-2 and Topo I with the IC50 value of 0.24 μM and 4.42 μM, respectively. Topo I/COX-2-IN-1 can induce apoptosis and inhibit migration of cancer cells, has anti-cancer activity.
  • HY-153340
    I-152

    		Keap1-Nrf2 Metabolic Disease
    I-152 is a conjugate containing N-acetyl-cysteine (NAC) and cysteamine (MEA). I-152 activates NRF2 and ATF4 signals. I-152 has anti-proliferative properties.
  • HY-E70040
    Endoglycoceramidase I (EGCase I)

    		Endogenous Metabolite Metabolic Disease
    Endoglycoceramidase I (EGCase I) is a glycosidase, is often used in biochemical studies. Endoglycoceramidase I catalyzes a transglycosylation reaction, which transfers the sugar moiety of GSLs to the primary hydroxyl group of several 1-alkanols.
  • HY-143265
    Topoisomerase I inhibitor 2

    		Topoisomerase Apoptosis Caspase Cancer
    Topoisomerase I inhibitor 2 (ZML-8) is a highly selective inhibitor of DNA topoisomerase I (Top1). Topoisomerase I inhibitor 2 inhibits Top1 activity and results DNA damage. Topoisomerase I inhibitor 2 blocks G2/M phase and induces apoptosis, exhibits anti-tumor effect.
  • HY-153365
    I-138

    		Deubiquitinase Cancer
    I-138 is an orally active compound structurally related to ML323 (HY-17543). I-138 and ML-323 are potent reversible inhibitors of USP1-UAF1. I-138 displays synergistic binding with ubiquitin and mutual exclusive binding with ML323. I-138 induces the monoubiquitination of FANCD2 and PCNA in MDA-MB-436 cells, increases PCNA and FANCD2 monoubiquitination in HAP-1 USP1 WT cells. I-138 ablates USP1 autocleavage in cells.
  • HY-136538
    LQZ-7I

    		Survivin Cancer
    LQZ-7I is a survivin-targeting inhibitor. LQZ-7I inhibits survivin dimerization. LQZ-7I orally effectively inhibits xenograft tumor growth and induces survivin loss in tumors.
  • HY-N11172
    Schibitubin I

    		Others Neurological Disease
    Schibitubin I is a lignin. Schibitubin I has neuroprotective activity. Schibitubin I can be isolated from the fruits of Schisandra bicolor var. tuberculata.
  • HY-107301
    Dehydrosoyasaponin I

    Soyasaponin Be; DHS-I

    		 Potassium Channel Neurological Disease
    Dehydrosoyasaponin I (Soyasaponin Be;DHS-I), a triterpene glycoside, is a potent and reversible calcium-activated potassium (maxi-K) channels activator.
  • HY-P1768
    Urechistachykinin I

    Uru-TK I

    		 Bacterial Infection
    Urechistachykinin I (Uru-TK I), an invertebrate tachykinin-related peptides (TRPs) isolated from echiuroid worms, shows antimicrobial activities without a hemolytic effect.
  • HY-N2013
    Aristolactam I

    Aristololactam; Aristolactam

    		 Caspase Apoptosis Inflammation/Immunology
    Aristololactam I (AL-I), is the main metabolite of aristolochic acid I (AA-I), participates in the processes that lead to renal damage. Aristololactam I (AL-I) directly injures renal proximal tubule cells, the cytotoxic potency of AL-I is higher than that of AA-I and that the cytotoxic effects of these molecules are mediated through the induction of apoptosis in a caspase-3-dependent pathway.
  • HY-N6675
    Gardenia yellow

    		Sirtuin Neurological Disease Cancer
    Gardenia yellow is an active member of crocin, increases mRNA expression of SIRT3, and acts as an orally active antidepressant agent.
  • HY-N11455
    Lacto-N-difucohexaose I

    LDFH I

    		 Others Metabolic Disease
    Lacto-N-difucohexaose I (LNDFH I), a linker, could be used to combine oligosaccharides containing Lewis b sugar chain to water insoluble polysaccharide.
  • HY-117793
    I-191

    		Protease Activated Receptor (PAR) Cancer
    I-191 is a potent, selective protease-activated receptor 2 (PAR2) antagonist.
  • HY-107588
    TC-I 15

    		Integrin Cardiovascular Disease
    TC-I 15 (TC-I-15) is an allosteric, collagen-binding integrin α2β1 inhibitor with IC50 values of 26.8 μM and 0.4 μM for GFOGER and GLOGEN, respectively. TC-I 15 inhibits platelet adhesion to collagen and thrombus deposition.
  • HY-143402
    Topoisomerase I/II inhibitor 2

    		Topoisomerase Cancer
    Topoisomerase I/II inhibitor 2 (compound 1a) is a potent Topoisomerase inhibitor (IC50= 9.82 μM on Huh7 cells and 6.83 μM on LM9 cells). Topoisomerase I/II inhibitor 2 has dual inhibition on DNA topoisomerase I/II, also can obviously reduce the growth of xenograft tumor in mice model. Topoisomerase I/II inhibitor 2 has the potential value in researching liver cancer.
  • HY-15167
    Glyoxalase I inhibitor

    		Glyoxalase (GLO) Cancer
    Glyoxalase I inhibitor is a potent Glyoxalase I inhibitor, candidate for anticancer agents.
  • HY-P1777
    IGF-I (24-41)

    Insulin-like Growth Factor I (24-41)

    		 IGF-1R Metabolic Disease Inflammation/Immunology
    IGF-I (24-41) (Insulin-like Growth Factor I (24-41)) is amino acids 24 to 41 fragment of IGF-I. IGF-I, a 70 aa polypeptide hormone, is a trophic factor for both neurons and glial cells. IGF-I is partly responsible for systemic growth hormone (GH) activities. IGF-I has anabolic, antioxidant, anti-inflammatory and cytoprotective actions. IGF-I (24-41) regulates somatic growth and behavioral development.
  • HY-145840
    Pol I-IN-1

    		DNA/RNA Synthesis Cancer
    Pol I-IN-1 is a potent RNA polymerase I (Pol I) inhibitor with IC50 0.21 µM for the Pol I large catalytic subunit RPA194.
  • HY-110078
    Eeyarestatin I

    		p97 Apoptosis Cancer
    Eeyarestatin I, a potent endoplasmic reticulum-associated protein degradation (ERAD) inhibitor, is a potent protein translocation inhibitor. Eeyarestatin I inhibits Sec61 translocon. Eeyarestatin I targets the p97-associated deubiquitinating process (PAD) and inhibits atx3-dependent deubiquitination. Eeyarestatin I interferes at a step prior to proteasomal degradation. Eeyarestatin I induces cell death via the proapoptotic protein NOXA and has anticancer effects.
  • HY-N0331
    Ziyuglycoside I

    		MDM-2/p53 Apoptosis Cancer
    Ziyuglycoside I isolated from S. officinalis root, has anti-wrinkle activity, and increases the expression of type I collagen. Ziyuglycoside I could be used as an active ingredient for cosmetics. Ziyuglycoside I triggers cell cycle arrest and apoptosis mediated by p53, it can be a potential agent candidate for treating triple-negative breast cancer (TNBC).
  • HY-112134A
    (R)-CSN5i-3

    		Others Cancer
    (R)-CSN5i-3 is the (R)-enantiomer of CSN5i-3. CSN5i-3 is a potent, selective and orally available inhibitor of CSN5.
  • HY-W019806
    Lacto-N-fucopentaose I

    LNFP I

    		 Endogenous Metabolite CDK Reactive Oxygen Species Apoptosis Enterovirus Bacterial Infection Inflammation/Immunology
    Lacto-N-fucopentaose I (LNFPI) is a human milk oligosaccharide (HMO), possessing antiviral and antibacterial activity. Lacto-N-fucopentaose I can reduce capsid protein VP1 to block virus adsorption, promote CDK2 and reduce cyclin E to recover cell cycle S phase block. Lacto-N-fucopentaose I inhibits ROS production and apoptosis in virus-infected cells. Lacto-N-fucopentaose I can also regulate intestinal microbiota to affect immune system development.
  • HY-N2541
    Gymnemic acid I

    		Apoptosis Autophagy Metabolic Disease
    Gymnemic acid I is a bioactive triterpene saponin found in Gymnema sylvestre. Gymnemic acid I decreases the apoptosis under the high glucose stress.
  • HY-148093
    PM-81I

    		STAT Cancer Inflammation/Immunology
    PM-81I is a potent STAT6 inhibitor (targeting the SH2 structural domain) that effectively reduces STAT6 phosphorylation levels. PM-81I can be used in studies of allergic lung disease, allergic rhinitis, chronic obstructive pulmonary disease or cancer[1].
  • HY-115735
    SKI-I

    		SphK Apoptosis Cancer
    SKI-I is a potent and selective inhibitor of human sphingosine kinase (SK), with an IC50 of 1.2 μM for ST-hSK. SKI-I also inhibits hERK2 (IC50=11 μM). SKI-I induces apoptosis in tumor cell lines.
  • HY-N8355
    Beauveriolide I

    		Endogenous Metabolite Infection
    Beauveriolide I is the metabolite of Entomopathogenic Fungi Beauveria sp.. Beauveriolide I (1) exhibits moderate insecticidal activities against Spodoptera litura and Callosobruchus chinensis.
  • HY-N0407
    Picroside I

    6'-Cinnamoylcatalpol

    		 STAT Inflammation/Immunology
    Picroside I is the major ingredient of Picrorhiza scrophulariiflora. Picrorhiza scrophulariiflora is a high value medicinal herb due to rich source of hepatoprotective metabolites, Picroside-I and Picroside-II. Picroside I is a promising agent for the management of asthma. Picroside I reduces the inflammation significantly at its higher dose. Picroside I also downregulates pSTAT6 and GATA3 expressions. Picroside I dose-dependently increases the serum levels of IFN-γ.
  • HY-N1939
    Icariside I

    Icarisid I

    		 Others Others
    Icariside I is a metabolite of Icarlin, which could regulate bone remodeling and is recognized as an effective agent for the treatment of osteoporosis.
  • HY-N0887
    Isoastragaloside I

    Isoastragaloside-I

    		 Others Metabolic Disease
    Isoastragaloside I is a natural compound from the medicinal herb Radix Astragali; possesses the activity of elevating adiponectin production.
  • HY-N1985
    Acetylastragaloside I

    		Parasite Infection
    Acetylastragaloside I is a glycoside that can be isolated from the roots of Astragalus baibutensis. Acetylastragaloside I is the first cycloartane-type triterpene with remarkable trypanocidal activity with IC50 values of 9.5 and 5.0 μg/mL for T. brucei rhodesiense and T. cruzi, respectively. Acetylastragaloside I can be used for the research of trypanosome infection.
  • HY-P1777A
    IGF-I (24-41) (TFA)

    Insulin-like Growth Factor I (24-41) (TFA)

    		 IGF-1R Metabolic Disease Inflammation/Immunology
    IGF-I (24-41) (Insulin-like Growth Factor I (24-41)) TFA is amino acids 24 to 41 fragment of IGF-I. IGF-I TFA, a 70 aa polypeptide hormone, is a trophic factor for both neurons and glial cells. IGF-I TFA is partly responsible for systemic growth hormone (GH) activities. IGF-I TFA has anabolic, antioxidant, anti-inflammatory and cytoprotective actions. IGF-I (24-41) TFA regulates somatic growth and behavioral development.
  • HY-100838A
    L-CCG-I

    		mGluR Metabolic Disease
    L-CCG-I is an extended isomer of conformationally restricted glutamate analog. L-CCG-I also is a potent agonist for mGluR2 with an EC50 value of 0.3 nM. L-CCG-I can be used for the research of mGluR family.
  • HY-17389
    Genipin

    (+)-Genipin

    		 Autophagy Cancer Metabolic Disease Inflammation/Immunology Neurological Disease
    Genipin ((+)-Genipin) is a natural crosslinking reagent derived from Gardenia jasminoides Ellis fruits. Genipin inhibits UCP2 (uncoupling protein 2) in cells. Genipin has a variety of bioactivities, including modulation on proteins, antitumor, anti-inflammation, immunosuppression, antithrombosis, and protection of hippocampal neurons. Genipin also can be used for type 2 diabetes research.
  • HY-100383
    BH3I-1

    BHI1; BH 3I1

    		 Bcl-2 Family MDM-2/p53 E1/E2/E3 Enzyme Cancer
    BH3I-1 is a Bcl-2 family antagonist, which inhibits the binding of the Bak BH3 peptide to Bcl-xL with a Ki of 2.4±0.2 μM in FP assay. BH3I-1 has a Kd of 5.3 μM against the p53/MDM2 pair.
  • HY-N0047
    Polyphyllin I

    		JNK mTOR Akt PDK-1 Autophagy Apoptosis Cancer
    Polyphyllin I is a bioactive constituent extracted from Paris polyphylla, has strong anti-tumor activity. Polyphyllin I is an activator of the JNK signaling pathway and is an inhibitor of PDK1/Akt/mTOR signaling. Polyphyllin I induces autophagy, G2/M phase arrest and apoptosis.
  • HY-N7022
    Eclalbasaponin I

    		Others Cancer
    Eclalbasaponin I is isolated from Eclipta prostrata L with antitumor activity. Eclalbasaponin I inhibits the proliferation of hepatoma cell smmc-7721 with an IC50 value of 111.1703 μg/ml.
  • HY-148092
    (S)-PM-43I

    		STAT Cancer Inflammation/Immunology
    (S)-PM-43I is a potent STAT6 inhibitor and can reduce STAT6 phosphorylation level. (S)-PM-43I can be used in allergic lung disease, allergic rhinitis, chronic pulmonary obstructive disease and cancer research[1].
  • HY-145859
    Topo I-IN-1

    		Topoisomerase Apoptosis Reactive Oxygen Species Cancer
    Topo I-IN-1 (Compound 14d) is a potent Topo I inhibitor with antitumor activity and DNA intercalative capability. Topo I-IN-1 induces cell apoptosis.
  • HY-N0360
    Dihydrotanshinone I

    		SARS-CoV Cardiovascular Disease
    Dihydrotanshinone I is a natural compound extracted from Salvia miltiorrhiza Bunge which has been widely used for treating cardiovascular diseases. Dihydrotanshinone I exhibits entry-blocking effect for MERS-CoV.
  • HY-N3071
    Picrasidine I

    		Apoptosis Reactive Oxygen Species Inflammation/Immunology
    Picrasidine I is an anti-inflammatory and anti-osteoclastogenic dimeric alkaloid that can be isolated from Picrasma quassioides. Picrasidine I inducs cell cycle arrest, and triggers cell apoptosis by downregulats ERK and Akt pathways. Picrasidine I inhibits the activation of MAPKs, NF-κB and ROS generation, and suppresses the expression of c-Fos and NFATc1.
  • HY-N7141
    Spiramycin I

    		Parasite Antibiotic Bacterial Infection
    Spiramycin I is a macrolide antibiotic and antiparasitic.
  • HY-118044
    I-SAP

    		Prostaglandin Receptor Cardiovascular Disease
    I-SAP is a radioiodinated TXA2/PGH2 receptor antagonist. The bind between I-SAP and the receptors, is inhibited by the histidine modifying reagent diethyl-pyrocarbonate (DEPC).
  • HY-P1773A
    IGF-I (30-41) (TFA)

    Insulin-like Growth Factor I (30-41) (TFA)

    		 IGF-1R Metabolic Disease Inflammation/Immunology
    IGF-I (30-41) (TFA) is amino acids 30 to 41 fragment of Insulin-like Growth Factor I (IGF-I). IGF-I is partly responsible for systemic GH activities although it possesses a wide number of own properties (anabolic, antioxidant, anti-inflammatory and cytoprotective actions).
  • HY-147649
    Glyoxalase I inhibitor 7

    		Glyoxalase (GLO) Cancer
    Glyoxalase I inhibitor 7 (Compound 6) is a glyoxalase I (Glo-I) inhibitor with an IC50 of 3.65 μM. Glyoxalase I inhibitor 7 can be used as anticancer agent.
  • HY-119016A
    SK1-​I hydrochloride

    BML-258 hydrochloride

    		 SphK Cancer
    SK1-I hydrochloride (BML-258 hydrochloride), an analog of sphingosine, is an isozyme-specific competitive SPHK1 inhibitor with a Ki value of 10 µM. SK1-I hydrochloride shows no activity at SPHK1 PKCα, PKCδ, PKA, AKT1, ERK1, EGFR, CDK2, IKKβ or CamK2β. SK1-I hydrochloride enhances autophagy and has antitumor activity.
  • HY-119016
    SK1-I

    BML-258

    		 SphK Cancer
    SK1-I (BML-258), an analog of sphingosine, is an isozyme-specific competitive SPHK1 inhibitor with a Ki value of 10 µM. SK1-I shows no activity at SPHK1 PKCα, PKCδ, PKA, AKT1, ERK1, EGFR, CDK2, IKKβ or CamK2β. SK1-I enhances autophagy and has antitumor activity.
  • HY-B0175
    Toltrazuril

    BAY-i 9142

    		 Parasite Antibiotic Infection
    Toltrazuril (BAY-i 9142) is an antiprotozoal agent that acts upon Coccidia parasites.
  • HY-N3921
    Gancaonin I

    		Others Cancer
    Gancaonin I, an Isoflavone, exhibits moderate inhibition on human carboxylesterase 2 (hCES2A) with IC50 of 1.72 μM. Gancaonin I inhibits hCES2A-mediated fluorescein diacetate (FD) hydrolysis.
  • HY-147647
    Glyoxalase I inhibitor 5

    		Glyoxalase (GLO) Cancer
    Glyoxalase I inhibitor 5 (Compound 9h) is a glyoxalase I (Glo-I) inhibitor with an IC50 of 1.28 μM. Glyoxalase I inhibitor 5 can be used as anticancer agent.
  • HY-107284
    Officinalisinin I

    		Others Others
    Officinalisinin I is a steroidal saponin, isolated from Anemarrhena asphodeloides.
  • HY-N1085
    Viscidulin I

    		Others Others
    Viscidulin I is found in Scutellaria baicalensis Georgi.
  • HY-N0612
    Siamenoside I

    		Others Inflammation/Immunology
    Siamenoside I is one of the mogrosides that has several kinds of bioactivities.
  • HY-N2999
    Ganoderic acid I

    		Others Others
    Ganoderic acid I is a triterpenoid found in ganoderma lucidum.
  • HY-141881
    PROTAC-O4I2

    		PROTACs Apoptosis Cancer
    PROTAC-O4I2 is a PROTAC targets splicing factor 3B1 (SF3B1). PROTAC-O4I2 induces FLAG-SF3B1 degradation with an IC50 value of 0.244 μM in K562 cells. PROTAC-O4I2 also induces cellular apoptosis in K562 WT cells.
  • HY-147648
    Glyoxalase I inhibitor 6

    		Glyoxalase (GLO) Cancer
    Glyoxalase I inhibitor 6 (Compound 9j) is a glyoxalase I (Glo-I) inhibitor with an IC50 of 1.13 μM. Glyoxalase I inhibitor 6 can be used as anticancer agent with low toxicity.
  • HY-138181
    Contezolid phosphoramidic acid

    MRX-I phosphoramidic acid

    		 Others Others
    Contezolid phosphoramidic acid is an intermediate in the synthesis of proagents of antibacterial oxazolidinone agent MRX-I. Contezolid phosphoramidic acid is extracted from patent WO2015127316A1, Intermediate 3, Method I.
  • HY-N11461
    LNnDFH I

    Lacto-N-neo-difucohexaose I

    		 Others Others
    LNnDFH I is a natural product that can be isolated from human urine.
  • HY-110199
    TC-I 2014

    		TRP Channel Neurological Disease
    TC-I 2014 (compound 5) is a potent and orally active Benzimidazole-containing transient receptor potential melastatin 8 (TRPM8) antagonist, with IC50 values of 0.8 nM, 3.0 nM and 4.4 nM for canine, human and rat channels respectively. TC-I 2014 exhibits antiallodynic properties in pain models.
  • HY-N2466
    Melanotan I

    MT-I; [Nle4,D-Phe7]-α-MSH

    		 Melanocortin Receptor Cancer
    Melanotan I is a potent non-selective melanocortin receptor (MCR) agonist. Melanotan I is a synthetic analogue of α-melanocyte stimulating hormone (α-MSH) that stimulates melanogenesis. Melanotan I can induce skin tanning by mimicking the actions of a-MSH on the melanocortin type 1 receptors (MC1R) of melanocytes. Melanotan I can be used for sunlight-induced skin cancers research.
  • HY-N2466A
    Melanotan I acetate

    MT-I acetate; [Nle4,D-Phe7]-α-MSH acetate

    		 Melanocortin Receptor Cancer
    Melanotan I acetate is a potent non-selective melanocortin receptor (MCR) agonist. Melanotan I acetate is a synthetic analogue of α-melanocyte stimulating hormone (α-MSH) that stimulates melanogenesis. Melanotan I acetate can induce skin tanning by mimicking the actions of a-MSH on the melanocortin type 1 receptors (MC1R) of melanocytes. Melanotan I acetate can be used for sunlight-induced skin cancers research.
  • HY-N8183
    Shancigusin I

    		Others Others
    Shancigusin I is a natural compound found in Cremastra appendiculata.
  • HY-N3030
    Sylvestroside I

    		Others Inflammation/Immunology
    Sylvestroside I is an iridoid isolated from Acicarpha tribuloides.
  • HY-76293
    I2906

    		Bacterial Infection
    I2906 showed antimycobacterial and cytotoxic activity against mycobacterium tuberculosis.
  • HY-144061
    INSCoV-601I(1)

    		SARS-CoV Infection
    INSCoV-601I(1) is a potent inhibitor of M pro (3CL pro). Proteases (PL pro and 3CL pro) are involved with transcription and replication of the virus. INSCoV-601I(1) has the potential for the research of SARS-CoV-2 infection (extracted from patent WO2021219089A1).
  • HY-141627
    Heparin disaccharide I-S tetrasodium

    		Biochemical Assay Reagents Others
    Heparin disaccharide I-S tetrasodium is the major disaccharide produced from heparin by heparanases I and II.
  • HY-135680
    I-OMe-Tyrphostin AG 538

    I-OMe-AG 538

    		 IGF-1R Cancer Metabolic Disease
    I-OMe-Tyrphostin AG 538 (I-OMe-AG 538) is a specific inhibitor of IGF-1R (insulin-like growth factor-1 receptor tyrosine kinase). I-OMe-Tyrphostin AG 538 inhibits IGF-1R-mediated signaling and is preferentially cytotoxic to nutrient-deprived PANC1 cells. I-OMe-Tyrphostin AG 538 is an ATP-competitive inhibitor of phosphatidylinositol-5-phosphate 4-kinase α (PI5P4Kα), with an IC50 of 1 µM.
  • HY-148761
    PSMA I&T

    		Others Cancer
    PSMA I&T is a potent PSMA (prostate-specific membrane antigen) inhibitor. PSMA I&T can be used for SPECT/CT imaging and radionuclide research of prostate cancer (PCa).
  • HY-15167A
    Glyoxalase I inhibitor free base

    		Glyoxalase (GLO) Cancer
    Glyoxalase I inhibitor (free base) is a potent Glyoxalase I (GLO1) inhibitor, candidate for anticancer agents.
  • HY-N6579
    Arvenin I

    		Others Cancer
    Arvenin I is a natural cucurbitacin glucoside with moderate anticancer effects.
  • HY-148058
    Topoisomerase I inhibitor 8

    		Topoisomerase Cancer
    Topoisomerase I inhibitor 8 is a potent topoisomerase I inhibitor. Topoisomerase I inhibitor 8 is a hexacyclic analogue of camptothecin, and displays cytotoxic effect against tumor cells.
  • HY-D1116
    MitoMark Red I

    		Fluorescent Dye Others
    MitoMark Red I is a fluorescent mitochondrial marker. MitoMark Red I is a red fluorescent dye which accumulates in mitochondria in viable cells and has an excitation wavelength of 578 nm and emission of 599 nm.
  • HY-N2286
    Kushenol I

    		Others Inflammation/Immunology
    Kushenol I is a natural compound isolated from the roots of Sophora flavescens.
  • HY-N4213
    Anemarrhenasaponin I

    		Others Cardiovascular Disease
    Anemarrhenasaponin I, a traditional Chinese medicine, shows remarkable inhibiting effect on platelet aggregation.
  • HY-125684
    Trichodecenin I

    		Endogenous Metabolite Others
    Trichodecenin I, a fungal metabolite, is a peptaibol composed of 7 amino acid residues.
  • HY-N5082
    Homodihydrocapsaicin I

    		Others Others
    Homodihydrocapsaicin I is a kind of capsaicinoid from the fruits of Capsicum annuum.
  • HY-N5095
    Eupteleasaponin I

    		Others Metabolic Disease
    Eupteleasaponin I is a component of Euptelea polyandra, may has gastroprotective activity.
  • HY-N11450
    Complanatin I

    		Others Others
    Complanatin I is a natural product that can be isolated from Astragalus complanatus.
  • HY-P2200
    Siamycin I

    BMY-29304

    		 HIV Antibiotic Infection Inflammation/Immunology
    Siamycin I (BMY-29304), a 21-residue tricyclic peptide, is a secondary metabolite in actinomycetes. Siamycin I is a HIV fusion inhibitor with ED50s of 0.05 to 5.7 μM for acute HIV type 1 (HIV-1) and HIV-2 infections. Siamycin I inhibits the gelatinase and gelatinase biosynthesis-activating pheromone (GBAP) signaling via the FsrC-FsrA two-component regulatory system in a noncompetitive manner. Siamycin I suppresses the expression of both fsrBDC and gelE-sprE transcripts. Siamycin I, a lasso peptide, interacts with lipid II and inhibits cell wall biosynthesis. Siamycin I, an antibiotic, has the potential for enterococcal infections research.
  • HY-44157
    ALS-I

    		Biochemical Assay Reagents Neurological Disease
    ALS-I, an acid-Liable surfactant, is adopted for in-solution enzymatic digestions, can help to solubilize hydrophobic proteins. ALS-I is significantly enhanced peptide recovery for mass spectrometry (MS) mapping in the study of the proteomes of regenerating rat retina and mouse brain.
  • HY-131318
    Lenalidomide-I

    		Ligands for E3 Ligase Cancer
    Lenalidomide-I (Compound 72), an analog of cereblon (CRBN) ligand Lenalidomide for E3 ubiquitin ligase, is used in the recruitment of CRBN protein. Lenalidomide-I can be connected to the ligand for protein by a linker to form PROTACs, such as the PROTAC BET degrader QCA570 (HY-112609).
  • HY-P3934
    HIV Protease Substrate I

    		HIV Protease Infection
    HIV Protease Substrate I is a chromogenic substrate of HIV-1 protease. HIV Protease Substrate I has the cleavage site of HIV protease.
  • HY-151894
    I-BET432

    		Epigenetic Reader Domain Cancer
    I-BET432 is a BET inhibitor. I-BET432 inhibits BRD4 N-terminal bromodomain (BD1) and the C-terminal bromodomain (BD2) with pIC50 values of 7.5 and 7.2, respectively. I-BET432 can be used as an oral candidate quality molecule for the research of multiple oncology and inflammatory diseases.
  • HY-146180
    FSDD0I

    		FAP Cancer
    FSDD0I is an albumin-binding fibroblast activation protein (FAP) ligand. FSDD0I can be labeled with 68Ga and 177Lu for single photon emission computed tomography (SPECT) imaging.
  • HY-D1148
    HKGreen-4I

    		Fluorescent Dye Others
    HKGreen-4I is a highly sensitive green fluorescent probe for the specific detection of H2O2 in living cells with a maximum excitation wavelength and emission wavelength of 520 nm and 543 nm, respectively.
  • HY-146181
    FSDD1I

    		FAP Cancer
    FSDD1I is an albumin-binding fibroblast activation protein (FAP) ligand. FSDD1I can be labeled with 68Ga and 177Lu for single photon emission computed tomography (SPECT) imaging.
  • HY-146182
    FSDD3I

    		FAP Cancer
    FSDD3I is an albumin-binding fibroblast activation protein (FAP) ligand. FSDD3I can be labeled with 68Ga and 177Lu for single photon emission computed tomography (SPECT) imaging.
  • HY-128206
    I3MT-3

    HMPSNE

    		 Hippo (MST) Metabolic Disease
    I3MT-3 (HMPSNE) is a potent, selective, and cell-membrane permeable inhibitor of 3-Mercaptopyruvate sulfurtransferase (3MST) (IC50=2.7 μM). I3MT-3 is inactive for other H2S/sulfane sulfur-producing enzymes. I3MT-3 targets a persulfurated cysteine residue located in the active site of 3MST.
  • HY-143266
    Topoisomerase I inhibitor 3

    		Topoisomerase Apoptosis Cancer
    Topoisomerase I inhibitor 3 (Compound ZML-14) is a topoisomerase I inhibitor and can interact with topoisomerase I-DNA complex. Topoisomerase I inhibitor 3 induces HepG2 cell apoptosis and arrests cell cycle at G2/M phase.
  • HY-D0140
    Chromoionophore I

    ETH 5294

    		 Fluorescent Dye Others
    Chromoionophore I (ETH 5294) is a hydrophobic pH indicator. Chromoionophore I is used as a transmissive or fluorescent probe molecule in many types of hydrophobic sensor membranes. Chromoionophore I is oil-soluble.
  • HY-N3983
    Gynosaponin I

    		Others Others
    Gynosaponin I (compound 1) is a natural product that can be found in Gynostemma pentaphyllum.
  • HY-P1542
    Urotensin I

    Catostomus urotensin I

    		 CRFR Cardiovascular Disease Endocrinology
    Urotensin I (Catostomus urotensin I), a CRF-like neuropeptide, acts as an agonist of CRF receptor with pEC50s of 11.46, 9.36 and 9.85 for human CRF1, human CRF2 and rat CRF2α receptors in CHO cells, and Kis of 0.4, 1.8, and 5.7 nM for hCRF1, rCRF2α and mCRF2β receptors, respectively.
  • HY-148170
    L-I-OddU

    		EBV DNA/RNA Synthesis Nucleoside Antimetabolite/Analog Infection
    L-I-OddU, a L-5'-halo- dioxolane nucleoside analogue, is a potent and selective anti-Epstein-Barr virus (EBV) agent with an EC50 value of 0.03μM. L-I-OddU has low cytotoxicity with a CC50 value of 1000 nM. L-I-OddU has antiviral activity by suppressing replicative EBV DNA and viral protein synthesis.
  • HY-124211S
    Dibenzo(a,i)pyrene-d14

    		Isotope-Labeled Compounds Others
    Dibenzo(a,i)pyrene-d14 is the deuterium labeled Dibenzo(a,i)pyrene[1].
  • HY-P1839
    Angiotensin I/II (1-5)

    		Angiotensin Receptor Cardiovascular Disease
    Angiotensin I/II 1-5 is a peptide that contains the amino acids 1-5, which is converted from Angiotensin I/II. Angiotensin I is formed by the action of renin on angiotensinogen. Angiotensin II is produced from angiotensin I. Angiotensin II has been investigated for the treatment, basic science, and diagnostic of Hypertension, Renin Angiotensin System, and Idiopathic Membranous Nephropathy.
  • HY-144774
    Topoisomerase I inhibitor 5

    		Topoisomerase DNA/RNA Synthesis Apoptosis Cancer
    Topoisomerase I inhibitor 5 is an effective topoisomerase inhibitor with IC50 value of. Topoisomerase I inhibitor 5 can interfere with DNA and significantly inhibit the activity of Topoisomerase I. Topoisomerase I inhibitor 5 can arrest cell cycle at the G1 phase and induce MCF-7 cells apoptosis. Topoisomerase I inhibitor 5 has potency in reversing P-gp-mediated resistance to Adriamycin.
  • HY-N7026
    Celosin I

    		Others Metabolic Disease
    Celosin I, an oleanane-type triterpenoid saponin isolated from the seeds of Celosia argentea L, could be used as chemical markers for the quality control of C. argentea seeds. Celosin I exhibits significant hepatoprotective effect on carbon tetrachloride-induced and N,N-dimethylformamide-induced hepatotoxicity in mice.
  • HY-N0201
    Atractylenolide I

    		Toll-like Receptor (TLR) JAK STAT Cancer
    Atractylenolide I is a sesquiterpene derived from the rhizome of Atractylodes macrocephala, possesses diverse bioactivities, such as neuroprotective, anti-allergic, anti-inflammatory and anticancer properties. Atractylenolide I reduces protein levels of phosphorylated JAK2 and STAT3 in A375 cells, and acts as a TLR4-antagonizing agent.
  • HY-P1396
    GRK2i

    		G Protein-coupled Receptor Kinase (GRK) Others
    GRK2i is a Gβγ-inhibitory peptide that selectively prevents Gβγ-mediated signaling. GRK2i corresponds to the Gβγ-binding domain of GRK2 (G-protein-coupled receptor kinase 2).
  • HY-124012
    PCNA-I1

    		DNA/RNA Synthesis Cancer
    PCNA-I1 is a potent PCNA (proliferating cell nuclear antigen) inhibitor. PCNA-I1 directly binds PCNA trimers with a Kd of 0.41 μM and exhibits antitumor activity both in vitro and in vivo.
  • HY-107300
    Dehydrosoyasaponin I methyl ester

    Soyasaponin Be methyl ester; DHS-I methyl ester

    		 Others Others
    Dehydrosoyasaponin I methyl ester (Soyasaponin Be methyl ester) is a saponin found in Trifolium alexandrinum.
  • HY-146654
    Glyoxalase I inhibitor 2

    		Glyoxalase (GLO) Cancer
    Glyoxalase I inhibitor 2 (compound 26) is a potent glyoxalase I (GLO1) inhibitor with an IC50 of 0.5 µM. Glyoxalase I inhibitor 2 has the potential for the research of depression and anxiety.
  • HY-N6889
    Rebaudioside I

    		Others Others
    Rebaudioside I is a natural non-claoric sweetener isolated from S. rebaudiana Morita.
  • HY-N8343
    Arjunglucoside I

    		Bacterial Infection Inflammation/Immunology
    Arjunglucoside I, a natural compound, possesses antimicrobial activity with a MIC of 1.9 μg/mL.
  • HY-146656
    Glyoxalase I inhibitor 4

    		Glyoxalase (GLO) Cancer
    Glyoxalase I inhibitor 4 (compound 14) is a potent glyoxalase I inhibitor with an Ki of 10 nM.
  • HY-111237
    Butyrolactone I

    Olomoucin

    		 CDK Cancer
    Butyrolactone I is an ATP-competitive inhibitor of CDK1 as a secondary metabolite from A. terreus. Butyrolactone I has antitumor effects in non-small cell lung, small cell lung, and prostate cancer cell lines.
  • HY-146655
    Glyoxalase I inhibitor 3

    		Glyoxalase (GLO) Cancer
    Glyoxalase I inhibitor 3 (compound 22g) is a potent glyoxalase I (GLO1) inhibitor with an IC50 of 0.011 µM. Glyoxalase I inhibitor 3 has the potential for the research of depression and anxiety.
  • HY-N10414
    Primulic acid I

    Primulasaponin 1; Primula acid I

    		 Others Others
    Primulic acid I (Primulasaponin 1) is a plant-derived triterpenoid saponin with one sugar chain (monodesmoid).
  • HY-N0745
    Senkyunolide I

    		Caspase Inflammation/Immunology
    Senkyunolide I, isolated from Ligusticum chuanxiong Hort, is an anti-migraine compound. Senkyunolide I protects rat brain against focal cerebral ischemia-reperfusion injury by up-regulating p-Erk1/2, Nrf2/HO-1 and inhibiting caspase 3.
  • HY-W127791
    Uroporphyrin I dihydrochloride

    		Biochemical Assay Reagents Others
    Uroporphyrin I dihydrochloride is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
  • HY-W073080
    Coproporphyrin I dihydrochloride

    		Biochemical Assay Reagents Others
    Coproporphyrin I dihydrochloride is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
  • HY-W127800
    Etioporphyrin I

    		Biochemical Assay Reagents Others
    Etioporphyrin I is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
  • HY-107400
    B I09

    		IRE1 Cancer
    B I09 is an IRE-1 RNase inhibitor, with an IC50 of 1230 nM.
  • HY-107202A
    Poly (I:C):Kanamycin (1:1)

    		Toll-like Receptor (TLR) Infection
    Poly (I:C):Kanamycin (1:1) is a mixture of poly (I:C) and kanamycin. Poly(I:C) is a synthetic double-stranded RNA (dsRNA), which is a Toll-like receptor 3 (TLR3) agonist. Kanamycin is positively charged (poly-NH3) and can thus neutralize the negative charge of Poly I:C and thereby stabilized the molecule.
  • HY-19541A
    I-CBP112 hydrochloride

    		Epigenetic Reader Domain Cancer
    I-CBP112 hydrochloride is a selective inhibitor of CBP/P300 that directly binds their bromodomains (Kds = 142 and 625 nM, respectively). I-CBP112 significantly reduces the leukemia-initiating potential of MLL-AF9(+) acute myeloid leukemia cells in a dose-dependent manner in vitro and in vivo. I-CBP112 increases the cytotoxic activity of BET bromodomain inhibitor JQ1 as well as doxorubicin.
  • HY-135748
    Polyinosinic-polycytidylic acid sodium

    Poly(I:C) sodium

    		 Toll-like Receptor (TLR) Apoptosis Cancer Inflammation/Immunology
    Polyinosinic-polycytidylic acid (Poly(I:C)) sodium is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid sodium can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid sodium can directly trigger cancer cells to undergo apoptosis.
  • HY-134958
    Polyinosinic-polycytidylic acid potassium

    Poly(I:C) potassium

    		 Toll-like Receptor (TLR) Apoptosis Cancer Inflammation/Immunology
    Polyinosinic-polycytidylic acid potassium (Poly(I:C) potassium) is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid sodium can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid potassium can directly trigger cancer cells to undergoApoptosis.
  • HY-P1829
    Angiotensin I/II (1-6)

    		Angiotensin Receptor Cardiovascular Disease
    Angiotensin I/II 1-6 contains the amino acids 1-6 and is converted from Angiotensin I/II peptide. The precursor angiotensinogen is cleaved by renin to form angiotensin I. Angiotensin I ishydrolyzed by angiotensin-converting enzyme (ACE) to form the biologically active angiotensin II. Angiotensin II has been investigated for the treatment, basic science, and diagnostic of Hypertension, Renin Angiotensin System, and Idiopathic Membranous Nephropathy.
  • HY-112476
    PRL-3 Inhibitor I

    		Phosphatase Cancer
    PRL-3 Inhibitor I is a potent PRL-3 inhibitor with an IC50 of 0.9 μM. PRL-3 Inhibitor I shows a reduced invasion in cell-based assay.
  • HY-19915
    Contezolid

    MRX-I

    		 Bacterial Antibiotic Monoamine Oxidase Infection Inflammation/Immunology
    Contezolid (MRX-I), a new and orally active oxazolidinone, is an antibiotic in study for complicated skin and soft tissue infections (cSSTI) caused by resistant Gram-positive bacteria. Contezolid (MRX-I) markedly reduces potential for myelosuppression and monoamine oxidase inhibition (MAOI).
  • HY-103078A
    I-XW-053 sodium

    		HIV Infection
    I-XW-053 sodium is a potent HIV-1 inhibitor with an IC50 value of 164.2 μM. I-XW-053 sodium is a novel antiviral that targets a unique site on the HIV-1 CA protein and inhibits by affecting virus uncoating[1] .
  • HY-N7532
    Yadanzioside I

    		TMV Infection
    Yadanzioside I is a potent anti-tobacco mosaic virus (TMV) quassinoid with an IC50 of 4.22 μM.
  • HY-N3775
    Dodoviscin I

    		Others Metabolic Disease
    Dodoviscin I is an adipogenesis agent that increases triglyceride content in 3T3L1 mouse fibroblasts.
  • HY-124813
    PDZ1i

    113B7

    		 FAK EGFR MMP Cancer
    PDZ1i is a potent, BBB-penetrated and specific MDA-9/Syntenin inhibitor. PDZ1i inhibits crucial GBM (glioblastoma multiforme) signaling involving FAK and EGFRvIII. PDZ1i reduces MMP secretion. PDZ1i can improve survival of brain tumor-bearing mice and reduce tumor invasion.
  • HY-146653
    Glyoxalase I inhibitor 1

    		Glyoxalase (GLO) Cancer
    Glyoxalase I inhibitor 1 (compound 23) is a potent glyoxalase I (GLO1) inhibitor with an IC50 of 26 nM.
  • HY-100341
    M2I-1

    		Others Others
    M2I-1 is a Mad2 inhibitor targeting the binding of Mad2 to Cdc20, an essential protein-protein interaction (PPI) within the spindle assembly checkpoint (SAC).
  • HY-P1194
    Spantide I

    		Neurokinin Receptor Inflammation/Immunology
    Spantide I, a substance P analog, is a selective NK1 receptor antagonist, with Ki values of 230 nM and 8150 nM for NK1 and NK2 receptor, respectively. Spantide I provides an approach to reduce type 1 and enhance the type 2 cytokine IL-10 in the infected cornea, leading to a significant reduction in corneal perforation.
  • HY-125733
    Thiocillin I

    		Bacterial Antibiotic Infection
    Thiocillin I is a thiopeptide antibiotic and has in vitro antibacterial activity against Gram-positive bacterial strains. The MIC values of Thiocillin I against S. aureus 1974149, E. faecalis 1674621, B. subtilis ATCC 6633 and S. pyogenes 1744264 are 2 μg/mL, 0.5 μg/mL, 4 μg/mL and 0.5 μg/mL, respectively.
  • HY-143301
    Topoisomerase I inhibitor 4

    		Topoisomerase Cancer
    Topoisomerase I inhibitor 4 (compound 7a) is a topoisomerase I inhibitor. Topoisomerase I inhibitor 4 inhibits HepG2, A549, MCF-7 and HeLa cancer cells proliferation with IC50s of 1.20, 2.09, 1.56 and 1.92 μM, respectively. Topoisomerase I inhibitor 4 can be used for the research of cancer.
  • HY-18975
    I-BRD9

    		Epigenetic Reader Domain Cancer Inflammation/Immunology
    I-BRD9 is a selective cellular chemical probe of bromodomain-containing protein 9 (BRD9) with pIC50 value of 7.3 μM. I-BRD9 has high selectivity for bromodomain and extra terminal domain (BET) family and highly homologous bromodomain-containing protein 7 (BRD7). I-BRD9 can be used to identify genes regulated by BRD9 in Kasumi-1 cells involved in oncology and immune response pathways.
  • HY-18772
    O4I2

    		Oct3/4 Others
    O4I2 is a potent Oct3/4 inducer. O4I2 induces the expression of pluripotent-associated genes Lin28, Sox2 and Nanog, and suppresses Rex1.
  • HY-152086
    DRP1i27

    		Dynamin Cardiovascular Disease
    DRP1i27 is a potent inhibitor of human Drp1 (dynamin-related protein 1). DRP1i27 binds to the GTPase site of Drp1, with hydrogen bonds to Gln34 and Asp218. DRP1i27 targets Drp1-mediated mitochondrial fission in cell line models and protects against simulated ischemia-reperfusion injury.
  • HY-146504
    Topoisomerase I/II inhibitor 3

    		Topoisomerase PI3K Apoptosis Reactive Oxygen Species Cancer
    Topoisomerase I/II inhibitor 3 (compound 7) is a potent topoisomerase I (Topo I) and II (Topo II) dual inhibitor. Topoisomerase I/II inhibitor 3 can inhibit cell proliferation, invasion and migration, and induce apoptosis by inhibiting PI3K/Akt/mTOR signaling pathway. Topoisomerase I/II inhibitor 3 can be used for liver cancer research.
  • HY-139865
    142I5

    		Apoptosis Cancer
    142I5 is a potent ML-IAP Lys-covalent inhibitor with an IC50 value of 11 nM.
  • HY-117426
    MO-I-500

    		Others Cancer
    MO-I-500 is a pharmacological of FTO inhibitor with an IC50 of 8.7 μM for the inhibition of purified FTO demethylase catalyzing demethylation of an artificial small methylated substrate. MO-I-500 can be used for the research of rare panresistant triple-negative inflammatory breast cancer.
  • HY-R01687
    hsa-miR-548i mimic

    		MicroRNA Cancer
    hsa-miR-548i mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.
  • HY-R03056
    mmu-miR-344i mimic

    		MicroRNA Cancer
    mmu-miR-344i mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.
  • HY-R04367
    rno-miR-344i mimic

    		MicroRNA Cancer
    rno-miR-344i mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.
  • HY-R03472
    mmu-miR-669i mimic

    		MicroRNA Cancer
    mmu-miR-669i mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.
  • HY-R00852
    hsa-miR-378i mimic

    		MicroRNA Cancer
    hsa-miR-378i mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.
  • HY-N8331
    Terpendole I

    		Acyltransferase Endogenous Metabolite Cancer
    Terpendole I, a fungal indoloditerpene, is a ACAT (acyl-CoA: cholesterol acyltransferase) inhibitor (IC50=145 µM).
  • HY-W008867
    Fmoc-Tyr(3,5-I2)-OH

    		Amino Acid Derivatives Others
    Fmoc-Tyr(3,5-I2)-OH is a tyrosine derivative.
  • HY-P1542B
    Urotensin I TFA

    Catostomus urotensin I TFA

    		 CRFR Endocrinology Cardiovascular Disease
    Urotensin I (Catostomus urotensin I) TFA, a CRF-like neuropeptide, acts as an agonist of CRF receptor with pEC50s of 11.46, 9.36 and 9.85 for human CRF1, human CRF2 and rat CRF2α receptors in CHO cells, and Kis of 0.4, 1.8, and 5.7 nM for hCRF1, rCRF2α and mCRF2β receptors, respectively.
  • HY-P1396A
    GRK2i TFA

    		G Protein-coupled Receptor Kinase (GRK) Others
    GRK2i TFA is a GRK2 inhibitory polypeptide that specifically inhibits Gβγ activation of GRK2. GRK2i TFA corresponds to the Gβγ-binding domain and acts as a cellular Gβγ antagonist.
  • HY-P1073
    ProTx-I

    		Calcium Channel Sodium Channel Potassium Channel Cancer
    ProTx-I, a venom toxin of the tarantula Thrixopelma pruriens, is a potent, selective CaV3.1 channel blocker with IC50 values of 0.2 μM and 31.8 μM for hCaV3.1 and hCaV3.2 respectively. ProTx-I is also a potent blocker for voltage-gated Na + channels and inhibits KV 2.1 channels.
  • HY-N7052
    Tubulysin I

    		Microtubule/Tubulin Apoptosis Cancer
    Tubulysin I is a highly cytotoxic peptide isolated from the myxobacterial species Archangium geophyra and Angiococcus disciformis. Tubulysin displays extremely potent cytotoxic activity in mammalian cells, including multidrug-resistant cell lines, with IC50 values in the lower nanomolar range. Tubulysin I is a cytotoxic activity tubulysin which inhibits tubulin polymerization and leads to cell cycle arrest and apoptosis.
  • HY-148152
    PSMA I&S

    		Others Others
    PSMA I&S is a precursor of the 99mTc-labeled PSMA-targeting ligand.
  • HY-112405
    BPIQ-I

    PD 159121

    		 EGFR Cancer
    BPIQ-I (PD 159121) is a potent and ATP-competitive EGFR tyrosine kinase inhibitor.. BPIQ-I shows anti-proliferative actively.
  • HY-142520
    I-BET567

    		Epigenetic Reader Domain Cancer Inflammation/Immunology
    I-BET567 is a potent and orally active inhibitor of pan-BET candidate with pIC50s of 6.9 and 7.2 for BRD4 BD1 and BD2, respectively. I-BET567 has been demonstrated efficacy in mouse models of oncology and inflammation.
  • HY-N0940
    Batatasin I

    		Bacterial Infection Inflammation/Immunology
    Batatasin I is a natural product that can be isolated from tuberous roots of Dioscorea batatas, with antifungal activity and anti-inflammatory effects.
  • HY-113318
    Coproporphyrin I

    		Endogenous Metabolite Metabolic Disease
    Coproporphyrin I is an endogenous metabolite present in Urine and Blood that can be used for the research of Liver Disease and Porphyria.
  • HY-N2102
    Tenacissoside I

    		Others Cancer
    Tenacissoside I is a C21 steroid from the Marsdenia tenacissima, which is detected at relatively high level in M. tenacissima.
  • HY-112134
    CSN5i-3

    		Others Cancer
    CSN5i-3 is a potent, selective and orally available inhibitor of CSN5/Jab1, and inhibits CSN-catalysed Cul1 deneddylation with an IC50 value of 5.8 nM.
  • HY-18771
    O4I1

    		Oct3/4 Others
    O4I1 is as a potent Oct3/4 inducer.
  • HY-P1829A
    Angiotensin I/II (1-6) (TFA)

    		Angiotensin Receptor Cardiovascular Disease
    Angiotensin I/II (1-6) TFA contains the amino acids 1-6 and is converted from Angiotensin I/II peptide. The precursor angiotensinogen is cleaved by renin to form angiotensin I. Angiotensin I ishydrolyzed by angiotensin-converting enzyme (ACE) to form the biologically active angiotensin II. Angiotensin II has been investigated for the treatment, basic science, and diagnostic of Hypertension, Renin Angiotensin System, and Idiopathic Membranous Nephropathy.
  • HY-124691
    D-I03

    		DNA/RNA Synthesis Cancer
    D-I03 is a selective RAD52 inhibitor with a Kd of 25.8 µM. D-I03 specifically inhibits RAD52-dependent single-strand annealing (SSA) and D-loop formation with IC50s of 5 µM and 8 µM, respectively. D-I03 suppresses growth of BRCA1- and BRCA2-deficient cells and inhibits formation of damage-induced RAD52 foci, but does not effect on RAD51 foci induced by Cisplatin.
  • HY-P0324
    Parasin I

    		Bacterial Infection
    Parasin I is a 19-amino acid histone H2A-derived peptide isolated from the skin of the catfish, and shows antimicrobial activity.
  • HY-P3572
    Adipokinetic hormone I (Locusta migratoria)

    Lom-AKH-I

    		 Endogenous Metabolite Endocrinology
    Adipokinetic hormone I (Locusta migratoria) (Lom-AKH-I) is a insect adipokinetic hormone (AKH), enhances fat body cAMP levels in vitro. Insect adipokinetic hormones (AKHs) controls flight-directed mobilization of carbohydrate and lipid from fat body stores, which depends on AKH receptor(s) coupling to cAMP formation and glycogen phosphorylase activation via the stimulatory guanine nucleotide-binding protein (Gs).
  • HY-N5032
    7Z-Trifostigmanoside I

    		Others Others
    7Z-Trifostigmanoside I is found in Polygala hongkongensis Hemsl.
  • HY-W073069
    Coproporphyrin I tetramethyl ester

    		Biochemical Assay Reagents Others
    Coproporphyrin I tetramethyl ester is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
  • HY-N5042
    Forsythoside I

    		Others Inflammation/Immunology
    Forsythoside I, a caffeoyl phenylethanoid glycoside (CPG) isolated from the fruits of Forsythia suspense (Thunb.) Vahl, may possesses anti-inflammatory activities.
  • HY-N4246
    Bacopaside I

    		Others Neurological Disease
    Bacopaside I, a saponin isolated from Bacopa monnieri, exbibits antioxidant properties and free radical scavenging capacity and exerts antidepressant-like effect.
  • HY-N10111
    Siegesbeckialide I

    		IKK Inflammation/Immunology
    Siegesbeckialide I most potently inhibits LPS-induced NO production in RAW264.7 murine macrophages by directly binding to IKKα/β.
  • HY-128044
    Ftase inhibitor I

    B581

    		 Farnesyl Transferase Cancer
    Ftase inhibitor I (B581) is a potent, selective and peptidomimetic farnesyl transferase (FTase) inhibitor. Ftase inhibitor I shows selectivity for FTase over geranylgeranyl isoprenoid (Ras-GG) or the fatty acid myristate (Myr-Ras).
  • HY-P1194A
    Spantide I TFA

    		Neurokinin Receptor Inflammation/Immunology
    Spantide I TFA, a substance P analog, is a selective NK1 receptor antagonist, with Ki values of 230 nM and 8150 nM for NK1 and NK2 receptor, respectively. Spantide I provides an approach to reduce type 1 and enhance the type 2 cytokine IL-10 in the infected cornea, leading to a significant reduction in corneal perforation.
  • HY-N0432
    Astragaloside I

    Astrasieversianin IV; Cyclosieversioside B

    		 Wnt β-catenin Metabolic Disease
    Astragaloside I, one of the main active ingredients in Astragalus membranaceus, has osteogenic properties. Astragaloside I stimulates osteoblast differentiation through the Wnt/β-catenin signaling pathway.
  • HY-N9317
    Tangshenoside I

    		Glucosidase Metabolic Disease
    Tangshenoside I, isolated from the roots of Codonopsis lanceolata, exhibits weak α-glucosidase inhibitory activities in vitro with an IC50 of 1.4 mM.
  • HY-P1097
    Gastrin I, human

    		Cholecystokinin Receptor Endocrinology
    Gastrin I, human is the endogenous peptide produced in the stomach, and increases gastric acid secretion via cholecystokinin 2 (CCK2) receptor.
  • HY-150755
    Topo I/COX-2-IN-2

    		Topoisomerase COX Apoptosis Reactive Oxygen Species Cancer
    Topo I/COX-2-IN-2 (Compound W10) is a potent dual-target inhibitor of Topo I and COX-2 with IC50 values of 0.90 μM and 2.31 μM, respectively. Topo I/COX-2-IN-2 induces cancer cell apoptosis through the mitochondrial pathway.
  • HY-A0126
    Epoprostenol

    Prostaglandin I2; Prostacyclin

    		 Endogenous Metabolite Cardiovascular Disease
    Epoprostenol (Prostaglandin I2), the synthetic form of the natural prostaglandin derivative Prostacyclin (Prostaglandin I2), is registered worldwide for the treatment of Pulmonary arterial hypertension (PAH. Epoprostenol is used in pulmonary hypertension and transplantation as a potent inhibitor of platelet aggregation.
  • HY-W008452
    H-Tyr(3-I)-OH

    		Endogenous Metabolite Metabolic Disease
    H-Tyr(3-I)-OH is a potent and effective tyrosine hydroxylase inhibitor. H-Tyr(3-I)-OH is an intermediate in the production of thyroid hormones and has a role as a human or mouse metabolite.
  • HY-W006103
    I-bu-rG Phosphoramidite

    		DNA/RNA Synthesis Nucleoside Antimetabolite/Analog Others
    I-bu-rG Phosphoramidite is a phosphinamide monomer which can be used in the synthesis of nucleotides and nucleic acids.
  • HY-15146
    NSC 74859

    S3I-201

    		 STAT Cancer
    NSC 74859 (S3I-201) is a selective Stat3 inhibitor with an IC50 of 86 μM.
  • HY-N11529
    9-Methoxyaristolactam I

    		Others Others
    9-Methoxyaristolactam I is a natural product that can be isolated from the roots of Asarum sieboldii Miq. var. Seoulense Nakai.
  • HY-108905
    Mecasermin

    Human IGF-I; FK 780

    		 IGF-1R Metabolic Disease
    Mecasermin (Human IGF-I; FK 780) is a recombinant human insulin-like growth factor I (IGF-I). Mecasermin has the potential for the study of the growth failure of growth hormone (GH) insensitivity caused by GH receptor defects or GH-inhibiting antibodies.
  • HY-148152A
    PSMA I&S TFA

    		Others Others
    PSMA I&S (TFA) is a precursor of the 99mTc-labeled PSMA-targeting ligand.
  • HY-135748A
    Poly (I:C):Kanamycin (1:1) (sodium)

    		Toll-like Receptor (TLR) Apoptosis Cancer Infection
    Poly (I:C):Kanamycin (1:1) sodium is an isometric complex of Poly (I:C) (HY-135748) and Kanamycin (HY-16566). Poly(I:C) sodium, a synthetic analog of double-stranded RNA, is a TLR3 and retinoic acid-inducible gene I receptor (RIG-I and b>MDA5) agonist. Poly(I:C) sodium can be used as a vaccine adjuvant to enhance innate and adaptive immune responses and induce apoptosis in cancer cells. Kanamycin is an orally active antibacterial agent (Gram-negative/positive bacteria) that inhibits translocation and causes miscoding by binding to the 70S ribosomal subunit. Kanamycin shows good inhibitory activity against Mycobacterium tuberculosis (susceptible and drug-resistant) and Klebsiella pneumoniae, and can be used in the research of tuberculosis and pneumonia.
  • HY-W019776
    Sudan I-d5

    Solvent Yellow 14-d5

    		 Bacterial Infection
    Sudan I-d5 is a the deuterated Sudan I. Sudan I is a diazo-conjugate red dye and can be used as an additive to products such as oils, solvents or polishes. Sudan I inhibits growth of bacterial strains Clostridium perfringens and L. rhamnosus[1].
  • HY-W013714
    Fmoc-Phe(4-I)-OH

    		Amino Acid Derivatives Others
    Fmoc-Phe(4-I)-OH is a phenylalanine derivative.
  • HY-W007615
    H-Phe(4-I)-OH

    		Amino Acid Derivatives Others
    H-Phe(4-I)-OH is a phenylalanine derivative.
  • HY-50713
    Calcium-Sensing Receptor Antagonists I

    		CaSR Others
    Calcium-Sensing Receptor Antagonists I is an antagonist of calcium-sensing parathyroid hormone receptors.
  • HY-W008452S
    H-Tyr(3-I)-OH-13C6

    		Endogenous Metabolite Metabolic Disease
    H-Tyr(3-I)-OH- 13C6 is the 13C-labeled H-Tyr(3-I)-OH. H-Tyr(3-I)-OH is a potent and effective tyrosine hydroxylase inhibitor. H-Tyr(3-I)-OH is an intermediate in the production of thyroid hormones and has a role as a human or mouse metabolite[1][2].
  • HY-P1593
    Mini Gastrin I, human

    		Cholecystokinin Receptor Cancer Endocrinology
    Mini Gastrin I, human is a shorter version of human gastrin, consists of amino acids 5-17 of the parent peptide.
  • HY-103351
    Cathepsin G Inhibitor I

    		Cathepsin Inflammation/Immunology
    Cathepsin G Inhibitor I is a potent, selective, reversible, competitive, non-peptide inhibitor of cathepsin G.
  • HY-P1270
    α-Conotoxin Im-I

    		nAChR Neurological Disease
    α-Conotoxin Im-I is a selective α7/α9 nAChR antagonist, blocking α7 nicotinic receptors with the highest apparent affinity, while having an 8-fold lower affinity for homomeric α9 nicotinic receptors. α-Conotoxin Im-I is toxic and induces seizures in rodents. α-Conotoxin Im-I is a tool for studying neuronal nAChR.
  • HY-N6724
    Altertoxin I

    Dihydroalterperylenol

    		 Others Metabolic Disease
    Altertoxin I (Dihydroalterperylenol) is a quinone-type mycotoxin produced by Alternaria alternata fungi, which is mutagenic and cytotoxic, and can weakly disrupts metabolic communication.
  • HY-W127440
    i-Cholesteryl methyl ether

    		Biochemical Assay Reagents Others
    i-Cholesteryl methyl ether is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
  • HY-W096157
    I-PEG5-OH

    		PROTAC Linkers Cancer
    I-PEG5-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
  • HY-W096156
    I-PEG6-OH

    		PROTAC Linkers Cancer
    I-PEG6-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
  • HY-N0697
    Crocin

    Crocin I

    		 Endogenous Metabolite Cancer Inflammation/Immunology Neurological Disease
    Crocin (Crocin I) is a nutraceutical and the main constituent isolated from the stigmas of Crocus sativus with immense pharmacological properties as anti-inflammatory, anticancer, antidepressant and anticonvulsant.
  • HY-N10206
    11-epi-Chaetomugilin I

    		Endogenous Metabolite Cancer
    11-epi-Chaetomugilin I is a metabolite found in Chaetomium globosum. 11-epi-Chaetomugilin I exhibits significant cytotoxic activity against the murine P388 leukemia cell line, the human HL-60 leukemia cell line, the murine L1210 leukemia cell line, and the human KB epidermoid carcinoma cell line.
  • HY-13032B
    Molibresib besylate

    GSK 525762C; I-BET 762 besylate

    		 Epigenetic Reader Domain Cancer
    Molibresib besylate (GSK 525762C; I-BET 762 besylate) is a BET bromodomain inhibitor with IC50 of 32.5-42.5 nM.
  • HY-D0024
    Sudan I

    Solvent Yellow 14

    		 Bacterial Others
    Sudan I (Solvent Yellow 14) is a diazo-conjugate red dye and can be used as an additive to products such as oils, solvents or polishes. Sudan I inhibits growth of bacterial strains Clostridium perfringens and L. rhamnosus.
  • HY-112546
    MMP-2 Inhibitor I

    		MMP Cancer
    MMP-2 Inhibitor I (OA-Hy) is a potent MMP-2 inhibitor with a Ki of 1.7 μM.
  • HY-A0126A
    Epoprostenol sodium

    Prostaglandin I2 sodium salt; Prostacyclin sodium salt; Flolan

    		 Endogenous Metabolite Cardiovascular Disease
    Epoprostenol sodium (Prostaglandin I2 (sodium salt)), the synthetic form of the natural prostaglandin derivative prostacyclin (prostaglandin I2), is registered worldwide for the treatment of Pulmonary arterial hypertension (PAH). Epoprostenol sodium is used in pulmonary hypertension and transplantation as a potent inhibitor of platelet aggregation.
  • HY-P0324A
    Parasin I TFA

    		Bacterial Infection
    Parasin I (TFA) is a 19-amino acid histone H2A-derived peptide isolated from the skin of the catfish, and shows antimicrobial activity.
  • HY-138620
    MCU-i4

    		Mitochondrial Metabolism Metabolic Disease
    MCU-i4 blocks the IP3-dependent mitochondrial Ca 2+-uptake, maintaining the gatekeeping role of their target.
  • HY-101387
    rel-ACPT-I

    		mGluR
    rel-ACPT-I is an agonist of group III mGluRs with diverse biological activities including neuroprotective, anticonvulsant, and anxiolytic-like effects.
  • HY-R00014
    hsa-let-7i-5p mimic

    		MicroRNA Cancer
    hsa-let-7i-5p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.
  • HY-R00013
    hsa-let-7i-3p mimic

    		MicroRNA Cancer
    hsa-let-7i-3p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.
  • HY-R03181
    mmu-miR-466i-3p mimic

    		MicroRNA Cancer
    mmu-miR-466i-3p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.
  • HY-R03182
    mmu-miR-466i-5p mimic

    		MicroRNA Cancer
    mmu-miR-466i-5p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.
  • HY-19760
    I-BET282

    		Epigenetic Reader Domain Inflammation/Immunology
    I-BET282 is a pan-inhibitor of all eight BET bromodomains, and selectivity over other representative bromodomain-containing proteins. I-BET282 shows pIC50s ranging 6.4-7.7 for BRD2 (BD1/BD2), BRD2 (BD1/BD), BRD3 (BD1/BD), and BRD4 (BD1/BD).
  • HY-I0512
    Sofosbuvir impurity I

    		HCV Infection
    Sofosbuvir impurity I, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity.
  • HY-N5004
    Guanfu base I

    Acorine

    		 Others Cardiovascular Disease
    Guanfu base I (Acorine) is an active metabolite of Guanfu base A, isolated from Aconitum coreanum, and has a potent anti-arrhythmic effect.
  • HY-126548
    β-Secretase Inhibitor I

    		Beta-secretase Neurological Disease
    β-Secretase Inhibitor I is an extremely potent β-secretase inhibitor with reduced cardiovascular and liver toxicity.
  • HY-P1032
    Angiotensin I (human, mouse, rat)

    		Endogenous Metabolite Others
    Angiotensin I (human, mouse, rat) is the precursor to the vasoconstrictor peptide angiotensin II, cleaved by the angiotensin-converting enzyme (ACE).
  • HY-W016028
    Fmoc-D-Phe(4-I)-OH

    		Amino Acid Derivatives Others
    Fmoc-D-Phe(4-I)-OH is a phenylalanine derivative.
  • HY-N0890
    Tubeimoside I

    Tubeimoside-1; Lobatoside-H

    		 Apoptosis Cancer
    Tubeimoside I(Lobatoside-H) is an extract from Chinese herbal medicine Bolbostemma paniculatum (MAXIM.
  • HY-W011472
    H-D-Phe(4-I)-OH

    		Amino Acid Derivatives Others
    H-D-Phe(4-I)-OH is a phenylalanine derivative.
  • HY-W009284
    H-DL-Phe(4-I)-OH

    		Amino Acid Derivatives Others
    H-DL-Phe(4-I)-OH is a phenylalanine derivative.
  • HY-19541
    I-CBP112

    		Histone Acetyltransferase Epigenetic Reader Domain Cancer
    I-CBP112 is a specific and potent acetyl-lysine competitive protein-protein interaction inhibitor, that inhibits the CBP/p300 bromodomains, enhances acetylation by p300.
  • HY-N6854
    Mogroside I A1

    		Others Cancer Metabolic Disease
    Mogroside I A1 is a triterpenoid glycoside and a nonsugar sweetener. Mogrosides are sweeter than sucrose. Mogrosides exhibit antioxidant, antidiabetic and anticancer activities.
  • HY-N6853
    Mogroside I E1

    		Others Cancer Metabolic Disease
    Mogroside I E1 is a triterpenoid glycoside and a nonsugar sweetener. Mogrosides are sweeter than sucrose. Mogrosides exhibit antioxidant, antidiabetic and anticancer activities.
  • HY-P2643
    Angiotensin I/II (4-8)

    		Endogenous Metabolite Cardiovascular Disease
    Angiotensin I/II (4-8), a major metabolite of Angiotensin II, is a C-terminal 4-8 pentapeptide.
  • HY-P1593A
    Mini Gastrin I, human TFA

    		Cholecystokinin Receptor Cancer Endocrinology
    Mini Gastrin I, human (TFA) is a shorter version of human gastrin, consists of amino acids 5-17 of the parent peptide.
  • HY-149012
    AChE/hCA I/II-IN-1

    		Cholinesterase (ChE) Carbonic Anhydrase Endocrinology Neurological Disease
    AChE/hCA I/II-IN-1 (Compound 6) is a potent inhibitor of AChE/Hca with IC50 values of 22.21, 60.79 and 66.64 nM for AChE, Hca Ⅰ and Hca Ⅱ. AChE/hCA I/II-IN-1 can be used for the rsearch for glaucoma, Alzheimer's disease, diabetes.
  • HY-D0929
    Orange I

    α-Naphthol Orange

    		 Fluorescent Dye Others
    Orange I (α-Naphthol Orange) is an organic azo dye used as a food dye.
  • HY-B1411
    i-Inositol

    myo-Inositol; meso-Inositol

    		 Endogenous Metabolite Others
    i-Inositol is a chemical compound, associated lipids are found in many foods, in particular fruit, especially cantaloupe and oranges.
  • HY-P3673
    Lamprey LH-RH I

    		GnRH Receptor Endocrinology
    Lamprey LH-RH I is a gonadotropin-releasing hormone, elevates plasma steroid levels and stimulates ovulation in the lamprey without biological activity in other animal models.
  • HY-13329
    IRAK-1-4 Inhibitor I

    IRAK-1/4 Inhibitor I

    		 IRAK Inflammation/Immunology
    IRAK-1-4 Inhibitor I is an inhibitor of interleukin-1 receptor-associated kinase 1/4 (IRAK 1/4) with IC50s of 0.2 μM and 0.3 μM, respectively.
  • HY-N3930
    Gardenoin J

    		Others Cancer
    Gardenoin J, a cycloartane triterpene, is isolated from the exudate of Gardenia thailandica.
  • HY-N0134
    Tanshinone I

    Tanshinone A

    		 Phospholipase Cardiovascular Disease Cancer
    Tanshinone I is an inhibitor of type IIA human recombinant sPLA2 (IC50=11 μM) and rabbit recombinant cPLA2 (IC50=82 μM).
  • HY-N10418
    Isorhapontin

    		Fungal Infection
    Isorhapontin is an antifungal agent. Isorhapontin inhibits the hydrolytic activity of Trichoderma cellobiohydrolase I (CBH I) with a Ki of 57.2 μM. Isorhapontin also inhibits the activity of Trichoderma endoglucanase I.
  • HY-N6037
    Gardenin B

    		Apoptosis Cancer
    Gardenin B is a flavonoid isolated from Gardenia jasminoides. Gardenin B induces cell death in human leukemia cells involves multiple caspases.
  • HY-P1336
    Deltorphin I

    Deltorphin 1; Deltorphin C

    		 Opioid Receptor Neurological Disease
    Deltorphin I is a δ-opioid receptor agonist with high affinity and selectivity.
  • HY-P2416
    Gastrin I, rat

    Rat Gastrin-17

    		 Cholecystokinin Receptor Endocrinology
    Gastrin I, rat (Rat Gastrin-17) is a peptide hormone, can stimulate gastric acid secretion potently.
  • HY-P3064
    Scyllatoxin

    Leiurotoxin I

    		 Potassium Channel Neurological Disease
    Scyllatoxin (Leiurotoxin I) is a peptide toxin, it can be isolated from the venom of the scorpion (Leiurus quinquestriatus hebraeus). Scyllatoxin is a blocker of small-conductance KCa (SK) channel. Scyllatoxin enhances both norepinephrine (NE) and epinephrine (Epi) release in vivo.
  • HY-B1411S1
    i-Inositol-d1

    myo-Inositol-d1; meso-Inositol-d1

    		 Endogenous Metabolite Others
    i-Inositol-d is the deuterium labeled i-Inositol[1].
  • HY-19760B
    I-BET282E

    		Epigenetic Reader Domain Inflammation/Immunology
    I-BET282E is a pan-inhibitor of all eight BET bromodomains, and selectivity over other representative bromodomain-containing proteins. I-BET282E shows pIC50s ranging 6.4-7.7 for BRD2 (BD1/BD2), BRD2 (BD1/BD), BRD3 (BD1/BD), and BRD4 (BD1/BD).
  • HY-128026
    MMP-9/MMP-13 Inhibitor I

    		MMP Inflammation/Immunology
    MMP-9/MMP-13 Inhibitor I is a potent MMP-9 and MMP-13 inhibitor with IC50s of both 0.9 nM. MMP-9/MMP-13 Inhibitor I shows >20-folds selectivity for MMP-9/MMP-13 over other MMPs.
  • HY-136460
    Calcium ionophore I

    ETH 1001

    		 Calcium Channel Others
    Calcium ionophore I (ETH 1001) is a selective Ca 2+ ionophore for biological membranes. Calcium ionophore I can be used in Ca2+-selective microelectrodes that can be used for quantitative intracellular measurements of resting Ca2+-activities and of slowly changing Ca2+-levels.
  • HY-P99619
    Finotonlimab

    SCT-I10A

    		 PD-1/PD-L1 Cancer
    Finotonlimab (SCT-I10A) is a recombinant humanised IgG PD-1 antibody. Finotonlimab has the potential for solid tumors or lymphomas research.
  • HY-B1411S
    i-Inositol-d6

    myo-Inositol-d6; meso-Inositol-d6

    		 Endogenous Metabolite Others
    i-Inositol-d6 is the deuterium labeled i-Inositol. i-Inositol is a chemical compound, associated lipids are found in many foods, in particular fruit, especially cantaloupe and oranges.
  • HY-A0104D
    HPMC (Type I,Viscosity:4000mPa.s)

    Hypromellose (Type I,Viscosity:4000mPa.s); (Hydroxypropyl)methyl cellulose (Type I,Viscosity:4000mPa.s); Celacol HPM 5000 (Type I,Viscosity:4000mPa.s)

    		 Biochemical Assay Reagents Others
    Hydroxypropylmethylcellulose (Type I,Viscosity:4000mPa.s) is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
  • HY-A0104C
    HPMC (Type I,Viscosity:400mPa.s)

    Hypromellose (Type I,Viscosity:400mPa.s); (Hydroxypropyl)methyl cellulose (Type I,Viscosity:400mPa.s); Celacol HPM 5000 (Type I,Viscosity:400mPa.s)

    		 Biochemical Assay Reagents Others
    Hydroxypropylmethylcellulose (Type I,Viscosity:400mPa.s) is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
  • HY-A0104B
    HPMC (Type I,Viscosity:100mPa.s)

    Hypromellose (Type I,Viscosity:100mPa.s); (Hydroxypropyl)methyl cellulose (Type I,Viscosity:100mPa.s); Celacol HPM 5000 (Type I,Viscosity:100mPa.s)

    		 Biochemical Assay Reagents Others
    Hypromellose (Type I,Viscosity:100mPa.s) is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
  • HY-A0104A
    HPMC (Type I,Viscosity:30mPa.s)

    Hypromellose (Type I,Viscosity:30mPa.s); (Hydroxypropyl)methyl cellulose (Type I,Viscosity:30mPa.s); Celacol HPM 5000 (Type I,Viscosity:30mPa.s)

    		 Biochemical Assay Reagents Others
    Hydroxypropylmethylcellulose (Type I,Viscosity:30mPa.s) is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
  • HY-N7761
    Trijuganone B

    Tetrahydro tanshinone I

    		 Others Cancer
    Trijuganone B (Tetrahydro tanshinone I) can be extracted from from the roots of Salvia miltiorrhiza f. alba. Trijuganone B inhibits the proliferation of leukemia cells.
  • HY-103002
    SU5408

    VEGFR2 Kinase Inhibitor I

    		 VEGFR Cardiovascular Disease
    SU5408 (VEGFR2 Kinase Inhibitor I) is a potent and cell-permeable inhibitor of VEGFR2 kinase with an IC50 of 70 nM.
  • HY-13867A
    Bisindolylmaleimide I hydrochloride

    GF109203X hydrochloride; Go 6850 hydrochloride

    		 PKC GSK-3 Cancer Metabolic Disease
    Bisindolylmaleimide I (GF109203X) hydrochloride is a cell-permeable and reversible PKC inhibitor (IC50 of 20 nM, 17 nM, 16 nM, and 20 nM for PKCα, PKCβI, PKCβII, and PKCγ. Bisindolylmaleimide I hydrochloride is also a GSK-3 inhibitor.
  • HY-13867
    Bisindolylmaleimide I

    GF109203X; Go 6850

    		 PKC GSK-3 Metabolic Disease Cancer
    Bisindolylmaleimide I (GF109203X) is a cell-permeable and reversible PKC inhibitor (IC50 of 20 nM, 17 nM, 16 nM, and 20 nM for PKCα, PKCβI, PKCβII, and PKCγ. Bisindolylmaleimide I is also a GSK-3 inhibitor.
  • HY-N8086
    Korepimedoside C

    Epimedin I

    		 Others Metabolic Disease Inflammation/Immunology Cardiovascular Disease
    Korepimedoside C (Epimedin I), a flavonol glycoside, is isolated from the aerial parts of Epimedium koreanum Nakai. Epimedium koreanum Nakai is a famous Chinese herbal medicine for the research of impotence, osteoporosis, immune suppression and cardiovascular diseases.
  • HY-N0011
    Baohuoside I

    Icariin-II; Icariside-II

    		 CXCR Apoptosis Cancer Inflammation/Immunology Endocrinology
    Baohuoside I, a flavonoid isolated from Epimedium koreanum Nakai, acts as an inhibitor of CXCR4, downregulates CXCR4 expression, induces apoptosis and shows anti-tumor activity.
  • HY-W110927
    Alizarin red S indicator (C.I. 58005)

    		Biochemical Assay Reagents Others
    Alizarin red S indicator (C.I. 58005) is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
  • HY-W110884
    Eriochrome cyanine R indicator (C.I. 43820)

    		Biochemical Assay Reagents Others
    Eriochrome cyanine R indicator (C.I. 43820) is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
  • HY-N1405
    Cucurbitacin I

    Elatericin B; JSI-124; NSC-521777

    		 STAT JAK Cancer
    Cucurbitacin I is a natural selective inhibitor of JAK2/STAT3, with potent anti-cancer activity.
  • HY-N2795
    9-Hydroxycalabaxanthone

    Xanthone I

    		 Parasite Bacterial Infection
    9-Hydroxycalabaxanthone (Xanthone I) is a known xanthone isolated from Garcinia mangostana Linn. 9-Hydroxycalabaxanthone has quorum-sensing inhibitory, anti-microbial, and anti-malarial activities (IC50=1.2-1.5 µM).
  • HY-P3730
    Cdk2/Cyclin Inhibitory Peptide I

    		CDK Cancer
    Cdk2/Cyclin Inhibitory Peptide I (Tat-LFG), a CDK2 inhibitor, kills U2OS osteosarcoma cells in a dose-dependent manner.
  • HY-107613A
    R 59-022 hydrochloride

    DKGI-I hydrochloride; Diacylglycerol kinase inhibitor I hydrochloride

    		 PKC 5-HT Receptor Cancer Infection Inflammation/Immunology
    R 59-022 (DKGI-I) hydrochloride is a DGK inhibitor (IC50: 2.8 µM). R 59-022 hydrochloride inhibits the phosphorylation of OAG to OAPA. R 59-022 hydrochloride is a 5-HT Receptor antagonist, and activates protein kinase C (PKC). R 59-022 hydrochloride potentiates thrombin-induced diacylglycerol production in platelets and inhibits phosphatidic acid production in neutrophils.
  • HY-107613
    R 59-022

    DKGI-I; Diacylglycerol kinase inhibitor I

    		 PKC 5-HT Receptor Inflammation/Immunology
    R 59-022 (DKGI-I) is a DGK inhibitor (IC50: 2.8 µM). R 59-022 inhibits the phosphorylation of OAG to OAPA. R 59-022 is a 5-HT Receptor antagonist, and activates protein kinase C (PKC). R 59-022 potentiates thrombin-induced diacylglycerol production in platelets and inhibits phosphatidic acid production in neutrophils.
  • HY-107202
    Polyinosinic-polycytidylic acid

    Poly(I:C)

    		 Toll-like Receptor (TLR) Infection Inflammation/Immunology
    Polyinosinic-polycytidylic acid (Poly(I:C)) is a synthetic double-stranded RNA (dsRNA), which is a Toll-like receptor 3 (TLR3) agonist. Polyinosinic-polycytidylic acid presents in some viruses, and is therefore commonly used to model the actions of extracellular dsRNA.
  • HY-N10917
    Xanthohumol I

    		Cholinesterase (ChE) Cancer Infection
    Xanthohumol I, a chalkone, is a derivative of Xanthohumol (HY-N1067). Xanthohumol is a Cholinesterase (ChE) inhibitor, which inhibits acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) wih IC50s of 71.34 μM and 32.67 μM, respectively. The hydroxy compound of Xanthohumol (3-hydroxy-xanthohumol), also shoes inhibitory effect on AChE and BChE with IC50s of 51.25 μM and 63.07 μM.
  • HY-13032
    Molibresib

    I-BET762; GSK525762; GSK525762A

    		 Epigenetic Reader Domain Cancer
    Molibresib (I-BET762; GSK525762) is a BET bromodomain inhibitor with IC50 of 32.5-42.5 nM.
  • HY-P0269
    Magainin 1

    Magainin I

    		 Bacterial Fungal Antibiotic Infection
    Magainin 1 (Magainin I) is an antimicrobial and amphipathic peptide isolated from the skin of Xenopus laevis. Magainin 1 exhibits antibiotic activity against numerous Gram-negative and Gram-positive bacteria.
  • HY-110106
    I-BET151 dihydrochloride

    GSK1210151A dihydrochloride

    		 Epigenetic Reader Domain Cancer
    I-BET151 dihydrochloride (GSK1210151A dihydrochloride) is a BET bromodomain inhibitor which inhibits BRD4, BRD2, and BRD3 with pIC50 of 6.1, 6.3, and 6.6, respectively.
  • HY-13235
    I-BET151

    GSK1210151A

    		 Epigenetic Reader Domain Cancer
    I-BET151 (GSK1210151A) is a BET bromodomain inhibitor which inhibits BRD4, BRD2, and BRD3 with pIC50 of 6.1, 6.3, and 6.6, respectively.
  • HY-107443
    I-BET762 carboxylic acid

    Molibresib carboxylic acid; GSK525762A carboxylic acid; PROTAC BRD4-binding moiety 2

    		 Ligands for Target Protein for PROTAC Epigenetic Reader Domain Cancer
    I-BET762 carboxylic acid (Molibresib carboxylic acid) is an I-BET762-based warhead ligand for conjugation reactions of PROTAC targeting on BET. I-BET762 carboxylic acid (Molibresib carboxylic acid) is a BRD4 inhibitor with a pIC50 of 5.1.
  • HY-P3653
    α-Conotoxin M I

    		mAChR nAChR Neurological Disease
    α-Conotoxin M I is a potent and selective inhibitor of mAChR and α1β1γδ nAChR, but has no effect on nicotine-stimulated dopamine release. α-Conotoxins are small, disulfide-rich peptides that competitively inhibit muscle and neuronal nicotinic AChRs.
  • HY-N3625
    Coronalolic acid

    Coronalonic acid

    		 NF-κB Inflammation/Immunology
    Coronalolic acid, extract from the apical bud of Gardenia sootepenesis Hutch, inhibits TNF-α-induced NF-κB activity and NO production.
  • HY-W110910
    Eriochrome black T indicator (C.I. 14645), 1% solid

    		Biochemical Assay Reagents Others
    Eriochrome black T indicator (C.I. 14645), 1% solid is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
  • HY-D0293
    Acid Blue 1

    Xylene Blue; C.I. Acid Blue 1

    		 Biochemical Assay Reagents Others
    C.I. Acid Blue 1 is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
  • HY-N0170
    Indole-3-carbinol

    I3C; 3-Indolemethanol

    		 NF-κB Aryl Hydrocarbon Receptor E1/E2/E3 Enzyme Endogenous Metabolite Cancer
    Indole-3-carbinol (I3C) inhibits NF-κB activity and also is an Aryl hydrocarbon receptor (AhR) agonist, and an inhibitor of WWP1 (WW domain-containing ubiquitin E3 ligase 1).
  • HY-141488
    Lacto-N-biose I

    Galβ1-3GlcNAc

    		 Endogenous Metabolite Endocrinology
    Lacto-N-biose I (Galβ1-3GlcNAc), as an endogenous metabolite, is an acceptor for the α1,2-fucosyltransferase enzyme from Helicobacter pylori.
  • HY-P0269A
    Magainin 1 TFA

    Magainin I TFA

    		 Bacterial Fungal Antibiotic Infection
    Magainin 1 TFA (Magainin I TFA) is an antimicrobial and amphipathic peptide isolated from the skin of Xenopus laevis. Magainin 1 TFA exhibits antibiotic activity against numerous Gram-negative and Gram-positive bacteria.
  • HY-N5112B
    β,β-Dimethylacrylshikonin

    Isoarnebin I

    		 HIF/HIF Prolyl-Hydroxylase Cancer
    β,β-Dimethylacrylshikonin (Isoarnebin I) is a naphthoquinone derivative isolated from Lithospermum erythrorhizon Sieb. et Zucc. , promotes angiogenesis by inducing eNOS, VEGF and HIF-1α expression through the PI3K-dependent pathway.β,β-Dimethylacrylshikonin has anti-tumor activity.
  • HY-100738
    Ubiquitin Isopeptidase Inhibitor I, G5

    NSC144303

    		 Apoptosis Cancer
    Ubiquitin Isopeptidase Inhibitor I, G5 (NSC 144303) is an apoptosome-independent caspase and apoptosis activator with IC50 values of 1.76 and 1.6 μM in E1A and E1A/C9DN cells, respectively.
  • HY-N0698
    Crocin II

    		NO Synthase COX Endogenous Metabolite Cancer Inflammation/Immunology Neurological Disease
    Crocin II is isolated from the fruit of Gardenia jasminoides with antioxidant, anticancer, and antidepressant activity. Crocin II inhibits NO production with an IC50 value of 31.1 μM. Crocin II suppresses the expressions of protein and m-RNA of iNOS and COX-2.
  • HY-16721
    Cyclopropavir

    Filociclovir; ZSM-I-62; MBX-400

    		 CMV HSV Infection
    Cyclopropavir (Filociclovir; ZSM-I-62; MBX-400) is a broad-spectrum anti-herpesvirus compound, has good antiviral activity against cytomegalovirus (CMV), herpes simplex virus (HHV)-6 and HHV-8 with EC50s of 0.7 μM to 8 μM.
  • HY-W110794
    Crystal violet indicator (0.0-2.0)(C.I. 42555), AR

    		Biochemical Assay Reagents Others
    Crystal violet indicator (0.0-2.0)(C.I. 42555), AR is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
  • HY-154408
    2’-O-Me-5-I-U-3’-phosphoramidite

    		Nucleoside Antimetabolite/Analog Cancer
    2’-O-Me-5-I-U-3’-phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
  • HY-N0510
    Aristolochic acid A

    Aristolochic acid I; TR 1736

    		 NF-κB Cancer
    Aristolochic acid A (Aristolochic acid I; TR 1736) is the main component of plant extract Aristolochic acids, which are found in various herbal plants of genus Aristolochia and Asarum. Aristolochic acid A significantly reduces both activator protein 1 (AP-1) and NF-κB activities. Aristolochic acid A reduces BLCAP gene expression in human cell lines.
  • HY-16229
    GGTI-2154

    		ROS Kinase Apoptosis Cancer
    GGTI-2154 is a potent and selective inhibitor of geranylgeranyltransferase I (GGTase I), with an IC50 of 21 nM. GGTI-2154 shows more than 200-fold selectivity for GGTase I over FTase (IC50=5600 nM). GGTI-2154 can be used for the research of cancer.
  • HY-16229A
    GGTI-2154 hydrochloride

    		ROS Kinase Apoptosis Cancer
    GGTI-2154 hydrochloride is a potent and selective inhibitor geranylgeranyltransferase I (GGTase I), with an IC50 of 21 nM. GGTI-2154 hydrochloride shows more than 200-fold selectivity for GGTase I over FTase (IC50=5600 nM). GGTI-2154 hydrochloride can be used for the research of cancer.
  • HY-18964
    MG-101

    Calpain inhibitor I; Ac-LLnL-CHO; ALLN

    		 Proteasome Apoptosis Cancer
    MG-101 (ALLN) is an inhibitor of cysteine proteases which inhibits calpain I, calpain II, cathepsin B and cathepsin L with Kis of 190, 220, 150 and 500 pM, respectively. MG-101 induces apoptosis and inhibits tumor growth, it can be used for the research of colon cancer.
  • HY-P3884
    Arylomycin A2

    		Bacterial Antibiotic Infection
    Arylomycin A2, an antibiotic (Antibiotic), is a lipopeptide type I signal peptidase (SPase I) inhibitor. Arylomycin A2 has antibacterial effects.
  • HY-122521
    Sootepin D

    		NF-κB Inflammation/Immunology
    Sootepin D (compound 6), a triterpene from the apical bud of Gardenia sootepensis, inhibits TNF-α-induced NF-κB activity with an IC50 of 8.3μM. Sootepin D has anti-inflammatory activity.
  • HY-P99530
    Valanafusp alfa

    AGT-181; HIRMAb-IDUA

    		 Insulin Receptor Metabolic Disease
    Valanafusp alfa (AGT-181) is a brain penetrating recombinant fusion protein of a chimeric monoclonal antibody against the human insulin receptor (HIR) and human iduronidase (IDUA). Valanafusp alfa can be used for the research of Mucopolysaccharidosis type I (MPS I) .
  • HY-P2972
    Arylsulfatase

    		Endogenous Metabolite Others
    Arylsulfatase is a type I enzyme of prokaryotes and eukaryotes. Arylsulfatase is a sulfatase enzyme, is often used in biochemical studies.
  • HY-B1359
    Methylene blue trihydrate

    C.I. Basic Blue 9 trihydrate

    		 Guanylate Cyclase Monoamine Oxidase NO Synthase Parasite Cancer Infection Neurological Disease
    Methylene blue trihydrate (C.I. Basic Blue 9 trihydrate) is a guanylyl cyclase (sGC), monoamine oxidase A (MAO-A) and NO synthase (NOS) inhibitor. Methylene blue trihydrate is a vasopressor and is often used as a dye in several medical procedures. Methylene blue trihydrate has antinociception, antimalarial, antidepressant and anxiolytic activity effects. Methylene Blue trihydrate has the potential for methemoglobinemias, neurodegenerative disorders and ifosfamide-induced encephalopathytreatment.
  • HY-118581
    Coralyne chloride

    		Topoisomerase Cancer
    Coralyne chloride is a protoberberine alkaloid with potent anti-cancer activities. Coralyne chloride acts as a potent topoisomerase I poison and induces Top I mediated DNA cleavage. Coralyne chloride can be used for preparing coralyne derivatives as DNA binding fluorescent probes.
  • HY-12484
    BMH-21

    		DNA/RNA Synthesis Cancer
    BMH-21 is a first-in-class DNA intercalator which inhibits RNA polymerase I (Pol I) transcription. BMH-21 possesses anticancer activity.
  • HY-103559
    HexylHIBO

    		mGluR Neurological Disease
    HexylHIBO is a potent group I mGluR antagonist with Kbs of 140 and 110 μM at mGlu1a and mGlu5a receptors, respectively. HexylHIBO decreased sEPSC in rat.
  • HY-13622A
    Elomotecan

    BN 80927 free base

    		 Topoisomerase Cancer
    Elomotecan (BN 80927 free base) is a potent inhibitor of topoisomerases I and II. Elomotecan is a camptothecin analog belonging to the homocamptothecin family (hCPT). Elomotecan reduces the proliferation of different tumor cells with higher potency than other anticancer agents of reference targeting topoisomerases I and II.
  • HY-N3488
    Isodiospyrin

    		Topoisomerase Bacterial Fungal Cancer Infection
    Isodiospyrin, a natural dimeric naphthoquinone, is a human DNA topoisomerase I (Topoisomerase) inhibitor. Isodiospyrin can prevent both DNA relaxation and kinase activities of human topoisomerase I. Isodiospyrin shows anticancer, antibacterial and antifungal activities.
  • HY-13622
    Elomotecan hydrochloride

    BN 80927

    		 Topoisomerase Cancer
    Elomotecan hydrochloride (BN 80927) is a potent inhibitor of topoisomerases I and II. Elomotecan hydrochloride (BN 80927) is a camptothecin analog belonging to the homocamptothecin family (hCPT). Elomotecan hydrochloride (BN 80927) reduces the proliferation of different tumor cells with higher potency than other anticancer agents of reference targeting topoisomerases I and II.
  • HY-13218
    Acitazanolast

    WP-871

    		 Others Inflammation/Immunology
    Acitazanolast is an orally active antiallergic agent, can inhibit histamine release. Acitazanolast can be used in study of type I anaphylaxis (immediate) caused by IgE antibodies.
  • HY-145707
    BAY-179

    		Mitochondrial Metabolism Cancer
    BAY-179 is a potent, selective, and species cross-reactive complex I inhibitor (IC50=79 µM).
  • HY-W010452
    3-Hydroxybutyric acid sodium

    β-Hydroxybutyric acid sodium

    		 Endogenous Metabolite Metabolic Disease
    3-Hydroxybutyric acid sodium (β-Hydroxybutyric acid sodium) is a metabolite that is elevated in type I diabetes. 3-Hydroxybutyric acid sodium can modulate the properties of membrane lipids.
  • HY-113378
    3-Hydroxybutyric acid

    β-Hydroxybutyric acid

    		 Endogenous Metabolite Metabolic Disease
    3-Hydroxybutyric acid (β-Hydroxybutyric acid) is a metabolite that is elevated in type I diabetes. 3-Hydroxybutyric acid can modulate the properties of membrane lipids.
  • HY-17020A
    Miglustat hydrochloride

    N-Butyldeoxynojirimycin hydrochloride; NB-DNJ hydrochloride; OGT 918 hydrochloride

    		 Glucosylceramide Synthase (GCS) Neurological Disease
    Miglustat (N-Butyldeoxynojirimycin) hydrochloride is an orally active ceramide glucosyltransferase inhibitor. Miglustat hydrochloride can be used for the research of type I gaucher disease.
  • HY-17020
    Miglustat

    N-Butyldeoxynojirimycin; NB-DNJ; OGT 918

    		 Glucosylceramide Synthase (GCS) Neurological Disease
    Miglustat (N-Butyldeoxynojirimycin) is an orally active ceramide glucosyltransferase inhibitor. Miglustat can be used for the research of type I gaucher disease.
  • HY-148161
    L82-G17

    		DNA/RNA Synthesis Cancer
    L82-G17 is an uncompetitive DNA ligase I (Lig I)-selective inhibitor. L82-G17 inhibits the third step of the ligation reaction, phosphodiester bond formation. L82-G17can be used as a probe of the catalytic activity.
  • HY-12071
    LDN193189

    DM-3189

    		 TGF-β Receptor Cancer
    LDN193189 is a potent selective BMP type I receptor (BMP I) inhibitor. LDN-193189 efficiently inhibits transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 values of 5 nM and 30 nM, respectively. LDN-193189 can be used for the research of bone morphogenetic protein signalling, such as fibrodysplasia ossificans progressiva.
  • HY-D0983
    Trypan red

    C.I. 22850

    		 Fluorescent Dye Inflammation/Immunology
    Trypan red is a vital stain.
  • HY-16560
    Camptothecin

    Campathecin; (S)-(+)-Camptothecin; CPT

    		 Topoisomerase ADC Cytotoxin MicroRNA Influenza Virus Apoptosis Fungal Antibiotic Cancer Infection
    Camptothecin (CPT), a kind of alkaloid, is a DNA topoisomerase I (Topo I) inhibitor with an IC50 of 679 nM. Camptothecin (CPT) exhibits powerful antineoplastic activity against colorectal, breast, lung and ovarian cancers, modulates hypoxia-inducible factor-1α (HIF-1α) activity by changing microRNAs (miRNA) expression patterns in human cancer cells.
  • HY-13418
    Dorsomorphin dihydrochloride

    Compound C dihydrochloride; BML-275 dihydrochloride

    		 AMPK TGF-β Receptor Autophagy Cancer
    Dorsomorphin (Compound C) dihydrochloride is a potent, selective and ATP-competitive AMPK inhibitor, with a Ki of 109 nM. Dorsomorphin dihydrochloride inhibits BMP pathway by targeting the type I receptors ALK2, ALK3, and ALK6. Dorsomorphin dihydrochloride induces autophagy.
  • HY-13418A
    Dorsomorphin

    Compound C; BML-275

    		 AMPK TGF-β Receptor Autophagy Cancer
    Dorsomorphin (Compound C) is a selective and ATP-competitive AMPK inhibitor (Ki=109 nM in the absence of AMP). Dorsomorphin (BML-275) selectively inhibits BMP type I receptors ALK2, ALK3, and ALK6. Dorsomorphin induces autophagy.
  • HY-W010452S1
    3-Hydroxybutyric acid-13C4 sodium

    β-Hydroxybutyric acid-13C4 (sodium)

    		 Endogenous Metabolite Metabolic Disease
    3-Hydroxybutyric acid- 13C4 (sodium) is the 13C labeled 3-Hydroxybutyric acid sodium (HY-W010452). 3-Hydroxybutyric acid sodium is a metabolite that is elevated in type I diabetes, and can modulate the properties of membrane lipids[1].
  • HY-W010452S2
    3-Hydroxybutyric acid-13C2 sodium

    β-Hydroxybutyric acid-13C2 (sodium)

    		 Endogenous Metabolite Metabolic Disease
    3-Hydroxybutyric acid- 13C2 (sodium) is the 13C labeled 3-Hydroxybutyric acid sodium (HY-W010452). 3-Hydroxybutyric acid sodium is a metabolite that is elevated in type I diabetes, and can modulate the properties of membrane lipids[1].
  • HY-145304
    DX3-235

    		Mitochondrial Metabolism Cancer
    DX3-235 is an oxidative phosphorylation (OXPHOS) inhibitor. DX3-235 shows nanomolar inhibition of complex I function and ATP production in a galactose-containing medium resulting in significant cytotoxicity.
  • HY-139202
    XVA143

    		Integrin Inflammation/Immunology
    XVA143, an α/β I-like allosteric antagonist, inhibits LFA-1 dependent firm adhesion, while at the same time it enhances adhesion in shear flow and rolling both in vitro and in vivo.
  • HY-13611
    Diflomotecan

    BN 80915

    		 Topoisomerase Cancer
    Diflomotecan (BN 80915) is a potent and orally active inhibitor of topoisomerase I. Diflomotecan (BN 80915) causes enhanced plasma stability and has the superior preclinical anti-tumour activity compared with other established compounds.
  • HY-116933
    Murrayanol

    		Topoisomerase Bacterial Infection Inflammation/Immunology
    Murrayanol is a natural carbazole alkaloid with a variety of biological activities. Murrayanol shows anti-inflammatory, topoisomerase I and topoisomerase II (Topoisomerase) inhibition activities. Murrayanol also as a mosquitocidal and antimicrobial.
  • HY-148820
    Br-Val-Ala-NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT

    		Drug-Linker Conjugates for ADC Topoisomerase Cancer
    Br-Val-Ala-NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT (Formula V) is a agent-linker conjugate that composed of a potent topoisomerase I inhibitor and a linker to make antibody agent conjugate (ADC).
  • HY-152218
    Clathrin-IN-4

    		Dynamin Neurological Disease
    Clathrin-IN-4 (compound 8b), a Wiskostatin (HY-12534) analogue, is a potent inhibitor of clathrin mediated endocytosis with an IC50 of 2.1 μM. Clathrin-IN-4 is a dynamin I GTPase activity inhibitor with an IC50 of 9.1 μM.
  • HY-145303
    DX2-201

    		Mitochondrial Metabolism Cancer
    DX2-201 is a potent and selective oxidative phosphorylation (OXPHOS) complex I inhibitor with an IC50 of 312 nM. DX2-201 has anticancer effects.
  • HY-D0971
    Pyronin Y

    Pyronine G; C.I. 45005

    		 DNA Stain Others
    Pyronin Y (Pyronine G) is a cationic dye that intercalates RNA and has been used to target cell structures including RNA, DNA and organelles. Pyronin Y forms fluorescent complexes with double-stranded nucleic acids (especially RNA) enabling semi-quantitative analysis of cellular RNA. Pyronin Y can be used to identify specific RNA subspecies of ribonuclear proteins complexes in live cells. Storage: protect from light.
  • HY-134315
    8-Nitroguanosine

    		Nucleoside Antimetabolite/Analog Others
    8-Nitroguanosine is a guanosine analogue. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
  • HY-154506
    N2-Phenoxyacetylguanosine

    		Nucleoside Antimetabolite/Analog Cancer
    N2-Phenoxyacetylguanosine is a guanosine analog. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
  • HY-154361
    TLR7 agonist 13

    		Nucleoside Antimetabolite/Analog Cancer
    TLR7 agonist 13 is a guanosine analog. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
  • HY-152430
    8-Hydroxymethyl guanosine

    		Nucleoside Antimetabolite/Analog Cancer
    8-Hydroxymethyl guanosine is a guanosine analog. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
  • HY-154332
    8-(Phenylmethoxy)guanosine

    		Nucleoside Antimetabolite/Analog Cancer
    8-(Phenylmethoxy)guanosine is a guanosine analog. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
  • HY-137406
    1,2'-O-Dimethylguanosine

    		Nucleoside Antimetabolite/Analog Others
    1,2'-O-Dimethylguanosine is a guanosine analogue. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
  • HY-152610
    3′-C-Methylguanosine

    		Nucleoside Antimetabolite/Analog Others
    3′-C-Methylguanosine is a guanosine analogue. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
  • HY-152517
    8-(Methylthio)guanosine

    		Nucleoside Antimetabolite/Analog Others
    8-(Methylthio)guanosine is a guanosine analogue. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
  • HY-152652
    5’(R)-C-Methylguanosine

    		Nucleoside Antimetabolite/Analog Cancer
    5’(R)-C-Methylguanosine is a guanosine analog. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
  • HY-152478
    3’-β-C-Ethynylguanosine

    		Nucleoside Antimetabolite/Analog Cancer
    3’-β-C-Ethynylguanosine is a guanosine analog. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
  • HY-N9251
    Cyclo(Ile-Ala)

    		Others Others
    Cyclo(Ile-Ala) is found in marine actinomycete 11014 I..
  • HY-P1630
    Buforin II

    		Bacterial Infection
    Buforin II, derived from buforin I, a protein isolated from the stomach of the Asian toad Bufo bufo gargarizans, is a potent antimicrobial peptide. Buforin II has antimicrobial activity against a broad spectrum of Gram-positive and Gram-negative bacteria.
  • HY-B0825A
    Fenpyroximate

    		Parasite Mitochondrial Metabolism Infection
    Fenpyroximate is an acaricide and insecticide against many mites and insect pests of agricultural crops and ornamentals. Fenpyroximate is also a strong inhibitor of bovine heart mitochondrial NADH-ubiquinone oxidoreductase (complex I), binds to the ND5 subunit.
  • HY-152216
    Dynamin IN-2

    		Dynamin Neurological Disease
    Dynamin IN-2 (compound 43), a Wiskostatin (HY-12534) analogue, is a potent dynamin inhibitor, with an IC50 of 1.0 μM for dynamin I GTPase. Dynamin IN-2 also blocks clathrin mediated endocytosis (CME), with an IC50 of 9.5 μM.
  • HY-154111
    8-(N-Boc-aminomethyl)guanosine

    		Nucleoside Antimetabolite/Analog Cancer
    8-(N-Boc-aminomethyl)guanosine is a guanosine analog. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
  • HY-152673
    9-(β-D-Xylofuranosyl)guanine

    		Nucleoside Antimetabolite/Analog Cancer
    9-(β-D-Xylofuranosyl)guanine is a guanosine analog. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
  • HY-152742
    8-(N,N-Dimethylaminomethyl)guanosine

    		Nucleoside Antimetabolite/Analog Others
    8-(N,N-Dimethylaminomethyl)guanosine is a guanosine analogue. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
  • HY-N1068
    Xanthinin

    		Others Others
    Xanthinin is a plant growth-regulating compound from Xanthium pennsylvanicum. I.
  • HY-N0822
    Shikonin

    C.I. 75535; Isoarnebin 4

    		 Chloride Channel Pyruvate Kinase NF-κB TNF Receptor HIV AIM2 Cancer
    Shikonin is a major component of a Chinese herbal medicine named zicao. Shikonin is a potent TMEM16A chloride channel inhibitor with an IC50 of 6.5 μM. Shikonin is a specific pyruvate kinase M2 (PKM2) inhibitor and can also inhibit TNF-α and NF-κB pathway. Shikonin decreases exosome secretion through the inhibition of glycolysis. Shikonin inhibits AIM2 inflammasome activation.
  • HY-N4276
    Nortracheloside

    		Others Others
    Nortracheloside is a lignan isolated from Trachelospermum jasminoides (Lindl.) Lem.
  • HY-18600A
    Azimilide dihydrochloride

    NE-10064 dihydrochloride

    		 Potassium Channel Cardiovascular Disease
    Azimilide (NE-10064) dihydrochloride is a class III antiarrhythmic compound, inhibits I(Ks) and I(Kr) in guinea-pig cardiac myocytes and I(Ks) (minK) channels expressed in Xenopus oocytes.
  • HY-18600
    Azimilide

    NE-10064

    		 Potassium Channel Cardiovascular Disease
    Azimilide(NE-10064) is a class III antiarrhythmic compound, inhibits I(Ks) and I(Kr) in guinea-pig cardiac myocytes and I(Ks) (minK) channels expressed in Xenopus oocytes.
  • HY-103660
    18:0 LYSO-PE

    Stearoyl lysophosphatidylethanolamine

    		 Others Neurological Disease
    18:0 LYSO-PE is an agent that can induce [Ca 2+]i increase.
  • HY-128139
    2'-C-Methylguanosine

    2'-C-beta-Methylguanosine

    		 Nucleoside Antimetabolite/Analog Others
    2'-C-Methylguanosine (2'-C-beta-Methylguanosine) is a guanosine analogue. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
  • HY-152991
    6-Deoxo-8-oxo-3’-deoxy-guanosine

    		Others Others
    2′-Deoxy-N-(2-furanylmethyl)guanosine is a guanosine analog. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
  • HY-152493
    3’-O-(2-Methoxyethyl)guanosine

    		Nucleoside Antimetabolite/Analog Others
    3’-O-(2-Methoxyethyl)guanosine is a guanosine analogue. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
  • HY-152993
    2′-Deoxy-N-(2-furanylmethyl)guanosine

    		Others Others
    2′-Deoxy-N-(2-furanylmethyl)guanosine is a guanosine analog. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
  • HY-153368
    IRAK degrader-1

    		IRAK Cancer
    IRAK degrader-1 (example I-3) is a potent IRAK degrader.
  • HY-144641
    Carbonic anhydrase inhibitor 7

    		Carbonic Anhydrase Cancer
    Carbonic anhydrase inhibitor 7 (compound 5b) is a potent inhibitor of human carbonic anhydrase (hCA), with Kis of 6.5 nM, 7.1 nM, 72.1 nM, and 255.8 nM for hCA IX, hCA II, hCA XII and hCA I, respectively.
  • HY-144640
    Carbonic anhydrase inhibitor 6

    		Carbonic Anhydrase Cancer
    Carbonic anhydrase inhibitor 6 (compound 9b) is a potent inhibitor of human carbonic anhydrase (hCA), with Kis of 9.7 nM, 35.2 nM, 88.5 nM, and 91.8 nM for hCA IX, hCA II, hCA XII and hCA I, respectively.
  • HY-101380A
    BU226 hydrochloride

    		Imidazoline Receptor Neurological Disease
    BU226 hydrochloride is a selective imidazoline 2 (I2) receptors ligand with an Ki of 1.4 nM for I2 and an IC50 of 534.5 nM for I1. BU226 hydrochloride can be used for researching antidepressant.
  • HY-154482
    N2-iso-Butyroyl-3’-O-methylguanosine

    		Nucleoside Antimetabolite/Analog Cancer
    N2-iso-Butyroyl-3’-O-methylguanosine is a guanosine analog. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
  • HY-154448
    3,5-Bis-O-(2,4-dichlorobenzyl)guanosine

    		Nucleoside Antimetabolite/Analog Cancer
    3,5-Bis-O-(2,4-dichlorobenzyl)guanosine is a guanosine analog. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
  • HY-154336
    N-[2-[4-(1-Methylethyl)phenoxy]acetyl]guanosine

    		Nucleoside Antimetabolite/Analog Cancer
    N-[2-[4-(1-Methylethyl)phenoxy]acetyl]guanosine is a guanosine analog. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
  • HY-154349
    N2-iso-Butyroyl-2’-O-propargylguanosine

    		Nucleoside Antimetabolite/Analog Cancer
    N2-iso-Butyroyl-2’-O-propargylguanosine is a guanosine analog. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
  • HY-154549
    3’-O-MOE-G(iBu)-2’-phosphoramidite

    		Nucleoside Antimetabolite/Analog Cancer
    3’-O-MOE-G(iBu)-2’-phosphoramidite is a guanosine analog. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
  • HY-152797
    N4-Desmethyl-N5-Methyl wyosine

    		Nucleoside Antimetabolite/Analog Others
    N4-Desmethyl-N5-Methyl wyosine is a guanosine analogue. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
  • HY-154484
    3’-O-Me-G(iBu)-2’-phosphoramidite

    		Nucleoside Antimetabolite/Analog Cancer
    3’-O-Me-G(iBu)-2’-phosphoramidite is a guanosine analog. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
  • HY-152684
    2′-O-2-Propyn-1-ylguanosine

    		Nucleoside Antimetabolite/Analog Others
    2′-O-2-Propyn-1-ylguanosine is a guanosine analogue. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
  • HY-144106
    HCV-IN-33

    		HCV Infection
    HCV-IN-33 (Compound (S)-3i) is an HCV entry inhibitor.
  • HY-116448
    Metaflumizone

    BAS-320I

    		 Sodium Channel Parasite Infection
    Metaflumizone is a semicarbazone insecticide, acts as a potent sodium channel blocker.
  • HY-B2171A
    Carubicin hydrochloride

    Carminomycin hydrochloride; Carminomicin I hydrochloride

    		 Apoptosis Cancer Infection
    Carubicin hydrochloride is a microbially-derived compound. Carubicin hydrochloride is an effective inhibitor of VHL-defective (VHL−/−) CCRCC cell proliferation. Carubicin hydrochloride also induces apoptosis by a mechanism independent of p53 or hypoxia-inducible factor HIF2. Carubicin hydrochloride has the potential for the research of cancer diseases.
  • HY-N6798
    Myriocin

    Thermozymocidin; ISP-I

    		 HCV Antibiotic Infection
    Myriocin (Thermozymocidin), a fungal metabolite could be isolated from Myriococcum albomyces, Isaria sinclairi and Mycelia sterilia, is a potent inhibitor of serine-palmitoyl-transferase (SPT) and a key enzyme in de novo synthesis of sphingolipids. Myriocin suppresses replication of both the subgenomic HCV-1b replicon and the JFH-1 strain of genotype 2a infectious HCV, with an IC50 of 3.5 µg/mL for inhibiting HCV infection.
  • HY-N1166
    Tephrosin

    Deguelinol I; Hydroxydeguelin

    		 EGFR Cancer
    Tephrosin is a natural rotenoid which has potent antitumor activities. Tephrosin induces degradation of of EGFR and ErbB2 by inducing internalization of the receptors.
  • HY-N0864
    Macranthoidin B

    Macranthoiside I

    		 Others Cancer
    Macranthoidin B is a major bioactive saponin in rat plasma after oral administration of extraction of saponins from Flos Lonicerae.
  • HY-N6790
    Nonactin

    Ammonium ionophore I

    		 Potassium Channel Mitochondrial Metabolism Bacterial Influenza Virus Apoptosis Antibiotic Cancer Infection
    Nonactin is a naturally occurring macrotetrolide antibiotic from Streptomyces griseus. Nonactin acts as an ionophore for monovalent cations, including K +, and NH4 +. Nonactin is able to uncouple the oxidative phosphorylation (OXPHOS) of mitochondria. Nonactin selectively induces apoptosis in cell lines harboring active mutant β-catenin. Nonactin inhibits the surface expression of endogenous HSP60.
  • HY-B2171
    Carubicin

    Carminomycin; Carminomicin I

    		 Apoptosis Cancer Infection
    Carubicin (Carminomycin) is a microbially-derived compound. Carubicin is an effective inhibitor of VHL-defective (VHL−/−) CCRCC cell proliferation. Carubicin also induces apoptosis by a mechanism independent of p53 or hypoxia-inducible factor HIF2. Carubicin has the potential for the research of cancer diseases.
  • HY-135780
    3'-Deoxyuridine-5'-triphosphate

    3'-dUTP

    		 Nucleoside Antimetabolite/Analog DNA/RNA Synthesis Endogenous Metabolite Metabolic Disease
    3'-Deoxyuridine-5'-triphosphate (3'-dUTP) is a nucleotide analogue that inhibits DNA-dependent RNA polymerases I and II. 3'-Deoxyuridine-5'-triphosphate strongly and competitively inhibits the incorporations of UTP into RNA with a Ki value of 2.0 μM.
  • HY-152988
    N2-iso-Butyroyl-7'-O-DMT-morpholinoguanine

    		Others Others
    N2-iso-Butyroyl-7'-O-DMT-morpholinoguanine is a guanosine analog. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
  • HY-152992
    7-Cyano-7-deaza-2'-deoxy guanosine

    		Others Others
    7-Cyano-7-deaza-2'-deoxy guanosine is a guanosine analog. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
  • HY-154547
    N2-iso-Butyroyl-3’-O-(methoxyethyl)guanosine

    		Nucleoside Antimetabolite/Analog Cancer
    N2-iso-Butyroyl-3’-O-(methoxyethyl)guanosine is a guanosine analog. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
  • HY-141889
    MLKL-IN-2

    		Mixed Lineage Kinase Inflammation/Immunology
    MLKL-IN-2 is a MLKL inhibitor extracted from patent WO2021224505A1, compound (i).
  • HY-115984
    Carbonic anhydrase inhibitor 8

    		Carbonic Anhydrase Cancer
    Carbonic anhydrase inhibitor 8 (compound R-13), a benzyl-derivative, is a potent human carbonic anhydrase (hCA) inhibitor with Ki values of 60.7 nM, 320.7 nM, 2298 nM for hCA I, hCA II, hCA IV, respectively.
  • HY-152545
    N1,N2-Dimethyl-2’-O-methylguanosine

    		Nucleoside Antimetabolite/Analog Cancer
    N1,N2-Dimethyl-2’-O-methylguanosine is a guanosine analog. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
  • HY-154350
    5'-O-DMT-N2-isobutyryl-2'-O-propargylguanosine

    		Nucleoside Antimetabolite/Analog Cancer
    5'-O-DMT-N2-isobutyryl-2'-O-propargylguanosine is a guanosine analog. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
  • HY-154606
    2'-F-2'-ara-N2-ibu-dG Phosphoramidite

    		Nucleoside Antimetabolite/Analog Cancer
    2'-F-2'-ara-N2-ibu-dG Phosphoramidite is a guanosine analog. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
  • HY-W073825
    N2-iso-Butyryl-2'-O-(2-methoxyethyl)guanosine

    		Nucleoside Antimetabolite/Analog Cancer
    N2-iso-Butyryl-2'-O-(2-methoxyethyl)guanosine is a guanosine analog. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
  • HY-16562
    Irinotecan

    (+)-Irinotecan; CPT-11; VAL-413(free base)

    		 Topoisomerase Autophagy Cancer
    Irinotecan ((+)-Irinotecan) is a topoisomerase I inhibitor, preventing religation of the DNA strand by binding to topoisomerase I-DNA complex.
  • HY-132827
    Ocedurenone

    		Mineralocorticoid Receptor Endocrinology
    Ocedurenone is a corticosteroid receptor antagonist. Ocedurenone can be used for the research of kidney disease (WO2018054357, compound I).
  • HY-132893
    AZ14145845

    		TAM Receptor Cancer
    AZ14145845 is a highly selective type I1/2 dual Mer/Axl kinase inhibitor with in vivo efficacy.
  • HY-D0932
    Sudan IV

    Solvent Red 24; C.I. 26105

    		 Fluorescent Dye Others
    Sudan IV is a lysochrome (fat-soluble dye) diazo dye used for the staining of lipids, triglycerides and lipoproteins on frozen paraffin sections.
  • HY-B1102
    Evans Blue

    Direct Blue 53; C.I. 23860

    		 EAAT2 Others
    Evans Blue is a potent inhibitor of L-glutamate uptake via the membrane bound excitatory amino acid transporter (EAAT).
  • HY-18600AS
    Azimilide-d8 dihydrochloride

    NE-10064-dd8 (dihydrochloride)

    		 Potassium Channel Cardiovascular Disease
    Azimilide-d8 (dihydrochloride) is the deuterium labeled Azimilide dihydrochloride. Azimilide Dihydrochloride (NE-10064 Dihydrochloride) is a class III antiarrhythmic compound, inhibits I(Ks) and I(Kr) in guinea-pig cardiac myocytes and I(Ks) (minK) channels expressed in Xenopus oocytes.
  • HY-154548
    N2-iso-Butyroyl-5’-O-DMT-3’-O-(methoxyethyl)guanosine

    		Nucleoside Antimetabolite/Analog Others
    N2-iso-Butyroyl-5’-O-DMT-3’-O-(methoxyethyl)guanosine is a guanosine analog. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
  • HY-154507
    N2-Phenoxyacetyl-3′,5′-O-(tetraisopropyldisiloxane-1,3-diyl)guanosine

    		Nucleoside Antimetabolite/Analog Cancer
    N2-Phenoxyacetyl-3′,5′-O-(tetraisopropyldisiloxane-1,3-diyl)guanosine is a guanosine analog. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
  • HY-15481
    KU14R

    		Insulin Receptor Metabolic Disease Endocrinology
    KU14R is a new I(3)-R antagonist, which selectively blocks the insulin secretory response to imidazolines.
  • HY-146385
    hCAI/II-IN-1

    		Carbonic Anhydrase Cancer
    hCAI/II-IN-1 (Compound 3h) is a human carbonic anhydrase I and II (hCA I/II) inhibitor with IC50 values of 0.047 µM and 0.024 µM against hCA I and hCA II, respectively.
  • HY-N11537
    2-Methoxy-6-pentadecyl-1,4-benzoquinone

    		Others Others
    2-Methoxy-6-pentadecyl-1,4-benzoquinone (1c) is a pentadecyl derivative that can be isolated from seed oils of different iris plants such as I. pseudacorus, I. missouriensis and I. sibirica.
  • HY-N10495
    Seconeolitsine

    		Antibiotic Bacterial Topoisomerase Infection
    Seconeolitsine, an antibiotic, and is an inhibitor of targeting topoisomerase I (TopA). Seconeolitsine also is a new antimicrobial agent that can inhibit S. pneumoniae growth. Seconeolitsine can inhibit TopA relaxation activity with an IC50 value of 17 μM. Seconeolitsine can be used for the research of S. pneumoniae infections resistant to other antibiotics.
  • HY-112275
    TNF-α-IN-1

    		TNF Receptor Cancer Inflammation/Immunology
    TNF-α-IN-1 is a TNF-α inhibitor extracted from patent US20030096841A1, compound example I-7.
  • HY-152547
    N2-[(N,N-Dimethyl amino]methylene-N1-methyl-2’-O-methylguanosine

    		Nucleoside Antimetabolite/Analog Cancer
    N2-[(N,N-Dimethyl amino]methylene-N1-methyl-2’-O-methylguanosine is a guanosine analog. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
  • HY-154464
    N2-iso-Butyroyl-5'-O-DMT-3'-deoxy-3'-fluoroguanosine

    		Nucleoside Antimetabolite/Analog Cancer
    N2-iso-Butyroyl-5'-O-DMT-3'-deoxy-3'-fluoroguanosine is a guanosine analog. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
  • HY-P1934
    Cyclo(Phe-Pro)

    Cyclo(phenylalanylprolyl); A-64863

    		 HCV Infection
    Cyclo(Phe-Pro) (Cyclo(phenylalanylprolyl)), a Vibrio vulnificus quorum-sensing molecule, inhibits retinoic acid-inducible gene-I (RIG-I) polyubiquitination, through its specific interaction with RIG-I, to blunt IRF-3 activation and type-I IFN production. Cyclo(Phe-Pro) (Cyclo(phenylalanylprolyl)) enhances susceptibility to hepatitis C virus (HCV), as well as Sendai and influenza viruses.
  • HY-108938
    SDZ285428

    		Cytochrome P450 Fungal Parasite Infection
    SDZ285428 is a CYP51 inhibitor. SDZ285428 inhibits Trypanosoma cruzi (TC) CYP51 with I/E2 <1 (5 min) and I/E2=9 (1 h). SDZ285428 inhibits Trypanosoma brucei (TB) CYP51 with I/E2 <1 (5 min) and I/E2=35 (1 h).
  • HY-144468
    IDO1-IN-17

    		Indoleamine 2,3-Dioxygenase (IDO) Cancer
    IDO1-IN-17 (I-4) is an IDO1 inhibitor, with an IC50 of 0.44 μM in hela cells.
  • HY-N7089
    Benzoyleneurea

    		Bacterial Infection
    Benzoyleneurea possesses anti-bacterial activity. Benzoyleneurea scaffold can be used in the synthesis of novel protein geranylgeranyltransferase-I (PGGTase-I) inhibitors.
  • HY-139170
    CAY10746

    		ROCK Metabolic Disease
    CAY10746 is a selective Rho kinase (ROCK) inhibitor. CAY10746 has inhibitory activity for ROCK I, ROCK II with IC50 values of 0.014 μM and 0.003 μM, respectively. CAY10746 can be used for the research of diabetic retinopathy (DR).
  • HY-154351
    N2-iBu-5’-O-DMTr-2’-O-propargylguanosine-3’-CED-phosphoramidite

    		Nucleoside Antimetabolite/Analog Cancer
    N2-iBu-5’-O-DMTr-2’-O-propargylguanosine-3’-CED-phosphoramidite is a guanosine analog. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
  • HY-154483
    N2-iso-Butyroyl-5’-O-(4,4’-dimethoxytrityl)-3’-O-methylguanosine

    		Nucleoside Antimetabolite/Analog Cancer
    N2-iso-Butyroyl-5’-O-(4,4’-dimethoxytrityl)-3’-O-methylguanosine is a guanosine analog. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).
  • HY-13217
    Vanoxerine dihydrochloride

    GBR-12909 dihydrochloride; I893 dihydrochloride

    		 Dopamine Transporter Neurological Disease
    Vanoxerine dihydrochloride (GBR-12909 dihydrochloride) is a competitive, potent, and highly selective dopamine reuptake inhibitor (Ki=1 nM). Vanoxerine dihydrochloride (GBR-12909 dihydrochloride) binds to the target site on the dopamine transporter (DAT).
  • HY-N10181
    11-Keto fusidic acid

    Simplifusidic acid I

    		 Bacterial Infection
    11-Keto fusidic acid shows strong antibacterial activity toward Staphylococcus aureus with an MIC value of 0.078 μg/mL.
  • HY-106668
    Isepamicin

    Sch 21420

    		 Antibiotic Bacterial Infection
    Isepamicin (Sch 21420) is an aminoglycoside antibacterial. Isepamicin has better activity against strains producing type I 6'-acetyltransferase. Isepamicin’s antibacterial spectrum includes Enterobacteriaceae and staphylococci. Anaerobes, Neisseriaceae and streptococci are resistant. Isepamicin exhibits a strong concentration-dependent bactericidal effect, a long post-antibiotic effect (several hours) and induces adaptive resistance.
  • HY-12598
    (S)-3,5-DHPG

    		mGluR Neurological Disease
    (S)-3,5-DHPG is a weak, but selective group I metabotropic glutamate receptors (mGluRs) agonist with Ki values of 0.9 µM and 3.9 µM for mGluR1a and mGluR5a, respectively. (S)-3,5-DHPG exhibits anxiolytic activity in rats subjected to hypoxia.
  • HY-145483
    PROTAC IRAK4 degrader-7

    		PROTACs IRAK Cancer
    PROTAC IRAK4 degrader-7 (Compound I-417) is an orally active PROTAC IRAK4 degrader with antitumor activities.
  • HY-N11106
    Gardenin C

    		Others Others
    Gardenin C, a flavone, can be isolated from the Gardenia lucida.
  • HY-138746
    EGFR-IN-15

    		EGFR Cancer
    EGFR-IN-15 (compound I-005) is a EGFR inhibitor with an IC50 of 4 nM. EGFR-IN-15 can be used for oncological diseases research.
  • HY-19990
    ALK kinase inhibitor-1

    		Anaplastic lymphoma kinase (ALK) Cancer
    ALK kinase inhibitor-1 is an anaplastic lymphoma kinase (ALK) inhibitor extracted from patent US20130261106A1 compound I-202.
  • HY-144466
    IDO1-IN-16

    		Indoleamine 2,3-Dioxygenase (IDO) Cancer
    IDO1-IN-16 (I-1) is an IDO1 inhibitor targeting holo-IDO1, with an IC50 of 127 nM.
  • HY-W008719
    MPP+ iodide

    		Mitochondrial Metabolism Neurological Disease
    MPP+ iodide, a toxic metabolite of the neurotoxin MPTP, causes symptom of Parkinson's disease in animal models by selectively destroying dopaminergic neurons in substantia nigra. MPP+ iodide is taken up by the dopamine transporter into dopaminergic neurons where it exerts its neurotoxic action on mitochondria by affecting complex I of the respiratory chain. MPP+ iodide is also a high affinity substrate for the serotonin transporter (SERT).
  • HY-13456
    LY-404187

    		iGluR Neurological Disease
    LY-404187 is a potent, selective and centrally active positive allosteric modulator of AMPA receptors, with the EC50s of 5.65, 0.15, 1.44, 1.66 and 0.21 µM for GluR1i, GluR2i, GluR2o, GluR3i and GluR4i, respectively. LY-404187 has therapeutic potential in a number of psychiatric disorders and neurodegenerative diseases.
  • HY-100530B
    Sp-cAMPS

    		PKA Phosphodiesterase (PDE) Metabolic Disease Neurological Disease
    Sp-cAMPS, a cAMP analog, is potent activator of cAMP-dependent PKA I and PKA II. Sp-cAMPS is also a potent, competitive phosphodiesterase (PDE3A) inhibitor with a Ki of 47.6 µM. Sp-cAMPS binds the PDE10 GAF domain with an EC50 of 40 μM.
  • HY-100530C
    Sp-cAMPS sodium salt

    		PKA Phosphodiesterase (PDE) Metabolic Disease Neurological Disease
    Sp-cAMPS sodium salt, a cAMP analog, is potent activator of cAMP-dependent PKA I and PKA II. Sp-cAMPS sodium salt is also a potent, competitive phosphodiesterase (PDE3A) inhibitor with a Ki of 47.6 µM. Sp-cAMPS sodium salt binds the PDE10 GAF domain with an EC50 of 40 μM.
  • HY-139316
    PROTAC IRAK4 degrader-5

    		IRAK PROTACs Cancer
    PROTAC IRAK4 degrader-5 is a Cereblon-based IRAK4 degrader extracted from patent US20190192668A1, compound I-171.
  • HY-145587
    Paltimatrectinib

    		Tyrosinase Trk Receptor Cancer Inflammation/Immunology
    Paltimatrectinib (compound I-147) is a potent tyrosine kinase inhibitor with an IC50 of <10 nM for tropomyosin kinases A (TrkA). Paltimatrectinib has the potential for cancer and inflammatory diseases.
  • HY-147135
    TEAD-IN-3

    		YAP Cancer
    TEAD-IN-3 (compound I-177) is a potent TEAD transcription factor inhibitor. TEAD-IN-3 can be used for the research of proliferative diseases (such as cancer) .
  • HY-123052
    Ac-PAL-AMC

    		Proteasome Inflammation/Immunology
    Ac-PAL-AMC is a fluorogenic substrate specific for 20S proteasome LMP2/β1i activity.
  • HY-B0817
    Pyridaben

    		Parasite Infection
    Pyridaben is a mitochondrial electron transport inhibitor (METI) acaricide that promotes the formation of damaging oxygen and nitrogen radicals. Pyridaben selectively inhibits complex I (NADH dehydrogenase) with an IC50 value of 2.4 nM (assay sites: rat liver and bovine heart mitochondria). Pyridaben also significantly inhibits rat mitochondrial mtNOS function.
  • HY-112037
    IACS-010759

    IACS-10759

    		 Mitochondrial Metabolism Apoptosis Cancer
    IACS-010759 is an orally active, potent mitochondrial complex I of oxidative phosphorylation (OXPHOS) inhibitor. IACS-010759 inhibits proliferation and induces apoptosis in models of brain cancer and acute myeloid leukemia (AML) reliant on OXPHOS. IACS-010759 has the potential for relapsed/refractory AML and solid tumors research.
  • HY-N6621
    Hippeastrine

    		Topoisomerase Cancer
    Hippeastrine, an active alkaloid, exhibits a good dose-dependent inhibitory effect against topoisomerase I (Top I) with an IC50 at 7.25 μg/mL. Antiproliferative and anticancer activities.
  • HY-145107
    HPK1-IN-19

    		MAP4K Cancer Inflammation/Immunology
    HPK1-IN-19 is a hematopoietic progenitor kinase 1 (HPK1) inhibitor extracted from patent WO2018102366A1 compound I-47.
  • HY-10257
    BAY 11-7085

    BAY 11-7083

    		 NF-κB Ferroptosis Apoptosis Cancer
    BAY 11-7085 (BAY 11-7083) is an inhibitor of NF-κB activation and phosphorylation of IκBα; it stabilizes IκBα with an IC50 of 10 μM.
  • HY-110005
    Sp-cAMPS triethylamine

    		PKA Phosphodiesterase (PDE) Metabolic Disease Neurological Disease
    Sp-cAMPS triethylamine, a cAMP analog, is potent activator of cAMP-dependent PKA I and PKA II. Sp-cAMPS triethylamine is also a potent, competitive phosphodiesterase (PDE3A) inhibitor with a Ki of 47.6 µM. Sp-cAMPS triethylamine binds the PDE10 GAF domain with an EC50 of 40 μM.
  • HY-W008343
    1,3-Dimethyluracil

    		Endogenous Metabolite Metabolic Disease
    1,3-Dimethyluracil is a pyrimidone derives from a uracil. 1,3-Dimethyluracil found occasionally in human urine. 1,3-Dimethyluracil shows inhibition activity against hCA I and hCA II (human carbonic anhydrase) with Ki of 316.2 μM and 166.4 μM, respectively.
  • HY-10432
    A 83-01

    		TGF-β Receptor Cancer
    A 83-01 is a potent inhibitor of TGF-β type I receptor ALK5 kinase, type I nodal receptor ALK4 and type I nodal receptor ALK7, with IC50s of 12 nM, 45 nM and 7.5 nM against the transcription induced by ALK5, ALK4 and ALK7, respectively.
  • HY-112037A
    IACS-010759 hydrochloride

    IACS-10759 hydrochloride

    		 Mitochondrial Metabolism Apoptosis Cancer
    IACS-010759 hydrochlorideis an orally active, potent mitochondrial complex I of oxidative phosphorylation (OXPHOS) inhibitor. IACS-010759 hydrochlorideinhibits proliferation and induces apoptosis in models of brain cancer and acute myeloid leukemia (AML) reliant on OXPHOS. IACS-010759 hydrochloride has the potential for relapsed/refractory AML and solid tumors research.
  • HY-16562S1
    Irinotecan-d10 hydrochloride

    		Topoisomerase Autophagy Cancer
    Irinotecan-d10 (hydrochloride) is the deuterium labeled Irinotecan. Irinotecan ((+)-Irinotecan) is a topoisomerase I inhibitor, preventing religation of the DNA strand by binding to topoisomerase I-DNA complex[1][2].
  • HY-142518
    EGFR-IN-26

    		VEGFR Cancer
    EGFR-IN-26 is a EGFR inhibitor extracted from patent WO2019162323A1 compound I-028. EGFR-IN-26 can be used for the research of cancer.
  • HY-16562S
    Irinotecan-d10

    (+)-Irinotecan-d10; CPT-11-d10; VAL-413-d10

    		 Topoisomerase Autophagy Cancer
    Irinotecan-d10 is a deuterium labeled Irinotecan ((+)-Irinotecan). Irinotecan ((+)-Irinotecan) is a topoisomerase I inhibitor, preventing religation of the DNA strand by binding to topoisomerase I-DNA complex[1].
  • HY-15871
    GGTI298 Trifluoroacetate

    		Ras Apoptosis Cancer
    GGTI298 Trifluoroacetate is a CAAZ peptidomimetic geranylgeranyltransferase I (GGTase I) inhibitor, which can inhibit Rap1A with IC50 of 3 μM; little effect on Ha-Ras with IC50 of >20 μM.
  • HY-101692
    AZ-1355

    		Prostaglandin Receptor Metabolic Disease Endocrinology
    AZ-1355 is an effctive lipid-lowering compound, which also inhibits platelet aggregation in vivo and elevates the prostaglandin I2/thromboxane A2 ratio in vitro.
  • HY-N2063
    12-Ethyl-9-hydroxycamptothecin

    		Topoisomerase Others
    12-Ethyl-9-hydroxycamptothecin is a derivative of Camptothecin. Camptothecin (CPT), a kind of alkaloid, is a DNA topoisomerase I (Topo I) inhibitor with an IC50 of 679 nM.
  • HY-N3710
    Dehydrocrenatidine

    Kumujian G; O-Methylpicrasidine I

    		 JAK Apoptosis Cancer Neurological Disease
    Dehydrocrenatidine, a natural alkaloid, is a specific JAK inhibitor. Dehydrocrenatidine inhibits voltage-gated sodium channels and ameliorates mechanic allodia in a rat model of neuropathic pain.
  • HY-10324
    D4476

    Casein Kinase I Inhibitor

    		 Casein Kinase Autophagy Apoptosis Cancer
    D4476 is a potent, selective and cell-permeable inhibitor of casein kinase 1(CK1) with an IC50 value of 0.3 μM in vitro.
  • HY-13960
    GSK1324726A

    I-BET726

    		 Epigenetic Reader Domain Apoptosis Cancer
    GSK1324726A is a novel, potent, and selective inhibitor of BET proteins with high affinity to BRD2 (IC50=41 nM), BRD3 (IC50=31 nM), and BRD4 (IC50=22 nM).
  • HY-W008820
    Glutaric acid

    		Endogenous Metabolite Metabolic Disease
    Glutaric acid, C5 dicarboxylic acid, is an intermediate during the catabolic pathways of lysine and tryptophan. Glutaric acid affects pericyte contractility and migration. Glutaric acid is an indicator of glutaric aciduria type I.
  • HY-148099
    USP1-IN-2

    		Deubiquitinase Cancer
    USP1-IN-2 (Compound I-193) is a potent ubiquitin-specific protease 1 (USP1) inhibitor with an IC50 of less than about 50 nM.
  • HY-131334
    AMPK activator 4

    		AMPK Metabolic Disease
    AMPK activator 4 is a potent AMPK activator without inhibition of mitochondrial complex I. AMPK activator 4 selectively activates AMPK in the muscle tissues. AMPK activator 4 dose-dependently improves glucose tolerance in normal mice, and significantly lowers fasting blood glucose level and ameliorates insulin resistance in db/db diabetic mice. Anti-hyperglycemic effect.
  • HY-148094
    TREM2 agonist-1

    		Others Neurological Disease
    TREM2 agonist-1 (I-246) is a triggering receptor expressed on myeloid cells 2 (TREM2) agonist (EC50 between 3.0 μM and 100 μM).
  • HY-150545
    AChE-IN-21

    		Cholinesterase (ChE) Neurological Disease
    AChE-IN-21 (Compound I-8) is a potent, selective and orally active AChE inhibitor with an IC50 of 2.66 nM. AChE-IN-21 displays excellent BBB permeability in vitro.
  • HY-113970A
    Nebracetam hydrochloride

    WEB 1881 FU hydrochloride

    		 mAChR Neurological Disease
    Nebracetam hydrochloride, a nootropic M1-muscarinic agonist, induces a rise of intracellular Ca 2+ concentration. Nebracetam hydrochloride exhibits an EC50 of 1.59 mM for elevating [Ca 2+]i.
  • HY-16231
    GGTI-2418

    		ROS Kinase Apoptosis Cancer
    GGTI-2418 is a highly potent, competitive, and selective geranylgeranyltransferase I (GGTase I) inhibitor. GGTI-2418 inhibits GGTase I and FTase activities with IC50s of 9.5 nM and 53 μM, respectively. GGTI-2418 also increases p27(Kip1) and induces significant regression of breast tumors.
  • HY-D0256
    Direct Black 38

    Chlorazol Black E; Ferristatin II disodium; C.I. 30235

    		 DNA/RNA Synthesis Others
    Direct Black 38 (Chlorazol Black E) is an azo dye. Direct Black 38 induces unscheduled DNA synthesis in liver and micronucleus in bone marrow of rats in vivo. Storage: protect from light.
  • HY-14821
    Namitecan

    ST-1968

    		 Topoisomerase Cancer
    Namitecan is a potent topoisomerase I inhibitor, with antitumor property.
  • HY-U00232
    Bidisomide

    SC40230

    		 Others Cardiovascular Disease
    Bidisomide (SC40230) is a class I antiarrhythmic agent.
  • HY-148095
    TREM2 agonist-2

    		Others Neurological Disease
    TREM2 agonist-2 (I-192) is an orally active triggering receptor expressed on myeloid cells 2 (TREM2) agonist (EC50<0.05 μM).
  • HY-15466
    Izorlisib

    CH5132799

    		 PI3K Cancer
    Izorlisib (CH5132799) is a selective class I PI3K inhibitor. Izorlisib inhibits class I PI3Ks, particularly PI3Kα, with an IC50 of 14 nM.
  • HY-152244
    PARP7-IN-14

    		PARP Cancer
    PARP7-IN-14 (I-1) is a potent and selective PARP7 inhibitor with an IC50 value of 7.6 nM. PARP7-IN-14 has anticancer activity.
  • HY-W062216
    2-Aminoimidazole

    		Bacterial Arginase Infection
    2-Aminoimidazole is a potent antibiofilm agent that can be used as an adjuvant to antimicrobial. 2-aminoimidazoles disrupts the ability of bacteria to protect themselves by inhibiting biofilm formation and genetically-encoded antibiotic resistance traits. 2-Aminoimidazole is also a weak noncompetitive inhibitor of human arginase I with a Ki of 3.6 mM.
  • HY-125930A
    T-2513 hydrochloride

    		Topoisomerase DNA/RNA Synthesis Cancer
    T-2513 hydrochloride is a selective topoisomerase I inhibitor. T-2513 hydrochloride binds covalently to and stabilizes the topoisomerase I-DNA complex and inhibits DNA replication and RNA synthesis, ultimately leading to cell death.
  • HY-125930
    T-2513

    		Topoisomerase DNA/RNA Synthesis Cancer
    T-2513 is a selective topoisomerase I inhibitor. T-2513 binds covalently to and stabilizes the topoisomerase I-DNA complex and inhibits DNA replication and RNA synthesis, ultimately leading to cell death.
  • HY-147107
    OfHex1-IN-2

    		Others Others
    OfHex1-IN-2 (compound I-79) is a potent β-N-acetylhexosaminidase OfHex1 inhibitor. OfHex1-IN-2 can be used in control of insect.
  • HY-100876
    GGTI298

    		Ras Apoptosis Cancer
    GGTI298 is a CAAZ peptidomimetic geranylgeranyltransferase I (GGTase I) inhibitor, strongly inhibiting the processing of geranylgeranylated Rap1A with little effect on processing of farnesylated Ha-Ras, with IC50 values of 3 and > 20 μM in vivo, respectively.
  • HY-112197
    PKG drug G1

    		Others Cardiovascular Disease
    PKG agent G1 targets C42 of PKG Iα. PKG agent G1 can couple to vasodilation and blood pressure lowering by a C42 PKG Iα-independent mechanism.
  • HY-E70008
    Lumbokinase capsules

    		Sirtuin Inflammation/Immunology
    Lumbokinase capsules attenuates myocardial ischemia-reperfusion (I-R) injury through the activation of Sirt1 signaling, and thus enhances autophagic flux and reduces I-R-induced oxidative damage, inflammation and apoptosis.
  • HY-143545
    RET-IN-8

    		RET Cancer
    RET-IN-8 is a rearranged during transfection (RET) kinase inhibitor extracted from patent WO2021093720A1 compound I-1. RET-IN-8 can be used for the research of cancer.
  • HY-19825
    Rebeccamycin

    		Topoisomerase ADC Cytotoxin Antibiotic Cancer
    Rebeccamycin, an antitumor antibiotic, inhibits DNA topoisomerase I. Rebeccamycin appears to exert its primary antineoplastic effect by poisoning topoisomerase I and has negligible effect on protein kinase C and topoisomerase II.
  • HY-N10791
    Neobritannilactone B

    		Others Infection
    Neobritannilactone B, a sesquiterpene, can be isolated from the chloroform fraction of the I. britannica. Neobritannilactone B is cytotoxic. Other extracts of I. britannica are also Dihydrofolate reductase (DHFR) inhibitors, which inhibit Shigella dysenteriae type 1.
  • HY-P2983
    Angiotensin-converting enzyme

    ACE; kininase II; CD143

    		 Endogenous Metabolite Cardiovascular Disease
    Angiotensin-converting enzyme (ACE) is a dicarboxypeptidase, it converts inactive Angiotensin I (Ang I) to active Ang II and degrades active bradykinin (BK). Angiotensin-converting enzyme is a potent vasoconstrictor, is often used in biochemical studies.
  • HY-19332
    Kifunensine

    FR-900494

    		 Others Inflammation/Immunology
    Kifunensine, a potent and selective inhibitor of class I α-mannosidases isolated from Actinomycete, prevents α-mannosidases I from trimming mannose residues on glycoproteins. Kifunensine inhibits ERAD.
  • HY-15320
    NBI-74330

    		CXCR Inflammation/Immunology Endocrinology
    NBI-74330 is a potent antagonist for CXCR3, and exhibits potent inhibition of ( 125I)CXCL10 and ( 125I)CXCL11 specific binding with Ki of 1.5 and 3.2 nM, respectively.
  • HY-107578
    Macbecin

    Macbecin I; NSC 330499

    		 HSP Cancer
    Macbecin is a stable HSP90 inhibitor by binding to the ATP-binding site with an IC50 of 2 μM and a Kd of 0.24 μM. Macbecin exhibits antitumor and cytocidal activities.
  • HY-100110
    KNK437

    Heat Shock Protein Inhibitor I

    		 HSP Cancer
    KNK437 is a HSP inhibitor, and inhibits the induction of HSP105, HSP70, and HSP40.
  • HY-N0077
    Ginkgolic Acid

    Ginkgolic acid (15:1); Ginkgolic acid I; Romanicardic acid

    		 E1/E2/E3 Enzyme Cancer
    Ginkgolic Acid is a natural compound that inhibits SUMOylation with an IC50 of 3.0 μM in in vitro assay.
  • HY-13217A
    Vanoxerine

    GBR 12909; I893

    		 Dopamine Transporter Neurological Disease
    Vanoxerine (GBR-12909) is a competitive, potent, and highly selective dopamine reuptake inhibitor (Ki=1 nM). Vanoxerine (GBR-12909) binds to the target site on the dopamine transporter (DAT).
  • HY-139315
    PROTAC IRAK4 degrader-4

    		PROTACs IRAK Cancer
    PROTAC IRAK4 degrader-4 is a Cereblon-based PROTAC as interleukin-1 receptor-associated kinase 4 (IRAK4) degrader extracted from patent US20190192668A1, compound I-127.
  • HY-107593
    PS-1145 dihydrochloride

    		IKK Inflammation/Immunology
    PS-1145 (dihydrochloride) is a potent IκB kinase-2 inhibitor with an IC50 value of 88 nM. PS-1145 (dihydrochloride) inhibits activity of NF-κB by blocking IκB kinase phosphorylation in tumor-bearing rats.
  • HY-139317
    PROTAC IRAK4 degrader-6

    		PROTACs IRAK Cancer
    PROTAC IRAK4 degrader-6 is a Cereblon-based PROTAC as interleukin-1 receptor-associated kinase 4 (IRAK4) degrader extracted from patent US20190192668A1, compound I-172.
  • HY-W008820S
    Glutaric acid-d6

    		Endogenous Metabolite Metabolic Disease
    Glutaric acid-d6 is the deuterium labeled Glutaric acid. Glutaric acid is an intermediate during the catabolic pathways of lysine and tryptophan. Glutaric acid affects pericyte contractility and migration. Glutaric acid is an indicator of glutaric aciduria type I[1][2][3].
  • HY-128829
    Kv3 modulator 2

    		Potassium Channel Inflammation/Immunology
    Kv3 modulator 2 (formula (I)) is a potent Kv3 channels modulator extracted from patent WO2018109484A1, compound formula (I) , has analgesic activity and is used in the prophylaxis or treatment of related disorders.
  • HY-U00159
    McN3716

    Methyl palmoxirate; NSC359682

    		 Mitochondrial Metabolism Metabolic Disease
    McN3716 is a carnitine palmitoyltransferase I (CPT-1) inhibitor.
  • HY-13768A
    Topotecan Hydrochloride

    SKF 104864A Hydrochloride; NSC 609669 Hydrochloride

    		 Topoisomerase Autophagy Apoptosis Cancer
    Topotecan Hydrochloride (SKF 104864A Hydrochloride) is a Topoisomerase I inhibitor with potent antineoplastic activities.
  • HY-14812
    Karenitecin

    Cositecan; BNP 1350

    		 Topoisomerase Cancer
    Karenitecin (Cositecan) is a topoisomerase I inhibitor, with potent anti-cancer activity.
  • HY-N5028
    Enmein

    		Others Inflammation/Immunology
    Enmein is isolated from I. serra with immunosuppressive effect.
  • HY-N10115
    Huanglongmycin N

    		Topoisomerase Cancer
    Huanglongmycin N is a DNA topoisomerase I inhibitor (EC50 = 14 μM).
  • HY-105661
    IMD-0560

    		IKK Cancer
    IMD-0560 is a novel IκB kinase β inhibitor.
  • HY-B0483
    Tioxolone

    		Carbonic Anhydrase Metabolic Disease
    Tioxolone, a metalloenzyme carbonic anhydrase I inhibitor, is an anti-acne preparation.
  • HY-P0030
    5-Tamra-DRVYIHP

    		Fluorescent Dye Others
    5-Tamra-DRVYIHP i a Peptide with TAMRA labeling oligonucleotide.
  • HY-146115
    TRK-IN-19

    		Trk Receptor Cancer
    TRK-IN-19 (Compound I-10 ) is a potent inhibitor of TRK (TRKA IC50 = 1.1 nM, TRKA G595R IC50 = 5.3 nM). TRK-IN-19 has the potential for the research of cancer diseases.
  • HY-145046
    SOS1-IN-3

    		Ras Cancer
    SOS1-IN-3 is a potent SOS1 (son of sevenless homolog 1) inhibitor with an IC50 of 5 nM. SOS1-IN-3 has anticancer effects (WO2019122129A1; compound I-1).
  • HY-147093
    vc-PAB-DMEA-PNU159682

    		ADC Linker Cancer
    vc-PAB-DMEA-PNU159682 (compound I.47) can be used to synthesize the ADC molecule based on Sulfomaleimide-based Linker. vc-PAB-DMEA-PNU159682 has good serum stability.
  • HY-50856S
    Deuruxolitinib

    CTP-543; Ruxolitinib d8; Deuterated Ruxolitinib

    		 JAK Inflammation/Immunology
    Deuruxolitinib, a deuterated Ruxolitinib (HY-50856), modulates the activity of JAK1/JAK2. Deuruxolitinib can be used for the research hair loss disorders (from patent WO2017192905A1, compound I).
  • HY-113133
    Kojibiose

    		Glucosidase Infection Metabolic Disease Inflammation/Immunology
    Kojibiose, an orally active prebiotic disaccharide, can specifically inhibit the activity of α-glucosidase I. kojibiose is a proliferation factor for Bifidobacterium, lactic acid bacteria, and eubacteria. kojibiose is a low-calorie sweetener capable of increasing the absorption of iron. Kojibiose exhibits antitoxic activity. Kojibiose reduces hepatic expression of inflammatory markers in vivo.
  • HY-D0256A
    Direct Black 38 free acid

    Chlorazol Black E free acid; Ferristatin II; C.I. 30235 free acid

    		 DNA/RNA Synthesis Inflammation/Immunology
    Direct Black 38 free acid is a polysulphonated dye. Direct Black 38 free acid promotes degradation of transferrin receptor-1 in vitro and in vivo. Storage: protect from light.
  • HY-75161
    (-)-Menthol

    		TRP Channel Endogenous Metabolite Cancer
    (-)-Menthol is a key component of peppermint oil that binds and activates transient receptor potential melastatin 8 (TRPM8), a Ca 2+-permeable nonselective cation channel, to increase [Ca 2+]i. Antitumor activity.
  • HY-12071G
    LDN193189

    DM-3189

    		 TGF-β Receptor Cancer
    LDN193189 (DM-3189) (GMP) is LDN193189 (HY-12071) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. LDN193189 is selective BMP type I receptor inhibitor.
  • HY-13566A
    Belotecan hydrochloride

    CKD-602

    		 Topoisomerase Cancer
    Belotecan hydrochloride (CKD-602 hydrochloride), a Topoisomerase I inhibitor, is a synthetic camptothecin derivative.
  • HY-U00432
    S-MTC

    		NO Synthase Neurological Disease
    S-MTC is a selective type I nitric oxide synthase (NOS) inhibitor.
  • HY-18008
    PS-1145

    		IKK Apoptosis Cancer
    PS-1145 is an IκB kinase (IKK) inhibitor with an IC50 of 88 nM.
  • HY-W008820S1
    Glutaric acid-d4

    		Endogenous Metabolite Metabolic Disease
    Glutaric acid-d4 is the deuterium labeled Glutaric acid. Glutaric acid, C5 dicarboxylic acid, is an intermediate during the catabolic pathways of lysine and tryptophan. Glutaric acid affects pericyte contractility and migration. Glutaric acid is an indicator of glutaric aciduria type I[1][2][3].
  • HY-W008820S2
    Glutaric acid-d2

    		Endogenous Metabolite Metabolic Disease
    Glutaric acid-d2 is the deuterium labeled Glutaric acid. Glutaric acid, C5 dicarboxylic acid, is an intermediate during the catabolic pathways of lysine and tryptophan. Glutaric acid affects pericyte contractility and migration. Glutaric acid is an indicator of glutaric aciduria type I[1][2][3].
  • HY-13686
    PQ401

    		IGF-1R Apoptosis Cancer
    PQ401 is a potent inhibitor of IGF-IR signaling. PQ401 inhibits IGF-I-stimulated IGF-IR autophosphorylation with an IC50 of 12.0 μM in a series of studies in MCF-7 cells. PQ401 is effective at inhibiting IGF-I-stimulated growth of MCF-7 cells (IC50, 6 μM). PQ401 is a potential agent for breast and other IGF-I-sensitive cancers. PQ401 induces caspase-mediated apoptosis.
  • HY-B1416A
    Efaroxan hydrochloride

    		Adrenergic Receptor Imidazoline Receptor Metabolic Disease Cardiovascular Disease
    Efaroxan hydrochloride is a potent, selective and orally active α2-adrenoceptor antagonist, with antidiabetic activity. Efaroxan hydrochloride is a selective I1-Imidazoline receptor antagonist. Efaroxan hydrochloride can be used for the research of cardiovascular disease.
  • HY-100904
    RX 801077 hydrochloride

    2 BFI

    		 Imidazoline Receptor Inflammation/Immunology Neurological Disease
    RX 801077 hydrochloride (2 BFI) is a selective imidazoline I2 receptor (I2R) agonist with a Ki value of 70.1 nM. RX 801077 hydrochlorideshows anti-inflammation and neuroprotection. RX 801077 hydrochloride has the potential for the research of traumatic brain injury (TBI).
  • HY-110243
    CAIX Inhibitor S4

    		Carbonic Anhydrase Cancer
    CAIX Inhibitor S4 is a potent and selective inhibitor of carbonic anhydrase IX/XII (CA IX/XII), with a Ki of 7 nM and 2 nM, respectively. CAIX Inhibitor S4 also inhibits CA II and CA I (Ki=546 and 5600 nM, respectively). CAIX Inhibitor S4 can inhibit the number of lung metastasis in orthotopic MDA-MB-231 mouse model without affecting primary tumor growth.
  • HY-N0510A
    Aristolochic acid sodium salt

    Aristolochic acid I sodium; TR 1736 sodium; Sodium aristolochate

    		 Biochemical Assay Reagents Others
    Aristolochic acid sodium salt (Sodium aristolate 1) is a component of some Chinese herbal medicines and is responsible for nephrotoxicity. It is a proagent that is activated by reduction of nitro groups to amines, resulting in the formation of cytotoxic DNA adducts.
  • HY-15588
    L189

    		DNA/RNA Synthesis Cancer
    L189 is a DNA ligase inhibitor. L189 has inhibition effect for DNA Ligase I, III and IV with IC50 values of 5 μM, 9 μM and 5 μM, respectively. L189 has no cytotoxicity and individually increase cell death. L189 can be used for the research of cancer.
  • HY-16228
    Genz-644282

    		Topoisomerase Cancer
    Genz-644282 is a non-camptothecin topoisomerase I inhibitor, used for cancer research.
  • HY-16568
    Irinotecan hydrochloride trihydrate

    (+)-Irinotecan hydrochloride trihydrate; CPT-11 hydrochloride trihydrate

    		 Topoisomerase Autophagy Cancer
    Irinotecan hydrochloride trihydrate ((+)-Irinotecan hydrochloride trihydrate) is a topoisomerase I inhibitor with antitumor activity.
  • HY-100052
    6-Hydroxybentazon

    6-Hydroxybentazone

    		 Drug Metabolite Others
    6-Hydroxybentazon is a phase I metabolite of bentazone, and bentazone is a chemical for use in herbicides.
  • HY-143766
    Cap-dependent endonuclease-IN-13

    		Influenza Virus Infection
    Cap-dependent endonuclease-IN-13 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-13 has the potential for the research of influenza virus infection (only influenza A) (extracted from patent WO2021180147A1, compound I-1).
  • HY-114147
    Tuberculosis inhibitor 3

    		Bacterial Infection Inflammation/Immunology
    Tuberculosis inhibitor 3 (compound 2i) displays potent anti-TB activity (MIC < 0.016 μg/mL) against agent-sensitive/resistant MTB strains. Tuberculosis inhibitor 3 (compound 2i) shows acceptable PK profiles with oral bioavailability.
  • HY-147829
    hCAXII-IN-2

    		Carbonic Anhydrase Cancer
    hCAXII-IN-2 (compound 5i) is a potent human carbonic anhydrase XII (hCA XII) and hCA IX inhibitor with Ki values of 84.2 nM and 268.5 nM, respectively. hCAXII-IN-2 shows less active against hCA I and hCA II.
  • HY-143752
    Cap-dependent endonuclease-IN-8

    		Influenza Virus Infection
    Cap-dependent endonuclease-IN-8 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-8 inhibits replication of orthomyxoviruses (including influenza A, influenza B and influenza C) (extracted from patent CN111410661A, compound I-196).
  • HY-136546
    Stafia-1

    		STAT Cancer
    Stafia-1 is a potent STAT5a inhibitor (K i=10.9 μM, IC50=22.2 μM). Stafia-1 displays high selectivity over STAT5b and other STAT family members.
  • HY-123159
    AKI603

    		Aurora Kinase Cancer
    AKI603 is an inhibitor of Aurora kinase A (AurA), with an IC50 of 12.3 nM. AKI603 is developed to overcome resistance mediated by BCR-ABL-T315I mutation. AKI603 exhibits strong anti-proliferative activity in leukemic cells.
  • HY-N0009
    Geniposide

    		Amyloid-β Influenza Virus Neurological Disease
    Geniposide is an iridoid glucoside extracted from Gardenia jasminoidesEllis fruits; exhibits a varity of biological activities such as anti-diabetic, antioxidative, antiproliferative and neuroprotective activities.
  • HY-N0925
    Tetrahydroberberine

    Canadine

    		 Dopamine Receptor Neurological Disease
    Tetrahydroberberine is an isoquinoline alkaloid isolated from corydalis tuber; has micromolar affinity for dopamine D(2) (pK(i) = 6.08) and 5-HT(1A) (pK(i) = 5.38) receptors but moderate to no affinity for other relevant serotonin receptors (5-HT(1B), 5-HT(1D), 5-HT(3), and 5-HT(4); pK(i) < 5.00).
  • HY-100904A
    RX 801077

    2 BFI free base

    		 Imidazoline Receptor Inflammation/Immunology Neurological Disease
    RX 801077 (2 BFI free base) is a selective imidazoline I2 receptor (I2R) agonist with a Ki value of 70.1 nM. RX 801077 shows anti-inflammation and neuroprotection. RX 801077 has the potential for the research of traumatic brain injury (TBI).
  • HY-147037
    AMPK activator 7

    		AMPK Metabolic Disease Cardiovascular Disease
    AMPK activator 7 (compound I-3-24) is a an AMPK activator with the EC50 of 8.8 nM. AMPK activator 7 can be used for the research of diseases involving AMPK, particularly diseases such as type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia and/or hypertension.
  • HY-D0914
    Fast Green FCF

    FD&C Green No. 3; Food green 3; C.I. 42053

    		 Fluorescent Dye Others
    Fast Green FCF is a sea green triarylmethane food dye.
  • HY-100486
    BTTAA

    		Others Others
    BTTAA is a Cu(I)-stabilizing ligand, whch performs potently with ubiquitin Glu18AzF.
  • HY-18350
    Indimitecan

    LMP776

    		 Topoisomerase Cancer
    Indimitecan (LMP776) is a topoisomerase I (Top1) inhibitor with anticancer activities.
  • HY-16259
    Indecainide hydrochloride

    LY 135837

    		 Others Cardiovascular Disease
    Indecainide hydrochloride is a potent and orally active class I local anesthetic antiarrhythmic agent.
  • HY-B0788A
    LY2409881 trihydrochloride

    		IKK Apoptosis Cancer
    LY2409881 trihydrochloride is a selective IκB kinase β (IKK2) inhibitor with an IC50 of 30 nM.
  • HY-13758
    TAS-103

    BMS-247615

    		 Topoisomerase Cancer
    TAS-103 is a dual inhibitor of DNA topoisomerase I/II, used for cancer research.
  • HY-P1445
    HAEGTFTSDVSSYLE

    		GLP Receptor Metabolic Disease
    HAEGTFTSDVSSYLE is a polypeptide from patent CN 102920658 B. GLP-I analog contains the sequence.
  • HY-N3181
    Nodosin

    		Others Others
    Nodosin is a diterpenoid isolated from Isodon trichocarpus Kudo and I. Japonicus HARA.
  • HY-B0788
    LY2409881

    		IKK Cancer
    LY2409881 is a selective IκB kinase β (IKK2) inhibitor with an IC50 of 30 nM.
  • HY-N6905
    Acetylarenobufagin

    		HIF/HIF Prolyl-Hydroxylase Cancer
    Acetylarenobufagin is a steroidal hypoxia inducible factor-1 (HIF-I) modulator.
  • HY-13758A
    TAS-103 dihydrochloride

    BMS-247615 dihydrochloride

    		 Topoisomerase Cancer
    TAS-103 dihydrochloride is a dual inhibitor of DNA topoisomerase I/II, used for cancer research.
  • HY-148819
    NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT

    		Topoisomerase ADC Cytotoxin Cancer
    NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT (compound I) is a topoisomerase I inhibitor, which can be delivered to cells through conjugated antibody targeting, and has good ADC activity in vivo and in vitro.
  • HY-P1366
    des-​Gln14-​Ghrelin

    		GHSR Metabolic Disease
    des-Gln14-Ghrelin is a second endogenous ligand for the growth hormone secretagogue receptor. a). des-Gln14-ghrelin potently induces increases in [Ca 2+]i in CHO-GHSR62 cells, with an EC50 of 2.4 nM.
  • HY-130515
    Cdc7-IN-3

    		CDK Cancer
    Cdc7-IN-3 (compound I-A) is a potent Cdc7 kinase inhibitor extracted from patent WO2019165473A1, compound I-B. Cdc7 is a serine-threonine protein kinase enzyme which is essential for the initiation of DNA replication in the cell cycle.
  • HY-146094
    Antitumor agent-63

    		Topoisomerase Cancer
    Antitumor agent-63 (Compound 40), a 20 (S)-O-linked camptothecin (CPT) glycoconjugate, is an antitumor agent without toxicity towards normal cells. Antitumor agent-63 shows high stability and very weak direct topoisomerase I (Topo I) inhibition.
  • HY-130516
    Cdc7-IN-4

    		CDK Cancer
    Cdc7-IN-4 (compound I-C) is a potent Cdc7 kinase inhibitor extracted from patent WO2019165473A1, compound I-C. Cdc7 is a serine-threonine protein kinase enzyme which is essential for the initiation of DNA replication in the cell cycle.
  • HY-115999
    Carbonic anhydrase inhibitor 12

    		Carbonic Anhydrase Cancer
    Carbonic anhydrase inhibitor 12 is a potent CA II inhibitor, also has inhibitory activity in CA I (Kis of 1.72 and 271 nM in CA II and CA I, respectively). Carbonic anhydrase inhibitor 12 has potent anticancer activity against different cancer cell lines.
  • HY-149036
    PAA5

    		Ferroptosis Endogenous Metabolite Reactive Oxygen Species Cancer
    PAA5 is a methide carbon-centered polynuclear Au(I) cluster. PAA5 can release Au(I) causing Pro-oxidant response and accelerated ferroptosis. PAA5 increases the expression of pH2AX in a time-dependent manner. PAA5 has anticancer activity.
  • HY-130517
    Cdc7-IN-5

    		CDK Cancer
    Cdc7-IN-5 (compound I-B) is a potent Cdc7 kinase inhibitor extracted from patent WO2019165473A1, compound I-B. Cdc7 is a serine-threonine protein kinase enzyme which is essential for the initiation of DNA replication in the cell cycle.
  • HY-P1366A
    des-​Gln14-​Ghrelin TFA

    		GHSR Metabolic Disease
    des-Gln14-Ghrelin TFA is a second endogenous ligand for the growth hormone secretagogue receptor. a). des-Gln14-ghrelin potently induces increases in [Ca 2+]i in CHO-GHSR62 cells, with an EC50 of 2.4 nM.
  • HY-130519
    Cdc7-IN-7

    		CDK Cancer
    Cdc7-IN-7 (compound I-E) is a potent Cdc7 kinase inhibitor extracted from patent WO2019165473A1, compound I-E. Cdc7 is a serine-threonine protein kinase enzyme which is essential for the initiation of DNA replication in the cell cycle.
  • HY-139833
    Anti-inflammatory agent 6

    		NF-κB IKK Inflammation/Immunology
    Anti-inflammatory agent 6 blocks the phosphorylation of I kappa b kinase α/β (IKKα/β), IκBα, and nuclear factor kB p65 (NF-κB p65) which is a key controller of inflammation, thereby showing anti-inflammatory potential.
  • HY-144310
    DX3-213B

    		Mitochondrial Metabolism Cancer
    DX3-213B is a highly potent, orally active oxidative phosphorylation (OXPHOS) complex I inhibitor (IC50=3.6 nM). DX3-213B impairs ATP generation (IC50=11 nM), and blocks MIA PaCa-2 cell growth (GI50=11 nM). DX3-213B is used for the research of the pancreatic cancer.
  • HY-145080
    Dynole 2−24

    		Dynamin Neurological Disease
    Dynole 2−24 is an indole-based dynamin GTPase inhibitor (IC50=0.56 μM for dynamin I). Dynole 2−24 is nontoxic and shows increased potency against dynamin I and II in vitro and in cells (IC₅₀(CME)=1.9 μM). Dynole 2−24 also shows 4.4-fold selectivity for dynamin I. Dynole 2−24 is active in-cell inhibitor of clathrin-mediated endocytosis. CME: Clathrin mediated endocytosis
  • HY-151472
    hCAIX/XII-IN-6

    		Carbonic Anhydrase Infection
    hCAIX/XII-IN-6 is an orally active carbonic anhydrase (CA) inhibitor. hCAIX/XII-IN-6 inhibits human CA isoforms hCA I, II, IV, IX, and XII with Ki values of 6697 nM, 2950 nM, 4093 nM, 4.1 nM and 7.7 nM, respectively. hCAIX/XII-IN-6 can be used for the research of rheumatoid arthritis (RA).
  • HY-145350
    HDAC-IN-26

    		HDAC Infection
    HDAC-IN-26 is a highly selective class I HDAC inhibitor with an EC50 value of 4.7 nM.
  • HY-16273A
    L-778123 hydrochloride

    L-778,123 hydrochloride

    		 Farnesyl Transferase Cancer
    L-778123 hydrochloride is an inhibitor of FPTase and GGPTase-I with IC50 of 2 nM and 98 nM in enzyme inhibition determination.
  • HY-W015346
    Desaminotyrosine

    3-(4-Hydroxyphenyl)propionic acid

    		 Influenza Virus Endogenous Metabolite Infection
    Desaminotyrosine is a microbially associated metabolite protecting from influenza through augmentation of type I interferon signaling.
  • HY-13618
    Edotecarin

    J 107088; PF 804950

    		 Topoisomerase Cancer
    Edotecarin is a potent inhibitor of topoisomerase I that can induces single-strand DNA cleavage, with IC50 of 50 nM.
  • HY-139254
    Indirubin-3′-oxime

    IDR3O; I3O

    		 CDK GSK-3 JNK Neurological Disease
    Indirubin-3′-oxime (IDR3O), a synthetic derivative of indirubin, is a potent inhibitor of cyclin-dependent kinases (CDKs) and glycogen synthase kinase 3β (GSK3β). Indirubin-3′-oxime directly inhibits the activity of all three isoforms of JNK (JNK1, JNK2, and JNK3), with IC50s of 0.8 μM, 1.4 μM, and 1.0 μM, respectively. Indirubin-3′-oxime can enhance height growth via activation of Wnt/β-catenin signaling in chondrocytes.
  • HY-W040226
    Indigo carmine

    Indigotindisulfonate sodium; C.I.Acid Blue 74

    		 Fluorescent Dye Cancer
    Indigo carmine is an efficient reagent for the determination of ozone by chemlluminescence (CL).
  • HY-P9913
    Rituximab

    Anti-Human CD20 type I, Chimeric Antibody

    		 CD20 Cancer Inflammation/Immunology
    Rituximab is an anti-CD20 chimeric monoclonal antibody used for research of certain autoimmune diseases and cancer.
  • HY-15508
    JANEX-1

    WHI-P131; Jak3 inhibitor I

    		 JAK Cancer
    JANEX-1 (WHI-P131) is a potent and specific JAK3 inhibitor (estimated Ki=2.3 μM). JANEX-1 (WHI-P131) shows potent JAK3-inhibitory activity (IC50 of 78 μM), does not inhibit JAK1 and JAK2.
  • HY-128946
    CL2A-SN-38

    		Drug-Linker Conjugates for ADC Cancer Inflammation/Immunology
    CL2A-SN-38 is a agent-linker conjugate composed of a potent a DNA Topoisomerase I inhibitor SN-38 and a linker CL2A to make antibody agent conjugate (ADC). CL2A-SN-38 provides significant and specific antitumor effects against a range of human solid tumor types. CL2A-SN-38 uses hydrolyzable linker to deliver active agents within tumor cells and in the tumor microenvironment, resulting in bystander effects.
  • HY-151565
    Anticancer agent 86

    		Others Cancer
    Anticancer agent 86 (compound 6i) shows potential activity against breast adenocarcinoma.
  • HY-16562A
    Irinotecan hydrochloride

    (+)-Irinotecan hydrochloride; CPT-11 hydrochloride; VAL-413

    		 Topoisomerase Autophagy Cancer
    Irinotecan hydrochloride ((+)-Irinotecan hydrochloride) is a topoisomerase I inhibitor mainly used to treat colon cancer and rectal cancer.
  • HY-N2331
    Proscillaridin A

    		Topoisomerase Cancer
    Proscillaridin A is a potent poison of topoisomerase I/II activity with IC50 values of 30 nM and 100 nM, respectively.
  • HY-134864
    GnRH antagonist 2

    		GnRH Receptor Endocrinology
    GnRH antagonist 2 (formula I) is a GnRH receptor antagonist that can be used for endometriosis research.
  • HY-13565
    Becatecarin

    NSC 655649; BMS 181176; BMY 27557

    		 Topoisomerase Cancer
    Becatecarin is a rebeccamycin analog with antitumor effects. Becatecarin intercalates into DNA and inhibites the catalytic activity of topoisomerases I/II.
  • HY-N0275
    (±)-10-Hydroxycamptothecin

    (±)-10-HCPT

    		 Topoisomerase Cancer
    (±)-10-Hydroxycamptothecin is an indole alkaloid that inhibits the activity of topoisomerase I and has a broad spectrum of anticancer activity.
  • HY-105713
    Sulochrin

    		Bacterial Infection
    Sulochrin is a metabolite produced by Aspergillus terreus var. aureus. I. Sulochrin has antimicrobial activities.
  • HY-101954A
    Inarigivir ammonium

    ORI-9020 ammonium; SB-9000 ammonium

    		 HBV Infection Inflammation/Immunology
    Inarigivir (ORI-9020) ammonium is a dinucleotide antiviral drug that can significantly reduce liver HBV DNA in transgenic mice expressing hepatitis B virus. Inarigivir (ORI-9020) ammonium acts as a RIG-I (Retinoic acid-inducible gene-I) agonist to activate cellular innate immune responses.
  • HY-144452
    Immunoproteasome inhibitor 1

    		Proteasome Cancer
    Immunoproteasome inhibitor 1 is a potent, reversible, time-independent immunoproteasome and proteasome inhibitor (Kis of 1.18, 0.27, 1.91 μM in β5c, β1i, β5i submits, respectively). Immunoproteasome inhibitor 1 can be used for the research of certain neoplastic diseases.
  • HY-153008
    BCR-ABL-IN-7

    		Bcr-Abl Cancer
    BCR-ABL-IN-7 (compound 4) is a WT and T315I mutant ABL kinases inhibitor. BCR-ABL-IN-7 effectively inhibits activities of WT and T315I mutant ABL kinases. BCR-ABL-IN-7 can be used for the research of chronic myeloid leukemia (CML) research.
  • HY-P1533
    CRF, bovine

    Corticotropin Releasing Factor bovine

    		 CRFR Inflammation/Immunology Endocrinology
    CRF, bovine is a potent agonist of CRF receptor, and displaces [ 125I-Tyr]ovine CRF with a Ki of 3.52 nM.
  • HY-P2285
    AC 253

    		Amyloid-β Neurological Disease
    AC 253, an amylin antagonist, inhibits 125I-adrenomedullin binding, with an IC50 of 25 nM.
  • HY-U00314
    Anti-neurodegeneration agent 1

    		Others Neurological Disease
    Anti-neurodegeneration agent 1 a neurodegeneration-targeting compound extracted from patent WO2008039514A1, Compound I.
  • HY-100309
    9-Aminocamptothecin

    9-Amino-20(S)-camptothecin; 9-Amino-CPT

    		 Topoisomerase Cancer
    9-Aminocamptothecin (9-Amino-CPT) is a topoisomerase I inhibitor with potent anticancer activity.
  • HY-15775
    Arginase inhibitor 1

    		Arginase Cancer
    Arginase inhibitor 1 is a potent inhibitor of human arginases I and II with IC50s of 223 and 509 nM, respectively.
  • HY-12777
    Asivatrep

    PAC-14028

    		 TRP Channel Inflammation/Immunology
    Asivatrep (PAC-14028) is a potent and selective transient receptor potential vanilloid type I (TRPV1) antagonist.
  • HY-147922
    hCAI/II-IN-2

    		Carbonic Anhydrase Inflammation/Immunology
    hCAI/II-IN-2 (compound 2b) is a potent dual hCA I/II inhibitor with Ki values of 40.97, 15.15 and 61.88 nM for hCA I, hCA II and hCA Ⅸ. hCAI/II-IN-2 possesses anti-hypoxic activity against acute mountain sickness (AMS) and low cellular activity.
  • HY-147923
    hCAI/II-IN-3

    		Carbonic Anhydrase Inflammation/Immunology
    hCAI/II-IN-3 (compound 5b) is a potent dual hCA I/II inhibitor with Ki values of 51.25, 13.15 and 42.18 nM for hCA I, hCA II and hCA Ⅸ. hCAI/II-IN-3 possesses anti-hypoxic activity against acute mountain sickness (AMS) and low cellular activity.
  • HY-147414
    Vamotinib

    PF-114

    		 Bcr-Abl Cancer
    Vamotinib (PF-114) is a potent, selective and orally active tyrosine kinase inhibitor. Vamotinib inhibits the autophosphorylation of BCR/ABL and BCR/ABL-T315I. Vamotinib induces apoptosis. Vamotinib shows anti-proliferative and anti-tumor activity. Vamotinib has the potential for the research of resistant philadelphia chromosome-positive (Ph+) leukemia.
  • HY-125817
    BI-3406

    		Ras p38 MAPK Cancer
    BI-3406 (compound I-6) is an orally active, highly potent and selective inhibitor of the interaction between KRAS and Son of Sevenless 1 (SOS1) with an IC50 of 6 nM. BI-3406 potently reduces the formation of GTP-loaded KRAS, and inhibits MAPK pathway signaling. BI-3406 has anticancer activity.
  • HY-13012
    RepSox

    E-616452; SJN 2511

    		 TGF-β Receptor Metabolic Disease
    RepSox (E-616452) is a potent and selective transforming growth factor-beta receptor I/activin like kinase 5 (TGF-β-RI/ALK5) inhibitor. RepSox inhibits ALK5 autophosphorylation with an IC50 value of 4 nM. RepSox can be used for the research of obesity and associated metabolic diseases such as type 2 diabetes.
  • HY-14394
    TBB

    NSC 231634; Casein Kinase II Inhibitor I

    		 Casein Kinase Cancer
    TBB is a cell-permeable and ATP-competitive CK2 inhibitor with an IC50 of 0.15 μM for rat liver CK2.
  • HY-W052011
    Ruzinurad

    HR011303

    		 URAT1 Metabolic Disease
    Ruzinurad is a highly selective URATl inhibitor (WO2020088641, compound I). Ruzinurad can be used in the study of hyperuricemia.
  • HY-118091B
    LY300503

    		Others Others
    LY300503 is an enantiomer of LY191704. LY191704 is a human type I 5α-reductase inhibitor.
  • HY-N5038
    Mauritianin

    		Topoisomerase Cancer
    Mauritianin is a kaempferol glycoside isolated from the flowers and leaves of Acalypha indica. Mauritianin is a topoisomerase I inhibitor.
  • HY-15144
    Trichostatin A

    TSA

    		 HDAC Cancer
    Trichostatin A (TSA) is a potent and specific inhibitor of HDAC class I/II, with an IC50 value of 1.8 nM for HDAC.
  • HY-N8469
    cis-5-Dodecenoic acid

    		Endogenous Metabolite COX Inflammation/Immunology
    cis-5-Dodecenoic acid is an endogenous metabolite with inhibitory activities against COX-I and COX-II.
  • HY-100495
    FT011

    		MMP Inflammation/Immunology
    FT011 is an anti-fibrotic agent, reduces mRNA expression of collagens I and III and inhibits collagen synthesis.
  • HY-B0063
    Gimatecan

    ST1481

    		 Topoisomerase Cancer
    Gimatecan (ST1481) is a potent topoisomerase I inhibitor. Gimatecan is an orally bioavailable camptothecin analogue with antitumor activity.
  • HY-12075
    LY2109761

    		TGF-β Receptor Autophagy Cancer
    LY2109761 is an orally active, selective TGF-β receptor type I/II inhibitor with Kis of 38 nM and 300 nM, respectively.
  • HY-P99509
    Zelminemab

    AMG-301

    		 Adenylate Cyclase Neurological Disease
    Zelminemab (AMG-301) is a human monoclonal antibody that inhibits PACAP type I (PAC1) receptor.
  • HY-13226
    Galunisertib

    LY2157299

    		 TGF-β Receptor Cancer
    Galunisertib (LY2157299) is an oral and selective TGF-β receptor type I (TGF-βRI) kinase inhibitor with an IC50 of 56 nM.
  • HY-152157
    HIV-1 inhibitor-52

    		HIV Infection
    HIV-1 inhibitor-52 is a potent broad-spectrum HIV-1 activity inhibitor with EC50s of 1.6 nM-6.4 nM for WT HIV-1, HIV-1 V370A, HIV-1 ΔV370, HIV-1 V362I/V370A, HIV-1 T332S/V362I/prR41G, HIV-1 A326T/V362I/V370A, HIV-1 R361K/V362I/L363M.
  • HY-145424
    CDK7-IN-10

    		CDK Others
    CDK7-IN-10 is a CDK7 inhibitor with an IC50 of less than 100 nM, extracted from patent WO2021016388A1, compound I-1. CDK7-IN-10 is useful in inhibiting the activity of a kinase. CDK7-IN-10 has the potential of inhibiting cell growth and inducing cell apoptosis.
  • HY-N4237
    Saikogenin D

    		Prostaglandin Receptor Potassium Channel Inflammation/Immunology
    Saikogenin D is isolated from Bupleurum chinense, has anti-inflammatory effects. Saikogenin D activates epoxygenases that converts arachidonic acid to epoxyeicosanoids and dihydroxyeicosatrienoic acids, and the metabolites secondarily inhibit prostaglandin E2 (PGE2) production. Saikogenin D results in an elevation of [Ca 2+]i due to Ca 2+ release from intracellular stores.
  • HY-U00248
    LMP744

    MJ-III65; NSC706744

    		 Topoisomerase Cancer
    LMP744 (MJ-III65) is a DNA intercalator and Topoisomerase I (Top1) inhibitor with antitumor activity.
  • HY-W012382
    N-Acetyl-L-tyrosine

    		Endogenous Metabolite Metabolic Disease
    N-Acetyl-L-tyrosine originates from tyrosine through an AA acetylase, is associated with aromatic L-amino acid decarboxylase deficiency and tyrosinemia I.
  • HY-N0694
    Schisantherin A

    Gomisin-C; Schizantherin-A; Wuweizi ester-A

    		 NF-κB Inflammation/Immunology
    Schisantherin A is a dibenzocyclooctadiene lignan. Schisantherin A inhibits p65-NF-κB translocation into the nucleus by IκBα degradation.
  • HY-Y0801
    2,6-Dihydroxybenzoic acid

    		Endogenous Metabolite Others
    2,6-Dihydroxybenzoic acid is a secondary metabolite of salicylic acid which has been hydrolyzed by liver enzymes during phase I metabolism.
  • HY-U00248A
    LMP744 hydrochloride

    MJ-III65 hydrochloride; NSC706744 hydrochloride

    		 Topoisomerase Cancer
    LMP744 hydrochloride (MJ-III65 hydrochloride) is a DNA intercalator and Topoisomerase I (Top1) inhibitor with antitumor activity.
  • HY-113005
    Glutarylcarnitine

    		Endogenous Metabolite Metabolic Disease
    Glutarylcarnitine is the diagnostic metabolite for malonic aciduria and glutaric aciduria type I monitored in most tandem mass spectrometry newborn screening programmes.
  • HY-146657
    4BAB

    		Glyoxalase (GLO) Cancer
    4BAB (compound 29) is an irreversible glyoxalase I (GLO1) inhibitor. 4BAB has anticancer effects.
  • HY-N8884
    Coelonin

    		PTEN Akt NF-κB Interleukin Related TNF Receptor Inflammation/Immunology
    Coelonin is a dihydrophenanthrene with anti-inflammation activity. Coelonin inhibits LPS-induced PTEN phosphorylation. Coelonin inhibits NF-κB activation and p27Kip1 degradation by regulating the PI3K/AKT pathway negatively. Coelonin can inhibit IκBα phosphorylation and degradation and increases the expression of IκBα protein.
  • HY-110135A
    NBI-31772 hydrate

    		IGF-1R Neurological Disease
    NBI-31772 hydrate is a potent inhibitor of interaction between insulin-like growth factor (IGF) and IGF-binding proteins (IGFBPs). NBI-31772 hydrate is also a nonpeptide ligand that releases bioactive IGF-I from the IGF-I/IGFBP-3 complex (Kis=1-24 nM for all six human subtypes). Anxiolytic and antidepressant-like effects.
  • HY-12083
    PPY-A

    		Bcr-Abl Cancer
    PPY-A is a potent T315I mutant and wild-type Abl kinases inhibitor with IC50s of 9 and 20 nM, respectively. PPY-A inhibits Ba⁄F3 cells transformed with wild-type Abl and Abl T315I mutantl with IC50s of 390 and 180 nM, respectively. PPY-A can be used for the research of chronic myeloid leukemia (CML).
  • HY-N1987
    Cucurbitacin IIb

    		Apoptosis Inflammation/Immunology
    Cucurbitacin IIb is an active component isolated from Hemsleya amabilis, induces apoptosis with anti-inflammatory activity. Cucurbitacin IIb inhibits phosphorylation of STAT3, JNK and Erk1/2, enhances the phosphorylation of IκB and NF-κB (p65), blocks nuclear translocation of NF-κB (p65) and decreases mRNA levels of IκBα and TNF-α.
  • HY-147678
    GPR40 agonist 5

    		Free Fatty Acid Receptor Metabolic Disease
    GPR40 agonist 5 (compound I-14) is an orally active and potent GPR40 (G protein coupled receptor 40) agonist, with an EC50 of 47 nM. GPR40 agonist 5 decreases the levels of blood glucose and improves the glucose tolerance. GPR40 agonist 5 has sufficient effectiveness for the control of hyperglycemia state in type 2 diabetic mice.
  • HY-12383
    Pelubiprofen

    		COX Inflammation/Immunology Neurological Disease
    Pelubiprofen, an orally active and non-steroidal anti-inflammatory drug, is a member of the 2-arylpropionic acid family and has relatively selective effects on COX-2 activity. Pelubiprofen inhibits COX activity and the transforming growth factor-β activated kinase 1-IκB kinase β-NF-κB pathway, and has significant anti-inflammatory and analgesic effects.
  • HY-144715
    HIV-1 inhibitor-17

    		HIV Infection
    HIV-1 inhibitor-18 (compound V-25i) is a potent HIV-1 capsid inhibitor with an EC50 value of 2.57 μM for HIV-1 NL4-3. HIV-1 inhibitor-18 has certain cytotoxicity (MT-4 cells CC50 >8.55).
  • HY-B1756
    Rotenone

    		Mitochondrial Metabolism Autophagy Apoptosis Neurological Disease Cancer
    Rotenone is a mitochondrial electron transport chain complex I inhibitor. Rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production.
  • HY-13783
    BIBF0775

    		TGF-β Receptor Cancer
    BIBF0775 is a potent and selective transforming growth factor β (TGFβ) type I receptor (Alk5) inhibitor with an IC50 of 34 nM.
  • HY-13670
    Lurtotecan

    GI147211; OSI-211

    		 Topoisomerase Cancer
    Lurtotecan (GI147211; OSI-211), a semisynthetic Camptothecin analog, is a topoisomerase I inhibitor. Lurtotecan has anticancer effects.
  • HY-13631AS
    Exatecan-d5 mesylate

    DX8951f-d5; Exatecan-d5 (mesylate); Deuterated labeled Exatecan (mesylate)

    		 Topoisomerase Cancer
    Exatecan-d5 (mesylate) is deuterium labeled Exatecan mesylate. Exatecan mesylate is a DNA topoisomerase I inhibitor, with an IC50 of 0.975 μg/mL[1].
  • HY-106895
    Antiarrhythmic agent-1

    		Potassium Channel Cardiovascular Disease
    Antiarrhythmic agent-1 (example I) is an antiarrhythmic agent and an IKr potassium channel blocker (IC50<1 μM).
  • HY-19637
    SW044248

    		Topoisomerase Cancer
    SW044248 is a non-canonical topoisomerase I inhibitor, and selectively toxic for certain non-small cell lung cancer (NSCLC) cell lines.
  • HY-N10367
    Corydamine

    		Topoisomerase Cancer
    Corydamine, 3-arylisoquinoline alkaloid, is a potent DNA topoisomerase I/II inhibitor. Corydamine has anti-cancer activity.
  • HY-123450
    S116836

    		Bcr-Abl Apoptosis PDGFR Cancer
    S116836, a potent, orally active BCR-ABL tyrosine kinase inhibitor, blocks both wild-type as well as T315I Bcr-Abl. S116836 arrests the cells in the G0/G1 phase of cell cycle, induces apoptosis, increases ROS production, and decreases GSH production in BaF3/WT and BaF3/T315I cells. S116836 also inhibits SRC, LYN, HCK, LCK and BLK, and receptor tyrosine kinases such as FLT3, TIE2, KIT, PDGFR-β. Antitumor activies.
  • HY-11012
    TDZD-8

    GSK-3β Inhibitor I; NP 01139

    		 GSK-3 Cancer
    TDZD-8 is an inhibitor of GSK-3β, with an IC50 of 2 μM; TDZD-8 shows less potent activities against Cdk-1/cyclin B, CK-II, PKA, and PKC, with all IC50s of >100 μM.
  • HY-N0602
    Ginsenoside Rg2

    Chikusetsusaponin I; Panaxoside Rg2; Prosapogenin C2

    		 NF-κB Amyloid-β Neurological Disease Cardiovascular Disease Cancer
    Ginsenoside Rg2 is one of the major active components of ginseng. Ginsenoside Rg2 inhibits VCAM-1 and ICAM-1 expressions stimulated with lipopolysaccharide (LPS). Ginsenoside Rg2 also reduces Aβ1-42 accumulation.
  • HY-P3883
    [DAla4] Substance P (4-11)

    		Neurokinin Receptor Neurological Disease
    [DAla4] Substance P (4-11) is an analog of Substance P (Substance P (HY-P0201)) that inhibits the binding of 125I-Bolton Hunter-conjugated Eledoisin (Eledoisin (HY-P0006)) (IC50 of 0.5 μM) and 125I-Bolton Hunter-conjugated Substance P (IC50 of 0.15 μM) to rat brain cortex membranes.
  • HY-110261
    GS143

    		IKK E1/E2/E3 Enzyme NF-κB Inflammation/Immunology
    GS143 is a selec­tive IκBα ubiquitination inhibitor with an IC50 of 5.2 μM for SCF βTrCP1-mediated IκBα ubiquitylation. GS143 sup­presses NF-κB acti­va­tion and tran­scrip­tion of tar­get genes and does not inhibit proteasome activity. GS143 has anti-asthma effect.
  • HY-P1934A
    Cyclo(L-Phe-L-Pro)

    		Fungal IFNAR Reactive Oxygen Species Cancer Inflammation/Immunology Infection
    Cyclo(L-Phe-L-Pro), isolated from Pseudomonas fluorescens and Pseudomonas alcaligenes cell-free culture supernatants is an antifungal cyclic dipeptide. Cyclo(L-Phe-L-Pro) inhibits IFN-β production by interfering with retinoic-acid-inducible gene-I (RIG-I) activation. Cyclo(L-Phe-L-Pro) exhibits free-radical scavenging activity with the IC50 of 24 µM in the DPPH assay.
  • HY-129966
    PROTAC IRAK4 degrader-1

    		PROTACs IRAK Cancer
    PROTAC IRAK4 degrader-1 is a Cereblon-based PROTAC interleukin-1 receptor-associated kinase 4 (IRAK4) degrader extracted from patent US20190192668A1 Compound I-210, makes <20%, >20-50%, and >50% IRAK4 degradation at 0.01, 0.1, and 1 μM in OCI-LY-10 cells, respectively.
  • HY-147925
    hCAI/II-IN-4

    		Carbonic Anhydrase Others
    hCAI/II-IN-4 (compound 6d) is a potent dual hCA I/II inhibitor with Ki values of 16.95, 15.22 and 27.04 nM for hCA I, hCA II and hCA Ⅸ, respectively. hCAI/II-IN-4 has anti-hypoxia activities and low toxicity. hCAI/II-IN-4 can be used for acute mountain sickness (AMS) research.
  • HY-115915
    TS010

    		Glyoxalase (GLO) Cancer
    TS010 is a potent inhibitor of GLO-I with IC50 of 0.57 μM. TS010 has the potential for the research of cancer disease.
  • HY-111634
    Epsilon-momfluorothrin

    		Others Cancer
    Epsilon-momfluorothrin is a type I synthetic pyrethroid insecticide, activates constitutive androstane receptor (CAR), and induces hepatocellular tumors in rats.
  • HY-145471
    KSQ-4279

    USP1-IN-1

    		 PARP Deubiquitinase Cancer
    KSQ-4279 (USP1-IN-1, Formula I) is a USP1 and PARP inhibitor (extracted from patent WO2021163530).
  • HY-W145658
    De-N-sulfated heparin sodium salt

    Heparamine sodium salt

    		 Biochemical Assay Reagents Others
    De-N-sulfated heparin (Heparin I-H) sodium salt is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
  • HY-114161
    H-Val-Pro-Pro-OH

    		Angiotensin Receptor Metabolic Disease Inflammation/Immunology Endocrinology
    H-Val-Pro-Pro-OH, a milk-derived proline peptides derivative, is an inhibitor of Angiotensin I converting enzyme (ACE), with an IC50 of 9 μM.
  • HY-13631
    Exatecan

    DX-8951

    		 Topoisomerase Cancer
    Exatecan (DX-8951) is a DNA topoisomerase I inhibitor, with an IC50 of 2.2 μM (0.975 μg/mL), and can be used in cancer research.
  • HY-P1533A
    CRF, bovine TFA

    Corticotropin Releasing Factor bovine TFA

    		 CRFR Inflammation/Immunology Endocrinology
    CRF, bovine (TFA) is a potent agonist of CRF receptor, and displaces [ 125I-Tyr]ovine CRF with a Ki of 3.52 nM.
  • HY-126142
    Top1 inhibitor 1

    		Topoisomerase ADC Cytotoxin Cancer
    Top1 inhibitor 1 (compound 28) is a potent human topoisomerase I (Top1) inhibitor with an IC50 value of 29 nM.
  • HY-18310
    NIBR-17

    		PI3K Cancer
    NIBR-17 is a pan-class I PI3K inhibitor with suitable pharmacokinetic properties and inhibits tumor growth.
  • HY-13432
    Nanatinostat

    CHR-3996

    		 HDAC Cancer
    Nanatinostat (CHR-3996) is a potent, class I selective and orally active histone deacetylase (HDAC) inhibitor with an IC50 of 8 nM.
  • HY-101489A
    GZD856 formic

    		PDGFR Bcr-Abl Apoptosis Cancer
    GZD856 formic is a potent and orally active PDGFRα/β inhibitor, with IC50s of 68.6 and 136.6 nM, respectively. GZD856 formic is also a Bcr-Abl T315I inhibitor, with IC50s of 19.9 and 15.4 nM for native Bcr-Abl and the T315I mutant. GZD856 formic has antitumor activity.
  • HY-101489
    GZD856

    		PDGFR Bcr-Abl Apoptosis Cancer
    GZD856 formic is a potent and orally active PDGFRα/β inhibitor, with IC50s of 68.6 and 136.6 nM, respectively. GZD856 formic is also a Bcr-Abl T315I inhibitor, with IC50s of 19.9 and 15.4 nM for native Bcr-Abl and the T315I mutant. GZD856 formic has antitumor activity.
  • HY-143273
    DENV-IN-6

    		HIV DNA/RNA Synthesis Infection
    DENV-IN-6 is a potent DENV (I-IV) inhibitor with EC50s of 17.5, 13.20, 6.8 and 11.41 μM for the inhibition of DENV (I-IV) replication, respectively. DENV-IN-6 also exhibits activity of anti-HIV-1IIIB (EC50=0.0181 µM; CC50=64.92 µM).
  • HY-137460
    Vodobatinib

    K0706

    		 Bcr-Abl Cancer
    Vodobatinib (K0706) is a potent, third generation and orally active Bcr-Abl1 tyrosine kinase inhibitor with an IC50 of 7 nM. Vodobatinib exhibits activity against most BCR-ABL1 point mutants, and has no activity against BCR-ABL1T315I. Vodobatinib can be used for chronic myeloid leukemia (CML) research.
  • HY-147833
    ALK-IN-22

    		Anaplastic lymphoma kinase (ALK) Apoptosis Cancer
    ALK-IN-22 (compound I-24) is a potent ALK inhibitor with IC50 values of 2.3, 3.7 and 2.9 nM for ALK, ALK L1196M and ALK G1202R, respectively. ALK-IN-22 down-regulated the phosphorylation of ALK and its downstream proteins. ALK-IN-22 induces apoptosis. ALK-IN-22 can be used for tumor research.
  • HY-13631A
    Exatecan mesylate

    DX8951f

    		 Topoisomerase ADC Cytotoxin Cancer
    Exatecan mesylate (DX8951f) is a DNA topoisomerase I inhibitor, with an IC50 of 2.2 μM (0.975 μg/mL). Exatecan mesylate can be used in cancer research.
  • HY-113166
    Dodecanoylcarnitine

    		Endogenous Metabolite Metabolic Disease
    Dodecanoylcarnitine is present in fatty acid oxidation disorders such as long-chain acyl CoA dehydrogenase deficiency, carnitine palmitoyltransferase I/II deficiency, and is also associated with celiac disease.
  • HY-13566AS
    Belotecan-d7 hydrochloride

    		Topoisomerase Cancer
    Belotecan-d7 (hydrochloride) is the deuterium labeled Belotecan hydrochloride. Belotecan hydrochloride (CKD-602 hydrochloride), a Topoisomerase I inhibitor, is a synthetic camptothecin derivative[1][2].
  • HY-113005A
    Glutarylcarnitine lithium

    		Endogenous Metabolite Metabolic Disease
    Glutarylcarnitine lithium is the diagnostic metabolite for malonic aciduria and glutaric aciduria type I monitored in most tandem mass spectrometry newborn screening programmes.
  • HY-12163
    Entinostat

    MS-275; SNDX-275

    		 HDAC Autophagy Apoptosis Cancer
    Entinostat is an oral and selective class I HDAC inhibitor, with IC50s of 243 nM, 453 nM, and 248 nM for HDAC1, HDAC2, and HDAC3, respectively.
  • HY-114161A
    H-Val-Pro-Pro-OH TFA

    		Angiotensin Receptor Metabolic Disease Inflammation/Immunology Endocrinology
    H-Val-Pro-Pro-OH (TFA), a milk-derived proline peptides derivative, is an inhibitor of Angiotensin I converting enzyme (ACE), with an IC50 of 9 μM.
  • HY-139070
    D-Glyceric acid

    		Endogenous Metabolite Metabolic Disease
    D-Glyceric acid is an endogenous metabolite present in Urine that can be used for the research of Primary hyperoxaluria Type I and Glutaric Acidemia Type 2.
  • HY-111451
    Tuvusertib

    M1774; ATR inhibitor 1

    		 ATM/ATR Cancer
    Tuvusertib (ATR inhibitor 1) is a ATR inhibitor extracted from patent WO2015187451A1, compound I-l, with a Ki value below 1 μΜ.
  • HY-100409
    PHCCC

    		mGluR Cancer
    PHCCC is a Group I mGluR antagonist with an IC50 of 3 μM. PHCCC is a selective positive modulator of mGlu4 receptor. Antiparkinsonian effect.
  • HY-107133
    Simmitecan hydrochloride

    		Topoisomerase Cytochrome P450 Cancer
    Simmitecan hydrochloride, a 9-substituted lipophilic Camptothecin (HY-16560) derivative, is a potent topoisomerase I inhibitor. Simmitecan hydrochloride is an anticancer agent.
  • HY-P1075
    CALP3

    		Calcium Channel Cancer Neurological Disease
    CALP3, a Ca 2+-like peptide, is a potent Ca 2+ channel blocker that activates EF hand motifs of Ca 2+-binding proteins. CALP3 can functionally mimic increased [Ca 2+]i by modulating the activity of Calmodulin (CaM), Ca 2+ channels and pumps. CALP3 has the potential in controlling apoptosis in diseases such as AIDS or neuronal loss due to ischemia.
  • HY-146348
    Tuberculosis inhibitor 5

    		Bacterial Infection
    Tuberculosis inhibitor 5 (Compound 11i) is a potent antimycobacterial biphenyl analogue without noticeable cytotoxicity. Tuberculosis inhibitor 5 is an anti-tuberculosis agent.
  • HY-P99478
    Bifarcept

    		IFNAR Inflammation/Immunology
    Bifarcept is a recombinant antibody of interferon receptor type I (IFN-RI). Bifarcept can bind IFN-β and prolong its serum half-life.
  • HY-112729
    HC-056456

    3,4-Bis(2-thienoyl)-1,2,5-oxadiazole-N-oxide

    		 Calcium Channel Others
    HC-056456 is an effective but not perfectly-selective blocker of CatSper channels. The [Na +]i rise is slowed by HC-056456 (IC50~3 µM).
  • HY-16711
    SB225002

    		CXCR Inflammation/Immunology Endocrinology Cancer
    SB225002, a potent, selective and non-peptide CXCR2 antagonist, inhibits 125I-IL-8 binding to CXCR2 with an IC50 of 22 nM.
  • HY-145788
    5-Cyclopropylpentanal

    		Others Cancer
    5-Cyclopropylpentanal is an olfactory receptor agonist. 5-Cyclopropylpentanal enhance OR-I7 activation with an EC50 of 0.3 μM.
  • HY-U00068
    PPARα-MO-1

    		PPAR Metabolic Disease
    PPARα-MO-1 is a potent PPARα modulator extracted from patent WO/2004/110982A1, formula I.
  • HY-13277
    IRAK inhibitor 3

    		IRAK Inflammation/Immunology
    IRAK inhibitor 3 is an interleukin-1 (IL-I) receptor-associated kinase (IRAK) kinase modulator extracted from patent WO2008030579 A2.
  • HY-15542A
    FRAX597

    		PAK Cancer
    FRAX597 is a potent group I p21-activated Kinases (PAKs) inhibitor with IC50 of 8, 13 and 19 nM for PAK1, 2 and 3.
  • HY-131958
    D942

    		AMPK Cancer
    D942 is a cell penetrant AMPK activator and partially inhibits the mitochondrial complex I. In multiple myeloma cells, D942 inhibits cell growth.
  • HY-N0629
    Maslinic acid

    Crategolic acid; 2α-Hydroxyoleanolic acid

    		 NF-κB Bacterial HIV Endogenous Metabolite Inflammation/Immunology Cancer
    Maslinic acid can inhibit the DNA-binding activity of NF-κB p65 and abolish the phosphorylation of IκB-α, which is required for p65 activation.
  • HY-P4044
    HBV Seq2 aa:28-39

    		HBV Infection
    HBV Seq2 aa:28-39 is a HBsAg peptide, which binds to major histocompatibility complex (MHC) class I molecules.
  • HY-W145693
    Difucosyl-para-lacto-N-hexaose II (DFpLNH II)

    Difucosyllacto-N-hexaose I

    		 Biochemical Assay Reagents Endogenous Metabolite Others
    Difucosyl-para-lacto-N-hexaose II (DFpLNH II) is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
  • HY-124662
    IHVR-19029

    		Glucosidase Infection
    IHVR-19029 is a potent endoplasmic reticulum (ER) α-glucosidases I and II inhibitor, with an IC50 of 0.48 μM for ER a-glucosidase I. IHVR-19029 efficiently blocks the replication of several hemorrhagic fever viruses, such as Dengue virus (DENV), Ebola virus (EBOV) and Rift Valley fever virus. The combination of IHVR-19029 with Favipiravir (HY-14768) improves the antiviral efficacy.
  • HY-101170
    BU224 hydrochloride

    		Imidazoline Receptor Apoptosis TNF Receptor Inflammation/Immunology Neurological Disease
    BU224 hydrochloride is a selective and high affinity imidazoline I2 receptor ligand, with a Ki of 2.1 nM. BU224 hydrochloride is sometimes used as an I2 receptor antagonist. BU224 hydrochloride exerts neuroprotective effects, with anti-inflammatory and anti-apoptotic properties. BU224 hydrochloride improves memory in 5XFAD mice, enlarging dendritic spines and reducing Aβ-induced changes in NMDARs. BU224 hydrochloride can be used for Alzheimer's disease research.
  • HY-16560S
    Camptothecin-d5

    Campathecin-d5; (S)-(+)-Camptothecin-d5; CPT-d5

    		 Topoisomerase ADC Cytotoxin MicroRNA Influenza Virus Apoptosis Fungal Antibiotic Cancer Infection
    Camptothecin-d5 is the deuterium labeled Camptothecin. Camptothecin (CPT), a kind of alkaloid, is a DNA topoisomerase I (Topo I) inhibitor with an IC50 of 679 nM[1]. Camptothecin (CPT) exhibits powerful antineoplastic activity against colorectal, breast, lung and ovarian cancers, modulates hypoxia-inducible factor-1α (HIF-1α) activity by changing microRNAs (miRNA) expression patterns in human cancer cells[2][3].
  • HY-W009310
    9-cis-Retinal

    		Endogenous Metabolite Others
    9-cis-Retinal is a natural retinoid. Dietary 9-cis-β-carotene generates 9-cis-retinoids via cleavage into 9-cis-retinal. 9-cis Retinal binds to cellular retinol-binding protein-I (CRBP-I) and CRBP-II with Kds of 8 nM and 5 nM, respectively. 9-cis-Retinal expedites differentiation and maturation of rod photoreceptors in retinal organoids.
  • HY-P1075A
    CALP3 TFA

    		Calcium Channel Cancer Neurological Disease
    CALP3 TFA, a Ca 2+-like peptide, is a potent Ca 2+ channel blocker that activates EF hand motifs of Ca 2+-binding proteins. CALP3 TFA can functionally mimic increased [Ca 2+]i by modulating the activity of Calmodulin (CaM), Ca 2+ channels and pumps. CALP3 TFA has the potential in controlling apoptosis in diseases such as AIDS or neuronal loss due to ischemia.
  • HY-147400
    Sipagladenant

    KW-6356

    		 Adenosine Receptor Neurological Disease
    Sipagladenant (Compound I) is an orally active adenosine receptor A2A inverse agonist. Sipagladenant can be used in frontal lobe dysfunction research.
  • HY-126373
    SN-38 glucuronide

    SN-38G

    		 Drug Metabolite Cancer
    SN-38 glucuronide is an inactive metabolite of the cancer agent Irinotecan. Irinotecan is a topoisomerase I inhibitor which can be used for researching colon and rectal cancer.
  • HY-N8488
    Anhydro-6-epiophiobolin A

    		Others Others
    Anhydro-6-epiophiobolin A, an analog of Ophiobolin A, is a potent inhibitor of photosynthesis (I50s of 6.1 and 1 mM for photosynthesis in Chlorella and Spinach, respectively).
  • HY-W007648
    Methyl 3-aminopropanoate hydrochloride

    β-Alanine methyl ester hydrochloride

    		 Others Others
    Methyl 3-aminopropanoate hydrochloride is prepared by esterification of Β-Alanine (I). Methyl 3-aminopropanoate hydrochloride can be used in the synthesis of bidentate pyridine-acid ligand.
  • HY-136773
    ALK2-IN-4

    		TGF-β Receptor Metabolic Disease
    ALK2-IN-4 is a potent ALK2 inhibitor extracted from patent WO2020086963A1, compound Formula I free base.
  • HY-W013158
    Trimethyloctadecylammonium bromide

    		Dynamin Infection
    Trimethyloctadecylammonium bromide is an inhibitor of dynamin, with an IC50 value of 1.9 μM for dynamin I. Trimethyloctadecylammonium bromide exhibits antibacterial activity against Staphylococcus aureus.
  • HY-110363
    Miglustat-d9 hydrochloride

    N-Butyldeoxynojirimycin-d9 (hydrochloride); NB-DNJ-d9 (hydrochloride); OGT 918-d9 (hydrochloride)

    		 Isotope-Labeled Compounds Glucosylceramide Synthase (GCS) Neurological Disease
    Miglustat-d9 (hydrochloride) is the deuterium labeled Miglustat (hydrochloride). Miglustat hydrochloride is an inhibitor of glucosylceramide synthase, primarily to treat Type I Gaucher disease (GD1)[1][2].
  • HY-P1853
    Abz-FR-K(Dnp)-P-OH

    		Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Abz-FR-K(Dnp)-P-OH is an angiotensin I-converting enzyme (ACE) substrate and an internally quenched fluorogenic substrate for real time fluorescent assay.
  • HY-P2921
    Urate oxidase

    Uox

    		 Endogenous Metabolite Others
    Urate oxidase (Uox), i.e., uricase, is often used in biochemical studies. Urate oxidase is a peroxisomal enzyme that catalyzes the oxidation of uric acid to allantoin in most mammals.
  • HY-18623
    VI 16832

    		Others Cancer
    VI 16832 is a broad spectrum Type I kinase inhibitor which can be used as an enrichment tool for the comparative expression analysis of protein kinases in different cancer cell lines.
  • HY-100223
    Calpeptin

    		Cathepsin Proteasome Apoptosis Inflammation/Immunology
    Calpeptin is a potent, cell penetrating calpain inhibitor, with an ID50 of 40 nM for Calpain I in human platelets. Calpeptin is also an inhibitor of cathepsin K.
  • HY-146365
    HIV-1 inhibitor-30

    		HIV Infection Inflammation/Immunology
    HIV-1 inhibitor-30 (compound 10i) is a potent HIV-1 inhibitor with an EC50 value of 40 nM and an IC50 value of 80 nM for HIV-1 RT DNA polymerase. HIV-1 inhibitor-30 has highly antiretroviral activity against seven non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant HIV-1 strains (RT-K103N; RT-Y181C; RT-K103N,Y181C; RT-L100I,K103N; RT-Y188L; RT-K103N,G190A; RT-K103N,V108I) with IC50s of 0.04~1.42 μM. HIV-1 inhibitor-30 can be used for researching AIDS.
  • HY-133667
    Bromoiodoacetamide

    		Apoptosis Cancer
    Bromoiodoacetamide is a kind of iodinated haloacetamides (I-HAcAms), with cytotoxicity. Bromoiodoacetamide induces cytotoxicity by via reactive oxygen species (ROS) accumulation and apoptosis in HepG-2 cells.
  • HY-N10438
    Ganodermaones B

    		Integrin Inflammation/Immunology
    Ganodermaones B (Compound 2) is a renal fibrosis inhibitor. Ganodermaones B inhibits TGF-β1-induced collagen I and fibronectin expression.
  • HY-148385
    Ganglioside GM2

    		Others Cancer
    Ganglioside GM2 is a human tumor antigen (OFA-I-1). Ganglioside GM2 is the major lysosomal storage compound of Tay-Sachs disease.
  • HY-128589
    CHMFL-KIT-033

    		c-Kit Cancer
    CHMFL-KIT-033 is a potent and selective inhibitor of c-KIT T670I mutant for gastrointestinal stromal tumors (GISTs), with an IC50 of 0.045 μM.
  • HY-B0199A
    Mycophenolate mofetil hydrochloride

    RS 61443 hydrochloride; TM-MMF hydrochloride

    		 Endogenous Metabolite Bacterial Cancer
    Mycophenolate mofetil (RS 61443) hydrochloride is a immunosuppressant, a non-competitive, selective and reversible inhibitor of inosine monophosphate dehydrogenase (IMPD) type I/II with IC50s of 39 nM and 27 nM, respectively.
  • HY-78349
    A 77-01

    		TGF-β Receptor Cancer
    A 77-01 is a potent inhibitor of transforming growth factor (TGF)-β type I receptor superfamily activin-like kinase ALK5 with an IC50 of 25 nM.
  • HY-136773A
    ALK2-IN-4 succinate

    		TGF-β Receptor Metabolic Disease
    ALK2-IN-4 succinate is a potent ALK2 inhibitor extracted from patent WO2020086963A1, compound Formula I free base.
  • HY-113623
    Pyrenophorol

    		Others Others
    Pyrenophorol is a C9H12O3 compound isolated in low yield from culture filtrates of the phytopathogenic fungus Stemphylium radicinum, C.M.I. 105654.
  • HY-N1201
    Apigenin

    4',5,7-Trihydroxyflavone; Apigenol; C.I. Natural Yellow 1

    		 Autophagy Cytochrome P450 Endogenous Metabolite Inflammation/Immunology Cancer
    Apigenin (4',5,7-Trihydroxyflavone) is a competitive CYP2C9 inhibitor with a Ki of 2 μM.
  • HY-129721
    Acid Red 26

    Ponceau MX; xylidine ponceau 2R (C.I. 16150)

    		 Biochemical Assay Reagents Others
    Acid Red 26 is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
  • HY-151547
    MRS4719

    		P2X Receptor Neurological Disease
    MRS4719 is a potent P2X4 receptor antagonist with an IC50 value of 0.503 μM for human P2X4 receptor. MRS4719 can reduce infarct volume and reduce brain atrophy, showing neuroprotective and neuro-rehabilitative activities in ischemic stroke model. MRS4719 also reduces ATP-induced [Ca 2+]i influx in primary human monocyte-derived macrophages. MRS4719 can be used to research ischemic stroke.
  • HY-152955
    STING agonist-22

    		STING Infection Inflammation/Immunology
    STING agonist-22 (CF501) is a potent non-nucleotide STING agonist. STING agonist-22 is a adjuvant by activating STING to induce the type I interferon (IFN-I) response and proinflammatory cytokine production. STING agonist-22 can be used as an adjuvant to boost the original protein vaccine, producing potent, broad, and long-term immune protection. STING agonist-22 can be used for SARS-CoV-2 variants and sarbecovirus diseases research.
  • HY-12383S
    Pelubiprofen-13C,d3

    		Isotope-Labeled Compounds COX Inflammation/Immunology Neurological Disease
    Pelubiprofen- 13C,d3 is the 13C- and deuterium labeled Pelubiprofen. Pelubiprofen, an orally active and non-steroidal anti-inflammatory drug, is a member of the 2-arylpropionic acid family and has relatively selective effects on COX-2 activity. Pelubiprofen inhibits COX activity and the transforming growth factor-β activated kinase 1-IκB kinase β-NF-κB pathway, and has significant anti-inflammatory and analgesic effects[1].
  • HY-108608
    o-3M3FBS

    		Others Others
    o-3M3FBS is the negative control of m-3M3FBS. o-3M3FBS inhibits inward and outward currents via mechanisms independent of PLC acting in an antagonistic manner. In contrast, o-3M3FBS also causes an increase in [Ca 2+]i in an agonistic manner.
  • HY-13555
    β-Lapachone

    ARQ-501; NSC-26326

    		 Topoisomerase Autophagy Apoptosis Cancer
    β-Lapachone (ARQ-501;NSC-26326) is a naturally occurring O-naphthoquinone, acts as a topoisomerase I inhibitor, and induces apoptosis by inhibiting cell cycle progression.
  • HY-113005S
    Glutarylcarnitine-d9 chloride

    		Endogenous Metabolite Metabolic Disease
    Glutarylcarnitine-d9 (chloride) is the deuterium labeled Glutarylcarnitine chloride. Glutarylcarnitine is the diagnostic metabolite for malonic aciduria and glutaric aciduria type I monitored in most tandem mass spectrometry newborn screening programmes.
  • HY-N2198
    Podocarpusflavone A

    		Topoisomerase Apoptosis Cancer
    Podocarpusflavone A is a DNA topoisomerase I inhibitor. Podocarpusflavone A has moderated anti-proliferative activity and induces cell apoptosis in MCF-7. Podocarpusflavone A is developing anti-tumor agents.
  • HY-16134A
    Celgosivir hydrochloride

    MBI 3253 hydrochloride; MDL 28574 hydrochloride; MX3253 hydrochloride

    		 Glucosidase HCV HIV Infection
    Celgosivir hydrochloride (MBI 3253 hydrochloride; MDL 28574 hydrochloride; MX3253 hydrochloride) is an α-glucosidase I inhibitor; inhibits bovine viral diarrhoea virus (BVDV) with an IC50 of 1.27 μM in in vitro assay.
  • HY-128380
    Dibenamine hydrochloride

    N-​(2-​Chloroethyl)​dibenzylamine hydrochloride

    		 Adrenergic Receptor Metabolic Disease
    Dibenamine hydrochloride is a competitive and irreversible adrenergic blocking agent and is known to modify the pharmacological effects of epinephrine. Dibenamine hydrochloride cause a significant increase in the rate of destruction of I-epinephrine in the mouse.
  • HY-N0733S2
    Glucosamine-13C,15N hydrochloride

    D-(+)-Glucosamine-13C,15N (hydrochloride); Chitosamine-13C,15N (hydrochloride)

    		 Reactive Oxygen Species HIF/HIF Prolyl-Hydroxylase Endogenous Metabolite Autophagy Inflammation/Immunology Cancer
    Glucosamine- 13C, 15N (hydrochloride) is the 13C and 15N labeled Glucosamine hydrochloride. Glucosamine hydrochloride (D-Glucosamine hydrochloride) is an amino sugar and a prominent precursor in the biochemical synthesis of glycosylated proteins and lipids, i
  • HY-P1118
    Ac9-25

    		Formyl Peptide Receptor (FPR) Inflammation/Immunology
    Ac9-25, a N-terminal peptide of Annexin I, acts as a formyl peptide receptor (FPR) agonist and activates the neutrophil NADPH oxidase through FPR.
  • HY-N2270
    Chicanine

    		p38 MAPK ERK IKK Inflammation/Immunology
    Chicanine is a lignan compound of Schisandra chinesis, inhibits LPS-induced phosphorylation of p38 MAPK, ERK 1/2 and IκB-α, with anti-inflammatory activity.
  • HY-16134
    Celgosivir

    MBI 3253; MDL 28574; MX3253

    		 Glucosidase HCV HIV Infection
    Celgosivir (MBI 3253; MDL 28574; MX3253) is an α-glucosidase I inhibitor; inhibits bovine viral diarrhoea virus (BVDV) with an IC50 of 1.27 μM in in vitro assay.
  • HY-P1104A
    FC131 TFA

    		CXCR HIV Infection
    FC131 TFA is a CXCR4 antagonist, inhibits [ 125I]-SDF-1 binding to CXCR4, with an IC50 of 4.5 nM. Anti-HIV activity.
  • HY-151742
    Norbornene-methyl-NHS

    		ADC Linker Others
    Norbornene-methyl-NHS is a click chemistry reagent containing a TCO group. Dienophile for conjugation via Diels-Alder-reaction, i.e. copper-free click reaction with tetrazines.
  • HY-145078
    PNU-EDA-Gly5

    		Drug-Linker Conjugates for ADC Cancer
    PNU-EDA-Gly5 is an oligo-glycine linker-payload for ADC synthesis, composed of a DNA topoisomerase I inhibitor PNU-159682 and a linker EDA-Gly5.
  • HY-N0642
    α-L-Rhamnose monohydrate

    		Others Infection Metabolic Disease Cancer
    α-L-Rhamnose monohydrate is a component of the plant cell wall pectic polysaccharides rhamnogalacturonan I and rhamnogalacturonan II. α-L-Rhamnose monohydrate is also a component of bacterial polysaccharides where it plays an important role in pathogenicity.
  • HY-13955
    Telmisartan

    BIBR 277

    		 Angiotensin Receptor Autophagy Cardiovascular Disease Endocrinology
    Telmisartan is a potent, long lasting antagonist of angiotensin II type 1 receptor (AT1), selectively inhibiting the binding of 125I-AngII to AT1 receptors with IC50 of 9.2 nM.
  • HY-18819
    BCR-ABL-IN-2

    		Bcr-Abl Cancer
    BCR-ABL-IN-2 is an inhibitor of BCR-ABL1 tyrosine kinase, with IC50s of 57 nM, 773 nm for ABL1 native and ABL1 T315I, respectively.
  • HY-13592
    HDAC-IN-7

    Chidamide impurity

    		 HDAC Cancer
    HDAC-IN-7 (Chidamide impurity) is an impurity of Chidamide. Chidamide is a potent and orally bioavailable HDAC enzymes class I (HDAC1/2/3) and class IIb (HDAC10) inhibitor.
  • HY-12293
    LY2857785

    		CDK Apoptosis Cancer
    LY2857785 is a type I reversible and competitive ATP kinase inhibitor against CDK9 (IC50 11 nM) and other transcription kinases CDK8 (IC50 16 nM), and CDK7 (IC50 246 nM).
  • HY-107568
    Iodophenpropit dihydrobromide

    		Histamine Receptor Inflammation/Immunology
    Iodophenpropit dihydrobromide is a potent and selective histamine H3 receptor antagonist. The binding of [ 125I]Iodophenpropit is selective, saturable, readily reversible, and of high affinity (KD 0.32 nM).
  • HY-P1118A
    Ac9-25 TFA

    		Formyl Peptide Receptor (FPR) Inflammation/Immunology
    Ac9-25 TFA, a N-terminal peptide of Annexin I, acts as a formyl peptide receptor (FPR) agonist and activates the neutrophil NADPH oxidase through FPR.
  • HY-100183
    GSK2239633A

    		CCR Inflammation/Immunology Endocrinology
    GSK2239633A is a CC-chemokine receptor 4 (CCR4) antagonist, which inhibits the binding of [ 125I]-TARC to human CCR4 with a pIC50 of 7.96 ± 0.11.
  • HY-144376
    Carbonic anhydrase inhibitor 4

    		Carbonic Anhydrase Cancer
    Carbonic anhydrase inhibitor 4 is carbonic anhydrase photoprobe/inhibitor. Carbonic anhydrase inhibitor 4 is against human carbonic anhydrases (hCA I-XIV) with Ki values of 640-1166 nM.
  • HY-10339
    KW-2449

    		FLT3 FGFR Bcr-Abl Aurora Kinase Apoptosis Cancer
    KW-2449 is a multi-targeted kinase inhibitor of FLT3, ABL, ABL T315I and Aurora kinase with IC50s of 6.6, 14, 4 and 48 nM, respectively.
  • HY-13462
    LY-364947

    HTS466284

    		 TGF-β Receptor Cancer
    LY-364947 (HTS466284) is a potent ATP-competitive inhibitor of TGFβR-I with IC50 of 59 nM, and exhibits 7-fold selectivity over TGFβR-II.
  • HY-130272
    Anti-MI/R injury agent 1

    		Others Cardiovascular Disease
    Anti-MI/R injury agent 1 (compound 18), a Panaxatriol derivative, is an orally active, potent anti-myocardial ischemia/reperfusion (anti-MI/R) injury agent. Anti-MI/R injury agent 1 enhances oxygen-glucose deprivation and reperfusion (OGD/R)-induced cardiomyocyte injury cell viability. Anti-MI/R injury agent 1 can markedly reduce myocardial infarction size, decrease circulating cardiac troponin I (cTnI) leakage, and alleviate cardiac tissue damage in the rats.
  • HY-143557
    Trk-IN-7

    		Trk Receptor Cancer
    Trk-IN-7 (compound I-6) is a potent TRK inhibitor with IC50s of ranging from 0.25-10 nM for TRKA, TRKB and TRKC, respectively. Trk-IN-7 shows inhibition against EML4-ALK (IC50<15 nM) ALK G1202R, ALK C1156Y, ALK R1275Q, ALK F1174L, ALK L1197M, and ALK G1269A (IC50=5-50 nM).
  • HY-147955
    hCAI/II-IN-5

    		Carbonic Anhydrase Cholinesterase (ChE) Metabolic Disease Neurological Disease
    hCAI/II-IN-5 (compound MZ8) is a potent hCA I and hCA II (human carbonic anhydrase isoenzymes I and II) inhibitor, with IC50 values of 37.88 and 45.23 nM, respectively. hCAI/II-IN-5 also shows inhibition profile against α-Glycosidase and AChE, with IC50 values of 48.98 and 420.14 nM, respectively. hCAI/II-IN-5 can be used for the research of many diseases such as diabetes, Alzheimer’s disease, heart failure, ulcer, and epilepsy.
  • HY-13522
    Fimepinostat

    CUDC-907

    		 PI3K HDAC Apoptosis Cancer
    Fimepinostat (CUDC-907) potently inhibits class I PI3Ks as well as classes I and II HDAC enzymes with an IC50 of 19/54/39 nM and 1.7/5.0/1.8/2.8 nM for PI3Kα/PI3Kβ/PI3Kδ and HDAC1/HDAC2/HDAC3/HDAC10 , respectively.
  • HY-109165A
    Acoramidis hydrochloride

    AG10 hydrochloride

    		 Transthyretin (TTR) Endocrinology Metabolic Disease
    Acoramidis (AG10) hydrochloride is an orally active and selective kinetic stabilizer of WT and V122I-TTR (transthyretin). Acoramidis (AG10) hydrochloride is used in the study for transthyretin amyloidosis.
  • HY-13631D
    Dxd

    Exatecan derivative for ADC

    		 Topoisomerase ADC Cytotoxin Cancer
    Dxd (Exatecan derivative for ADC) is a potent DNA topoisomerase I inhibitor, with an IC50 of 0.31 μM, used as a conjugated drug of HER2-targeting ADC (DS-8201a).
  • HY-P1016A
    BQ-3020 TFA

    		Endothelin Receptor Cardiovascular Disease Endocrinology
    BQ-3020 (TFA) is a selective agonist of ETB receptor, inhibits [ 125I]ET-1 binding to ETB receptor with an IC50 of 0.2 nM in cerebellum, and causes vasoconstriction.
  • HY-109165
    Acoramidis

    AG10

    		 Transthyretin (TTR) Endocrinology Metabolic Disease
    Acoramidis (AG10) is an orally active and selective kinetic stabilizer of WT and V122I-TTR (transthyretin). Acoramidis (AG10) is used in the study for transthyretin amyloidosis.
  • HY-19348
    Pimelic Diphenylamide 106

    RGFA-8; TC-H 106; Histone Deacetylase Inhibitor VII

    		 HDAC Cancer
    Pimelic Diphenylamide 106 is a slow, tight-binding inhibitor of class I HDAC (HDAC 1, 2, and 3, with IC50 values of 150 nM , 760nM, and 370 nM, respectively), demonstrating no activity against class II HDACs.
  • HY-147124
    RIG012

    		IFNAR Cancer Infection
    RIG012 is a potent RIG-I inhibitor with an IC50 of 0.71 μM using the NADH-coupled ATPase assay. RIG012 inhibits IFN-β and ISG hRsad2 expression.
  • HY-D0980
    Biotin-DADOO

    Biotinyl-3,6-dioxaoctanediamine; EZ-Link Amine-PEO2-Biotin

    		 Biochemical Assay Reagents Metabolic Disease
    Biotin-DADOO is a biotinylation reagent, which can be used to synthesize a biotin-estradiol conjugate (i.e., biotin-DADOO-estradiol) to develop a direct, broad range enzyme immunoassay to measure plasma estradiol concentrations.
  • HY-131338
    RORγt inverse agonist 13

    		ROR Inflammation/Immunology
    RORγt inverse agonist 13 (Compound 3i) is a potent, orally active and selective RORγt inverse agonist, with improved agent-like properties, with an IC50 of 63.8 nM.
  • HY-P1295
    Urocortin, human

    Urocortin (human); Human urocortin; Human urocortin 1; Human urocortin I

    		 CRFR Neurological Disease Endocrinology
    Urocortin, human, a 40-aa neuropeptide, acts as a selective agonist of endogenous CRF2 receptor, with Kis of 0.4, 0.3, and 0.5 nM for hCRF1, rCRF2α and mCRF2β, respectively.
  • HY-112951
    ChX710

    		STING Cancer
    ChX710 could prime the type I interferon response to cytosolic DNA, which induces the ISRE promoter sequence, specific cellular Interferon-Stimulated Genes (ISGs), and the phosphorylation of Interferon Regulatory Factor (IRF) 3.
  • HY-142920
    LMP7-IN-1

    		Proteasome Inflammation/Immunology
    LMP7-IN-1, a Boronic acid derivative, is a potent and selective immunoproteasome subunit LMP7 (β5i) inhibitor with an IC50 of 1.83 nM (WO2021143923A1; compound 20).
  • HY-146441
    Prohibitin ligand 1

    		STAT Cardiovascular Disease Inflammation/Immunology
    Prohibitin ligand 1 (Compound 22i), a cardioprotectant prohibitin ligand, induces a phosphorylation of the pro-survival factor STAT3. Prohibitin ligand 1 exhibits in vitro cardioprotectant activities at nanomolar concentrations.
  • HY-16200
    Ethynylcytidine

    ECyD; TAS-106; 3'-C-Ethynylcytidine

    		 DNA/RNA Synthesis Nucleoside Antimetabolite/Analog Cancer
    Ethynylcytidine (ECyD), a nucleoside analog and a potent inhibitor of RNA synthesis, inhibits RNA polymerases I, II and II. Ethynylcytidine has robust antitumor activity in a wide range of models of cancer.
  • HY-W020033S
    Lanosterol-d6

    		Isotope-Labeled Compounds Endogenous Metabolite Neurological Disease
    Lanosterol-d6 is deuterium labeled Lanosterol. Lanosterol is an intermediate of cholesterol synthesis and use of lanosterol induces ubiquitination and degradation of a rate-controlling enzyme of cholesterol synthesis, i.e., HMG CoA reductase. Lanosterol s
  • HY-145513
    CL2-MMT-SN38

    		Topoisomerase Cancer
    CL2-MMT-SN38 is a SN-38 derivative. SN-38, an anticancer agent, is an active metabolite of the Topoisomerase I inhibitor Irinotecan (CPT-11).
  • HY-151730
    (Me)Tz-butanoic acid

    		ADC Linker Others
    (Me)Tz-butanoic acid is a click chemistry reagent containing an azide. (Me)Tz-butanoic acid is tetrazine linker for conjugation via Diels-Alder-reaction, i.e. copper-free Click reaction with dienophiles.
  • HY-D1705
    Ac-ANW-AMC

    		Proteasome Inflammation/Immunology
    Ac-ANW-AMC is a fluorogenic substrate for immunoproteasome. Ac-ANW-AMC can be used to measure β5i activity (Ex=345 nm, Em=445 nm).
  • HY-130278
    MitoPQ

    MitoParaquat

    		 ROS Kinase Cancer
    MitoPQ is a mitochondria-targeted redox cycler. MitoPQ produces superoxide by redox cycling at the flavin site of complex I, selectively increasing superoxide production within mitochondria. MitoPQ can be used in antioxidant study.
  • HY-10529
    Betulinic acid

    Lupatic acid; Betulic acid

    		 Apoptosis Topoisomerase HIV Autophagy Mitophagy NF-κB Endogenous Metabolite Parasite Cancer Infection Inflammation/Immunology
    Betulinic acid is a natural pentacyclic triterpenoid, acts as a eukaryotic topoisomerase I inhibitor, with an IC50 of 5 μM, and possesses anti-HIV, anti-malarial, anti-inflammatory and anti-tumor properties.
  • HY-112441
    Prolyl Hydroxylase inhibitor 1

    		HIF/HIF Prolyl-Hydroxylase Cardiovascular Disease
    Prolyl Hydroxylase inhibitor 1 (Compound 15i) is an orally active hypoxia inducible factor (HIF)-prolyl hydroxylase (PHD) inhibitor with an IC50 of 62.23 nM. Antianemia agent.
  • HY-116100
    (E/Z)-HA155

    		Phosphodiesterase (PDE) Cancer Inflammation/Immunology Neurological Disease
    (E/Z)-HA155 is a potent autotaxin (ATX) type I inhibitor. (E/Z)-HA155 can be used for researching cancer, fibrotic diseases, inflammation, pain and angiogenesis.
  • HY-125990
    SLC13A5-IN-1

    		Sodium Channel Metabolic Disease Cardiovascular Disease
    SLC13A5-IN-1 is a selective sodium-citrate co-transporter (SLC13A5) inhibitor. SLC13A5-IN-1 completely blocks the uptake of  14C-citrate with an IC50 value of 0.022 μM in HepG2 cells. SLC13A5-IN-1 has the potential for the treatment of metabolic and/or cardiovascular diseases. SLC13A5-IN-1 is extracted from patent WO2018104220A1, Compound I-5.
  • HY-146336
    PARP1/2/TNKS1/2-IN-1

    		PARP Apoptosis Cancer
    PARP1/2/TNKS1/2-IN-1 (Compound I-9) is a dual PARP-1, PARP-2, TNKS1 and TNKS2 inhibitor with IC50 values of 0.25 nM, 1.2 nM, 13.5 nM and 4.15 nM against PARP-1, PARP-2, TNKS1 and TNKS2, respectively. PARP1/2/TNKS1/2-IN-1 exhibits favorable synergistic antitumor efficacy and induces apoptosis.
  • HY-153011
    ROCK-IN-5

    		ROCK ERK GSK-3 Neurological Disease Cardiovascular Disease
    ROCK-IN-5 (compound I-B-37) is a potent inhibitor of ROCK, ERK, GSK, and AGC protein kinases. ROCK-IN-5 has the potential for proliferative, cardiac and neurodegenerative diseases research.
  • HY-W012382S
    N-Acetyl-L-tyrosine-d3

    		Endogenous Metabolite
    N-Acetyl-L-tyrosine-d3 is the deuterium labeled N-Acetyl-L-tyrosine. N-Acetyl-L-tyrosine originates from tyrosine through an AA acetylase, is associated with aromatic L-amino acid decarboxylase deficiency and tyrosinemia I.
  • HY-136742
    BACE2-IN-1

    		Beta-secretase Metabolic Disease
    BACE2-IN-1 (compound 3l) is a highly selective BACE2 inhibitor with a K i value of 1.6 nM. BACE2 inhibitors can be used to research of Type 2 Diabetes.
  • HY-B0109
    Dorzolamide

    L671152; MK507

    		 Carbonic Anhydrase Cancer
    Dorzolamide (L671152) is a potent carbonic anhydrase II inhibitor, with IC50 values of 0.18 nM and 600 nM for red blood cell CA-II and CA-I respectively. Dorzolamide possesses anti-tumor activity.
  • HY-N0847
    Micheliolide

    		NF-κB Others
    Micheliolide could effectively attenuate the high glucose-stimulated activation of NF-κB, the degradation of IκBα, and the expression of MCP-1, TGF-β1 and FN in rat mesangial cells (MCs).
  • HY-123390
    DB07107

    		Bcr-Abl Akt Cancer
    DB07107 is a potent agent resistant T315I mutant Bcr-Abl tyrosine kinase inhibitor. DB07107 is also a potent Akt1 inhibitor with an IC50 value of 360 nM.
  • HY-B0109A
    Dorzolamide hydrochloride

    L671152 hydrochloride; MK507 hydrochloride

    		 Carbonic Anhydrase Others
    Dorzolamide (L671152) hydrochloride is a potent carbonic anhydrase II inhibitor, with IC50 values of 0.18 nM and 600 nM for red blood cell CA-II and CA-I respectively. Dorzolamide possesses anti-tumor activity.
  • HY-A0116A
    Trandolaprilate hydrate

    Trandolaprilat hydrate; RU 44403 hydrate

    		 Angiotensin-converting Enzyme (ACE) Endogenous Metabolite Cardiovascular Disease
    Trandolaprilate hydrate is a potent angiotensin-converting enzyme (ACE) inhibitor. Trandolaprilate hydrate partially inhibits angiotensin-I-mediated c-fos induction. Trandolaprilate is main bioactive metabolite of Trandolapril. Trandolaprilate shows high lipophilicity.
  • HY-A0116
    Trandolaprilate

    Trandolaprilat; RU 44403

    		 Angiotensin-converting Enzyme (ACE) Endogenous Metabolite Cardiovascular Disease
    Trandolaprilate is a potent angiotensin-converting enzyme (ACE) inhibitor. Trandolaprilate partially inhibits angiotensin-I-mediated c-fos induction. Trandolaprilate is main bioactive metabolite of Trandolapril. Trandolaprilate shows high lipophilicity.
  • HY-147790
    MDH1-IN-1

    		Others Cancer
    MDH1-IN-1 (Compound 5i) is a potent inhibitor of MDH1 with an IC50 of 6.79 μM. MDH1-IN-1 has the potential for the research of cancer diseases.
  • HY-103245
    Cl-4AS-1

    		Androgen Receptor Cancer
    Cl-4AS-1, a potent steroidal androgen receptor (AR) agonist (IC50 = 12 nM), is also an inhibitor of 5α-reductase types I and II (IC50 = 6 and 10 nM, respectively).
  • HY-N0141
    Parthenolide

    (-)-Parthenolide

    		 NF-κB Autophagy Mitophagy Apoptosis Cancer
    Parthenolide is a sesquiterpene lactone found in the medicinal herb Feverfew. Parthenolide exhibits anti-inflammatory activity by inhibiting NF-κB activation; also inhibits HDAC1 protein without affecting other class I/II HDACs.
  • HY-I0096
    Indole-2-carboxylic acid

    		Endogenous Metabolite iGluR Neurological Disease
    Indole-2-carboxylic acid is a strong inhibitor of lipid peroxidation. Indole-2-carboxylic acid (I2CA) specifically and competitively inhibits the potentiation by glycine of NMDA-gated current.
  • HY-19529
    Ro 46-2005

    		Endothelin Receptor Cardiovascular Disease Endocrinology
    Ro 46-2005 is a novel synthetic non-peptide endothelin receptor antagonist, inhibits the specific binding of 125I-ET-1 to human vascular smooth muscle cells (ETA receptor) with IC50 of 220 nM.
  • HY-13566
    Belotecan

    CKD-602 free base

    		 Topoisomerase Apoptosis Cancer
    Belotecan (CKD-602 free base) is a DNA topoisomerase I inhibitor. Belotecan induces cell apoptosis and cell-cycle arrest. Belotecan is a camptothecin analogue with anti-tumor effects, it can be used for the research of cancer.
  • HY-114192
    TGFβRI-IN-1

    		TGF-β Receptor Cancer
    TGFβRI-IN-1 is an oral active and selective TGFβ receptor type I (TGFβRI) kinase inhibitor, with IC50 values of 2 nM and 7.6 μM for TGFβRI and TGFβRII, respectively .
  • HY-144268
    hCAII-IN-7

    		Carbonic Anhydrase Cancer
    hCAII-IN-7 (Compound R-13) is a potent human carbonic anhydrase (hCA) inhibitor with Kis of 60.7, 320.7, 2298, and 35.2 nM for hCA I, II, IV and IX, respectively.
  • HY-118922
    IW927

    		TNF Receptor Inflammation/Immunology
    IW927 is a potent small molecule antagonist that blocks the binding of TNF-α to TNFRc1 with an IC50 value of 50 nM and disrupts TNFα-induced IκB phosphorylation with an IC50 value of 600 nM.
  • HY-13768C
    Topotecan hydrochloride hydrate

    SKF 104864A hydrochloride hydrate; NSC 609669 hydrochloride hydrate

    		 Topoisomerase Apoptosis Autophagy Cancer
    Topotecan hydrochloride hydrate is an orally active and potent Topoisomerase I inhibitor. Topotecan hydrochloride hydrate induces cell cycle arrest in G0/G1 and S phases and promotes apoptosis. Topotecan hydrochloride hydrate shows anticancer activity.
  • HY-101653
    MHP 133

    		Cholinesterase (ChE) mAChR 5-HT Receptor Neurological Disease
    MHP 133 is a agent with multiple CNS targets, and inhibits acetylcholinesterase (AChE) with Ki of 69 μM; also active against muscarinic M1 and M2 receptors, serotonin 5HT4 receptors, and imidazole I2 receptors.
  • HY-109109
    Alteminostat

    CKD-581

    		 HDAC Apoptosis Cancer
    Alteminostat (CKD-581) is a potent HDAC inhibitor. Alteminostat inhibits the class I-II HDAC family via histone H3 and tubulin acetylation. Alteminostat can be used for lymphoma and multiple myeloma research.
  • HY-111188
    A55453

    		Adrenergic Receptor Others
    A55453 is a prazosin analogue and a potent α1-adrenergic antagonist. 125I-A55453 is a high-affinity alpha 1-adrenergic receptor probe.
  • HY-P1104
    FC131

    		CXCR HIV Infection
    FC131 is a potent CXCR4 antagonist. FC131 inhibits [ 125I]-SDF-1 binding to CXCR4 with an IC50 of 4.5 nM. FC131 has anti-HIV activity.
  • HY-N1478
    Gardenoside

    		P2X Receptor Neurological Disease
    Gardenoside is a natural compound found in Gardenia fruits, with hepatoprotective properties. Gardenoside suppresses the pain of chronic constriction injury by regulating the P2X3 and P2X7 receptors. Gardenoside has an inhibitory effect on free fatty acids (FFA)-induced cellular steatosis.
  • HY-101392
    Harmane

    		Imidazoline Receptor Monoamine Oxidase Adrenergic Receptor Cancer Neurological Disease
    Harmane, a β-Carboline alkaloid (BCA), is a potent neurotoxin that causes severe action tremors and psychiatric manifestations. Harmane shows 1000-fold selectivity for I1-Imidazoline receptor (IC50=30 nM) over α2-adrenoceptor (IC50=18 μM). Harmane is also a potent and selective inhibitor of monoamine oxidase (MAO) (IC50s=0.5 and 5 μM for human MAO A/B, respectively). Harmane exhibits comutagenic effect.
  • HY-146307
    TrxR-IN-3

    		TrxR Cancer
    TrxR-IN-3 (Compound 2c) is a potent inhibitor of TrxR. TrxR-IN-3 exhibits potent antiproliferative activities against five human cancer cell lines, especially against breast tumor cells. TrxR-IN-3 increases ROS levels and resulted in marked apoptosis by regulating apoptosis-related proteins expressed in the breast cancer cells. TrxR-IN-3 also triggers the formation of autophagosomes and autolysosomes by promoting the expression of LC3-II and Beclin-1 and diminishing the expression of LC3-I and p62 proteins.
  • HY-147954
    α-Glycosidase-IN-1

    		Carbonic Anhydrase Cholinesterase (ChE) Metabolic Disease Neurological Disease
    α-Glycosidase-IN-1 (compound MZ7) is a potent α-GLY (α-Glycosidase) inhibitor, with an IC50 of 44.72 nM and a KI of 41.74 nM. α-Glycosidase-IN-1 also shows inhibition profile against human carbonic anhydrase isoenzymes I and II (hCA I and hCA II), and acetylcholinesterase (AChE), with IC50 values of 104.87, 100.04, and 654.87 nM, respectively. α-Glycosidase-IN-1 can be used for the research of many diseases such as diabetes, Alzheimer’s disease, heart failure, ulcer, and epilepsy.
  • HY-148668A
    MC-Gly-Gly-Phe-Gly-(S)-Cyclopropane-Exatecan

    		Topoisomerase Drug-Linker Conjugates for ADC Cancer
    MC-Gly-Gly-Phe-Gly-(R)-Cyclopropane-Exatecan is a agent-linker conjugates for ADC, consisting Exatecan (HY-13631). Exatecan is a DNA Topoisomerase I inhibitor (IC50=2.2 μM).
  • HY-147608
    CSF1R-IN-7

    		c-Fms Neurological Disease
    CSF1R-IN-7 (Formula I) is a CSF-1R inhibitor. CSF1R-IN-7 can be used for Alzheimer’s disease research.
  • HY-147061
    2-Deoxyribose 5-phosphate disodium

    		Others Others
    2-Deoxyribose 5-phosphate disodium is a substrate of 2-deoxyribose-5-phosphate aldolase (DERA). DERA belongs to the class I aldolases and catalyzes the reversible aldol condensation reaction without any cofactors.
  • HY-129997
    Luteolinidin chloride

    		CD38 Inflammation/Immunology
    Luteolinidin is a natural deoxyanthocyanidin, isolated from Sorghum bicolor . Luteolinidin is a potent CD38 inhibitor which can protect the heart against I/R injury with preservation of eNOS function and prevention of endothelial dysfunction in vivo.
  • HY-152217
    Clathrin-IN-2

    		Dynamin Cancer Metabolic Disease Neurological Disease
    Clathrin-IN-2 is potent inhibitor of clathrin mediated endocytosis (CME) with an IC50 value of 2.3 μM. Clathrin-IN-2 also has inhibitiory for dyn I GTPase with an IC50 value of 7.7 μM.
  • HY-A0166A
    Cilastatin sodium

    MK0791 sodium

    		 Bacterial Antibiotic Infection
    Cilastatin sodium (MK0791 sodium) is a reversible, competitive renal dehydropeptidase I inhibitor with an IC50 of 0.1 μM. Cilastatin sodium inhibits the bacterial metallob-lactamase enzyme CphA with an IC50 of 178 μM. Cilastatin sodium is an antibacterial adjunct.
  • HY-115686
    8-Azaadenosine

    		Adenosine Deaminase Cancer Inflammation/Immunology
    8-Azaadenosine is a potent ADAR1 inhibitor and an A-to-I editing inhibitor. 8-Azaadenosine blocks RNA editing and inhibits proliferation, 3D growth, invasion, and migration in thyroid cancer cells.
  • HY-153013
    SN38-COOH

    		Drug-Linker Conjugates for ADC Cancer
    SN38-COOH is used for the synthesis of antibody-drug conjugates (ADCs). SN-38 is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 inhibits DNA and RNA synthesis.
  • HY-W020033
    Lanosterol

    		Endogenous Metabolite Neurological Disease
    Lanosterol is an intermediate of cholesterol synthesis and use of lanosterol induces ubiquitination and degradation of a rate-controlling enzyme of cholesterol synthesis, i.e., HMG CoA reductase. Lanosterol suppresses the aggregation and cytotoxicity of misfolded proteins linked with neurodegenerative diseases.
  • HY-119370
    CHMFL-ABL-121

    		Bcr-Abl Apoptosis Cancer
    CHMFL-ABL-121 is a highly potent type II ABL kinase inhibitor with IC50s of 2 nM and 0.2 nM against purified inactive ABL wt and T315I kinase protein, respectively.
  • HY-A0166
    Cilastatin

    MK0791

    		 Bacterial Antibiotic Infection
    Cilastatin (MK0791) is a reversible, competitive renal dehydropeptidase I inhibitor with an IC50 of 0.1 μM. Cilastatin inhibits the bacterial metallob-lactamase enzyme CphA with an IC50 of 178 μM. Cilastatin is an antibacterial adjunct.
  • HY-12508
    CMPDA

    		iGluR Neurological Disease
    CMPDA is a positive allosteric modulator of AMPA receptors with EC50s of 45.4 ± 4.2 nM/63.4 ± 5.6 nM for GluA2i/GluA2o receptor.
  • HY-146206
    HCAIX-IN-1

    		Carbonic Anhydrase Cancer
    HCAIX-IN-1 (compound 21e) is a potent and selective HCAIX inhibitor with KIs of 694.9, 126.6, 3.3, 9.8 nM for hCA I, hCA II, hCA IX, hCA XII, respectively.
  • HY-148668
    MC-Gly-Gly-Phe-Gly-(R)-Cyclopropane-Exatecan

    		Drug-Linker Conjugates for ADC Topoisomerase Cancer
    MC-Gly-Gly-Phe-Gly-(R)-Cyclopropane-Exatecan is a agent-linker conjugates for ADC, consisting Exatecan (HY-13631). Exatecan is a DNA Topoisomerase I inhibitor (IC50=2.2 μM).
  • HY-P2952
    Adenylate

    AMPK; Myokinase; Adk

    		 Endogenous Metabolite Others
    Adenylate (Adk), i.e., myokinase, is a phosphotransferase enzyme, is often used in biochemical studies. Adenylate catalyzes the interconversion of adenosine phosphates. Adenylate monitors phosphate nucleotide levels inside the cell, it plays an important role in cellular energy homeostasis.
  • HY-P2455
    LLO (91-99)

    Listeriolysin O (91-99)

    		 Bacterial Inflammation/Immunology
    LLO (91-99) (Listeriolysin O (91-99)), an exotoxin, is a class I MHC-restricted T-cell epitopes of listeriolysin (LLO). LLO (91-99) is an essential antigen for induction of T-cell mediated immunity in vivo.
  • HY-13744
    Rubitecan

    RFS 2000; 9-Nitrocamptothecin

    		 Topoisomerase Cancer
    Rubitecan (RFS 2000), a Camptothecin derivative, is an orally active topoisomerase I inhibitor with broad antitumor activity, and induces protein-linked DNA single-strand breaks, thereby blocking DNA and RNA synthesis in dividing cells.
  • HY-121309
    Doxorubicinone

    Adriamycin aglycone; Adriamycinone

    		 Endogenous Metabolite Cancer
    Doxorubicinone is a metabolite of an anti-cancer chemotherapy agent Doxorubicin. Doxorubicin is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC50s of 0.8 μM and 2.67 μM, respectively.
  • HY-151470
    Chitinase-IN-5

    		Parasite Others
    Chitinase-IN-5 (8i) is a potent chitinase OfChi-h inhibitor with an IC50 value of 0.051 μM. Chitinase-IN-5 shows good insecticidal activity, it can be used for the research of green pest control and management.
  • HY-19915A
    Contezolid acefosamil

    MRX-4

    		 Bacterial Antibiotic Infection Inflammation/Immunology
    Contezolid acefosamil (MRX-4) is the orally active proagent of the active antimicrobial metabolite Contezolid (MRX-I), an oxazolidinone which shows potent in vitro activity against various multidrug-resistant Gram-positive bacteria, including MRSA.
  • HY-12163S
    Entinostat-d4

    MS-275-d4; SNDX-275-d4

    		 Apoptosis Autophagy HDAC Cancer
    Entinostat-d4 is the deuterium labeled Entinostat[1]. Entinostat is an oral and selective class I HDAC inhibitor, with IC50s of 243 nM, 453 nM, and 248 nM for HDAC1, HDAC2, and HDAC3, respectively[2].
  • HY-P3674
    LH-RH (7-10)

    		GnRH Receptor Endocrinology
    LH-RH (7-10) is a tetrapeptide, one of major degradation products of luteinising-hormone releasing hormone (LHRH) via pituitary and hypothalamus. LH-RH (7-10) produced in macrophages, type I-like and type II pneumocytes.
  • HY-128575
    BNC375

    		nAChR Neurological Disease
    BNC375 is a potent, selective, and orally available type I positive allosteric modulator of α7 nAChRs with an EC50 of 1.9 μM. BNC375 exhibits good CNS-agent like properties and clinical candidate potential. .
  • HY-151173
    XO/COX/LOX-IN-1

    		Xanthine Oxidase Lipoxygenase COX Cancer Metabolic Disease Inflammation/Immunology
    XO/COX/LOX-IN-1 (compound 7i) is a potent xanthine oxidase/cyclooxygenases/lipoxygenases (XO/COX/LOX) inhibitor. XO/COX/LOX-IN-1 can be used in studies of inflammation, cancer and metabolic diseases.
  • HY-100372
    E4CPG

    (RS)-ECPG

    		 mGluR Neurological Disease
    E4CPG ((RS)-ECPG) is a Group I/Group II metabotropic glutamate receptor (mGluR) antagonist. E4CPG can inhibit the paired-pulse ratio of monosynaptic inhibitory postsynaptic currents (IPSC) potentiation.
  • HY-13631DS
    Dxd-d5

    Exatecan-d5 derivative for ADC

    		 Topoisomerase ADC Cytotoxin Cancer
    Dxd-d5 is a deuterium labeled Dxd. Dxd is a potent DNA topoisomerase I inhibitor, with an IC50 of 0.31 μM, used as a conjugated drug of HER2-targeting ADC (DS-8201a) [1].
  • HY-N6800A
    Netropsin dihydrochloride

    		DNA/RNA Synthesis Bacterial Influenza Virus Antibiotic Orthopoxvirus Infection Inflammation/Immunology
    Netropsin dihydrochloride is a small-molecule MGB (minor-groove binder), inhibits the catalytic activity of isolated topoisomerase and interferes with the stabilization of the cleavable complexes of topoisomerase II and I in nuclei. Netropsin dihydrochloride exhibits antiviral activity against the vaccinia virus.
  • HY-100406
    (S)-MCPG

    (+)-MCPG

    		 mGluR Neurological Disease
    (S)-MCPG ((+)-MCPG) is a potent group I/II metabotropic glutamate receptor (mGluRs) antagonist and the active isomer of (RS)-MCPG (HY-100371). (S)-MCPG can be used for the study of the function of mGluRs in spatial learning.
  • HY-101392S1
    Harmane-d2

    		Imidazoline Receptor Monoamine Oxidase Adrenergic Receptor Cancer Neurological Disease
    Harmane-d2 is the deuterium labeled Harmane. Harmane, a β-Carboline alkaloid (BCA), is a potent neurotoxin that causes severe action tremors and psychiatric manifestations. Harmane shows 1000-fold selectivity for I1-Imidazoline receptor (IC50=30 nM) over α2-adrenoceptor (IC50=18 μM). Harmane is also a potent and selective inhibitor of monoamine oxidase (MAO) (IC50s=0.5 and 5 μM for human MAO A/B, respectively)[1][2][3][4].
  • HY-13453
    BAY 11-7082

    BAY 11-7821

    		 IKK Deubiquitinase Autophagy Apoptosis NF-κB Cancer Inflammation/Immunology
    BAY 11-7082 is an IκBα phosphorylation and NF-κB inhibitor. BAY 11-7082 selectively and irreversibly inhibits the TNF-α-induced phosphorylation of IκB-α, and decreases NF-κB and expression of adhesion molecules. BAY 11-7082 inhibits ubiquitin-specific protease USP7 and USP21 (IC50=0.19, 0.96 μM, respectively). BAY 11-7082 inhibits gasdermin D (GSDMD) pore formation in liposomes and inflammasome-mediated pyroptosis and IL-1β secretion in human and mouse cells.
  • HY-101392S
    Harmane-d1

    		Imidazoline Receptor Monoamine Oxidase Adrenergic Receptor Cancer Neurological Disease
    Harmane-d is the deuterium labeled Harmane. Harmane, a β-Carboline alkaloid (BCA), is a potent neurotoxin that causes severe action tremors and psychiatric manifestations. Harmane shows 1000-fold selectivity for I1-Imidazoline receptor (IC50=30 nM) over α2-adrenoceptor (IC50=18 μM). Harmane is also a potent and selective inhibitor of monoamine oxidase (MAO) (IC50s=0.5 and 5 μM for human MAO A/B, respectively)[1][2][3][4].
  • HY-N4267
    Yangambin

    		Calcium Channel Infection Cardiovascular Disease
    Yangambin, a furofuran lignan, is already isolated from plants such as member of the Annonaceae family, including species of the genus Rollinia: R. pickeli, R. exalbidaand R. mucosa, as well from the Magnolia biondii. Yangambin, a selective PAF receptor antagonist, inhibits Ca 2+ influx through voltage-gated Ca 2+ channels, leading to the reduction in [Ca 2+]i in vascular smooth muscle cells and consequent peripheral vasodilation. Yangambin exhibits the antiallergic activity against β-hexosaminidase release with an IC50 of 33.8 μM and for anti-inflammatory activity with an IC50 of 37.4 μM.
  • HY-124726
    Aumitin

    		Autophagy Cancer Neurological Disease
    Aumitin is a diaminopyrimidine-based autophagy inhibitor which inhibits mitochondrial respiration by targeting complex I. Aumitin inhibits starvation- and rapamycin induced autophagy dose dependently with IC50s of 0.12 μM and 0.24 μM, respectively.
  • HY-117554
    BRD9757

    		HDAC Cancer
    BRD9757 is a potent, capless and selective HDAC6 inhibitor with an IC50 of 30 nM. BRD9757 shows excellent selectivity toward HDAC6 versus the class I (>20-fold) and class II (>400-fold) HDACs.
  • HY-P1338
    PL-017

    		Opioid Receptor Neurological Disease
    PL-017 is a potent and selective μ opioid receptor agonist with an IC50 of 5.5 nM for 125I-FK 33,824 binding to μ site. PL-017 produces long-lasting, reversible analgesia in rats.
  • HY-P3424
    NH2-AKK-COOH

    		Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    NH2-AKK-COOH, a synthetic tripeptide, is an ACE inhibitor, with IC50s of 0.090 μM, 0.178 μM, and 420.89 μM when FAPGG, HHL, and angiotensin-I are used as substrate respectively.
  • HY-N2237
    Piceatannol 3'-O-glucoside

    Quzhaqigan

    		 NO Synthase Arginase Cardiovascular Disease
    Piceatannol 3'-O-glucoside, an active component of Rhubarb, activates endothelial nitric oxide (NO) synthase through inhibition of arginase activity with IC50s of 11.22 µM and 11.06 µM against arginase I and arginase II, respectively.
  • HY-P1569
    LCMV gp33-41

    		Arenavirus Inflammation/Immunology
    LCMV gp33-41, the carboxyl-extended 11-aa-long peptide, is an lymphocytic choriomeningitis virus sequence restricted by MHC class I H-2Db molecules and presented to cytotoxic T lymphocytes.
  • HY-B0615A
    Moricizine Hydrochloride

    EN 313; Ethmosine; Ethmozin

    		 Others Cardiovascular Disease
    Moricizine Hydrochloride (EN 313) is an orally active Class I antiarrhythmic agent. Moricizine Hydrochloride decreases the maximum rate of phase 0 depolarization; increases rates of phase 2 and 3 repolarization, decreases action potential duration, and decreases effective refractory period.
  • HY-A0276A
    Gentamicin

    		Antibiotic Bacterial Infection
    Gentamicin, an orally active aminoglycoside antibiotic, inhibits the growth of both gram-positive and gram-negative bacteria and to inhibit several strains of mycoplasma in tissue culture. Gentamicin inhibits DNase I with an IC50 of 0.57 mM.
  • HY-127026A
    Quinaprilat hydrate

    		Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Quinaprilat hydrate is a non-mercapto Angiotensin Converting Enzyme (ACE) inhibitor, the active metabolite of Quinapril. Quinaprilat hydrate specifically blocks the conversion of angiotensin I to the vasoconstrictor angiotensin II and inhibits the degradation of bradykinin. Quinaprilat hydrate acts as anti-hypertensive agent and vasodilator.
  • HY-147988
    DNA Gyrase-IN-5

    		DNA/RNA Synthesis Bacterial Infection
    DNA Gyrase-IN-5 (Compound 8I-w) is a potent DNA gyrase inhibitor with an IC50 of 0.10 μM. DNA Gyrase-IN-5 shows antibacterial activities against wild type and drug-resistant strains.
  • HY-146693
    CJJ300

    		TGF-β Receptor Cancer
    CJJ300 is a transforming growth factor-β (TGF-β) inhibitor with an IC50 of 5.3 µM. CJJ300 inhibits TGF-β signaling by disrupting the formation of the TGF-β-TβR-I-TβR-II signaling complex.
  • HY-N6865
    Groenlandicine

    		Topoisomerase Cancer Metabolic Disease
    Groenlandicine is a protoberberine alkaloid isolated from Coptidis Rhizoma. Groenlandicine exhibits moderate inhibitory effect with IC50 value of 154.2 μM for human recombinant aldose reductase (HRAR). Groenlandicine selectively induces topoisomerase I-mediated DNA cleavage.
  • HY-13634B
    TLK117

    TER117

    		 Gutathione S-transferase Cancer Inflammation/Immunology
    TLK117, the active metabolite of TLK199, selective inhibits Glutathione S-transferase P1–1 (GSTP1-1) with a Ki of 0.4 μM for GSTP. TLK117 also competitively inhibits glyoxalase I with a Ki of 0.56 μM.
  • HY-113378S
    3-Hydroxybutyric acid-d4 sodium

    β-Hydroxybutyric acid-d4 (sodium)

    		 Endogenous Metabolite Metabolic Disease
    3-Hydroxybutyric acid-d4 (sodium) is the deuterium labeled 3-Hydroxybutyric acid. 3-Hydroxybutyric acid (β-Hydroxybutyric acid) is a metabolite that is elevated in type I diabetes. 3-Hydroxybutyric acid can modulate the properties of membrane lipids[1].
  • HY-W008351S
    L-Ribose-13C

    		Isotope-Labeled Compounds Antibiotic Cancer
    L-Ribose- 13C is the 13C labeled L-Ribose. L-Ribose, a non-naturally occurring pentose, is an ideal starting material for use in synthesizing L-nucleosides analogues. Many anticancer and antiviral agents are synthesized based on a backbone of L-Ribose and i
  • HY-P4551
    Hippuryl-His-Leu-OH

    		Amino Acid Derivatives Angiotensin-converting Enzyme (ACE) Others
    Hippuryl-His-Leu-OH is a substrate for detecting the activity of angiotensin I converting enzyme. The His-Leu released by Hippuryl-His-Leu-OH can react with o-phtbaldialdehyde or Fluorescamine (HY-D0715) for fluorescence detection.
  • HY-131233
    Anti-virus agent 1

    Remdesivir isopropyl ester analog

    		 Antibiotic Infection
    Anti-virus agent 1 (compound 4i), a phosphoramidate proagent of GS-5734 (HY-104077; Remdesivir), has potent antiviral activity. Anti-virus agent 1 is used for the research of coronavirus and Ebola virus (EBOV).
  • HY-N6714
    Alternariol

    		Topoisomerase Cancer Infection
    Alternariol is a mycotoxin produced by Alternaria species. AOH inhibits the catalytic activity of topoisomerase I and topoisomerase II enzymes. Alternariol exhibits a variety of therapeutic and biological properties such as phytotoxicity, cytotoxicity, anti-HIV, anti-cancer, and anti-microbial properties.
  • HY-118091A
    Bexlosteride

    LY300502

    		 Others Cancer
    Bexlosteride (LY300502) is a benzoquinolinone human type I 5α-reductase inhibitor. Bexlosteride shows metabolic inhibitory, antiproliferative, and antisecretory effects in LNCaP human prostatic adenocarcinoma cell cultures. Bexlosteride can be used for the research of prostatic cancer.
  • HY-128677
    NCC007

    		Casein Kinase Neurological Disease
    NCC007 is a dual casein kinase Iα (CKIα) and δ (CKIδ) inhibitor with IC50s of 1.8 and 3.6 μM, respectively. NCC007 can be used in research of modulating mammalian circadian rhythms.
  • HY-150041
    TL4830031

    		TAM Receptor Cancer
    TL4830031 (compound 8i), a quinolone antibiotic derivatives, is a potent Axl inhibitor with an IC50 value of 26 nM. TL4830031 inhibits the phosphorylation of Axl. TL4830031 inhibits cell invasion and migration. TL4830031 can be used for cancer research.
  • HY-120758
    SEL24-B489

    		Pim FLT3 Apoptosis Cancer
    SEL24-B489 is a potent, type I, orally active, dual PIM and FLT3-ITD inhibitor, with Kd values of 2 nM for PIM1, 2 nM for PIM2 and 3 nM for PIM3, respectively.
  • HY-115916
    NOS-IN-2

    		NO Synthase Inflammation/Immunology
    NOS-IN-2 (Compound 4i) is a potent, selective, imidamide derived NOS inhibitor with an IC50 against iNOS of 20 µM, without inhibiting eNOS. NOS-IN-2 has little toxicity and can be used for studying inflammatory disorders.
  • HY-146355
    hCAII-IN-2

    		Carbonic Anhydrase Cancer
    hCAII-IN-2 (Compound 11f) is a cytosolic human carbonic anhydrase (hCA) inhibitor with Ki values of 261.4, 3.8, 19.6 and 45.2 nM against hCA I, hCA II, hCA IX and hCA XII, respectively.
  • HY-13768
    Topotecan

    SKF 104864A; NSC 609669

    		 Topoisomerase Autophagy Apoptosis Cancer
    Topotecan (SKF 104864A; NSC 609669) is an orally active and potent Topoisomerase I inhibitor. Topotecan induces cell cycle arrest in G0/G1 and S phases and promotes apoptosis. Topotecan shows anticancer activity.
  • HY-10583
    Y-27632 dihydrochloride

    		ROCK Cancer Neurological Disease
    Y-27632 dihydrochloride is an orally active and ATP-competitive ROCK (Rho-kinase) inhibitor (ROCK-I Ki=220 nM; ROCK-II Ki=300 nM). Y-27632 dihydrochloride shows antiepileptic effects.
  • HY-P1569A
    LCMV gp33-41 TFA

    		Arenavirus Inflammation/Immunology
    LCMV gp33-41 (TFA), the carboxyl-extended 11-aa-long peptide, is an lymphocytic choriomeningitis virus sequence restricted by MHC class I H-2Db molecules and presented to cytotoxic T lymphocytes.
  • HY-150700
    RLX-33

    		ERK Metabolic Disease
    RLX-33 is a potent, selective and blood-brain barrier (BBB) penetrant relaxin family peptide 3 (RXFP3) antagonist, also blocks relaxin-3-induced ERK1/2 phosphorylation, with IC50 values of 2.36 μM for RXFP3, 7.82 and 13.86 μM for ERK1 and ERK2 phosphorylation, respectively. RLX-33 can block the stimulation of food intake induced by the RXFP3-selective agonist R3/I5 in rats. RLX-33 can be used for the research of metabolic syndrome.
  • HY-P1338A
    PL-017 TFA

    		Opioid Receptor Neurological Disease
    PL-017 TFA is a potent and selective μ opioid receptor agonist with an IC50 of 5.5 nM for 125I-FK 33,824 binding to μ site. PL-017 TFA produces long-lasting, reversible analgesia in rats.
  • HY-115755
    Thio-ITP

    6-Thioinosine 5′-triphosphate; 6-Mercaptopurine-riboside-5'-triphosphate; 6-Thio-ITP

    		 DNA/RNA Synthesis Cancer
    Thio-ITP (6-Thioinosine 5′-triphosphate) is an RNA polymerase activity competitive inhibitor. Thio-ITP has a high apparent affinity for the polymerases (RNA polymerase I Ki: 40.9 μM; RNA polymerase II Ki: 38.0 μM).
  • HY-131057
    Mc-VC-PAB-SN38

    		Drug-Linker Conjugates for ADC Cancer
    Mc-VC-PAB-SN38 consists a cleavable ADC linker (Mc-VC-PAB) and a DNA topoisomerase I inhibitor (SN38). Mc-VC-PAB-SN38 can be used in the synthesis of antibody-drug conjugates (ADCs).
  • HY-A0276
    Gentamicin sulfate

    		Bacterial Antibiotic Infection Cancer
    Gentamicin sulfate, an orally active aminoglycoside antibiotic, inhibits the growth of both gram-positive and gram-negative bacteria and to inhibit several strains of mycoplasma in tissue culture. Gentamicin sulfate inhibits DNase I with an IC50 of 0.57 mM.
  • HY-P2093
    S961

    		Insulin Receptor Metabolic Disease
    S961 is an high-affinity and selective insulin receptor (IR) antagonist with IC50s of 0.048, 0.027, and 630 nM for HIR-A, HIR-B, and human insulin-like growth factor I receptor (HIGF-IR) in SPA-assay, respectively.
  • HY-N0029
    Forsythoside B

    		TNF Receptor NF-κB Inflammation/Immunology
    Forsythoside B is a phenylethanoid glycoside isolated from Forsythia suspensa (Thunb.) Vahl, a Chinese folk medicinal plant for treating inflammatory diseases and promoting blood circulation. Forsythoside B could inhibit TNF-alpha, IL-6, IκB and modulate NF-κB.
  • HY-N11536
    erythro-Austrobailignan-6

    		Topoisomerase Apoptosis Cancer
    erythro-Austrobailignan-6 is an orally active anti-cancer agent. erythro-Austrobailignan-6 inhibits DNA topoisomerase I and II activity. erythro-Austrobailignan-6 induces cell apoptosis and increases phosphorylation of p38 and JNK.
  • HY-116055
    (2R)-Glycerol-O-β-D-galactopyranoside

    3-O-β-D-Galactopyranosyl-sn-glycerol

    		 Others Others
    (2R)-Glycerol-O-β-D-galactopyranoside (3-O-β-D-Galactopyranosyl-sn-glycerol) is a good substrate for all three components of the lac operon, i.e. β-galactosidase, the lactose transporter and thiogalactoside transacetylase.
  • HY-P2093B
    S961 acetate

    		Insulin Receptor Metabolic Disease
    S961 acetate is an high-affinity and selective insulin receptor (IR) antagonist with IC50s of 0.048, 0.027, and 630 nM for HIR-A, HIR-B, and human insulin-like growth factor I receptor (HIGF-IR) in SPA-assay, respectively.
  • HY-150070
    Butabindide

    UCL-1397

    		 Others Neurological Disease
    Butabindide (UCL-1397) is a potent, selective tripeptidvl peptidase II (TPP II) inhibitor with Ki values of 7 nM and 10 μM for TPP II and TPP I, respectively. Butabindide inhibits TPP II to protect CCK-8 against inactivation.
  • HY-13704
    SN-38

    NK012

    		 Topoisomerase ADC Cytotoxin Autophagy Cancer
    SN-38 (NK012) is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 (NK012) inhibits DNA and RNA synthesis with IC50s of 0.077 and 1.3 μM, respectively.
  • HY-114303
    CM-675

    		Phosphodiesterase (PDE) HDAC Neurological Disease
    CM-675 is a dual phosphodiesterase 5 (PDE5) and class I histone deacetylases-selective inhibitor, with IC50 values of 114 nM and 673 nM for PDE5 and HDAC1, respectively. CM-675 has potential to treat Alzheimer’s disease.
  • HY-13323
    CX-5461

    		DNA/RNA Synthesis Cancer
    CX-5461 is a potent and oral rRNA synthesis inhibitor. It inhibits RNA polymerase I-driven transcription of rRNA with IC50s of 142, 113, and 54 nM in HCT-116, A375, and MIA PaCa-2 cells, respectively.
  • HY-106784
    Ajoene

    		Fungal Apoptosis Cancer Infection
    Ajoene, a garlic-derived compound, is an antithrombotic and antifungal agent. Ajoene inhibits proliferation and induces apoptosis of human leukaemia CD34-negative cells including HL-60, U937, HEL and OCIM-I. Anticancer activities.
  • HY-127026
    Quinaprilat

    		Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Quinaprilat is an orally active non-mercapto Angiotensin Converting Enzyme (ACE) inhibitor, the active metabolite of Quinapril. Quinaprilat specifically blocks the conversion of angiotensin I to the vasoconstrictor angiotensin II and inhibits the degradation of bradykinin. Quinaprilat acts as anti-hypertensive agent and vasodilator.
  • HY-136741
    BOT-64

    		IKK Inflammation/Immunology
    BOT-64 is an inhibitory κB (IκB) kinase β (IKKβ) inhibitor with an IC50 of 1 µM. BOT-64 blocks lipopolysaccharide-induced nuclear factor-κB activation and nuclear factor-κB-regulated inflammatory gene transcription.
  • HY-100435
    Oxaquin

    MCB-3837; DNV3837

    		 Bacterial Infection
    Oxaquin (MCB-3837) is a injectable proagent that is rapidly converted to the active substance MCB3681 in vivo following intravenous (i.v.) administration, active against Gram-positive bacterial species. Oxaquin (MCB-3837) itself has no antimicrobial effects.
  • HY-144107
    HCV-IN-34

    		HCV Infection
    HCV-IN-34 (compound 3i) is an orally active and potent HCV entry inhibitor. HCV-IN-35 shows excellent antiviral activity, with an EC50 of 0.010 μM and a CC50 (half-maximal cytotoxic concentration) of 8.23 μM.
  • HY-135845
    TP3011

    CH0793011

    		 Topoisomerase Cancer
    TP3011 (CH0793011) is an active metabolite of CH-0793076 and is a potent topoisomerase I inhibitor equipotent as SN38. TP3011 is against cancer cell lines growth with IC50s at the range sub-nanomolar in vitro.
  • HY-70063
    Buparlisib

    BKM120; NVP-BKM120

    		 PI3K Apoptosis Cancer
    Buparlisib (BKM120; NVP-BKM120) is a pan-class I PI3K inhibitor, with IC50s of 52, 166, 116 and 262 nM for p110α, p110β, p110δ and p110γ, respectively.
  • HY-14180
    PHA 408

    		IKK Inflammation/Immunology
    PHA 408 (PHA-408) is a potent, selective and orally active IκB kinase-2 (IKK-2) inhibitor. PHA 408 is a powerful anti-inflammatory agent against lipopolysaccharide (LPS)- and cigarette smoke (CS)-mediated lung inflammation.
  • HY-A0230A
    Spirapril hydrochloride

    SCH 33844 hydrochloride

    		 Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Spirapril (SCH 33844) hydrochloride is a potent angiotensin converting enzyme (ACE) inhibitor with antihypertensive activity. Spirapril competitively binds to ACE and prevents the conversion of angiotensin I to angiotensin II. Spirapril is an orally active proagent of Spiraprilat and can be used for the research of hypertension, congestive heart failure.
  • HY-10432A
    A 83-01 sodium

    		TGF-β Receptor Cancer
    A 83-01 sodium is a potent inhibitor of TGF-β type I receptor ALK5 kinase, ALK4 and ALK7, with IC50s of 12 nM, 45 nM and 7.5 nM against the transcription induced by ALK5, ALK4 and ALK7, respectively.
  • HY-113607
    Asimicin

    Bullatacin

    		 Mitochondrial Metabolism Parasite Cancer Infection
    Asimicin (Bullatacin) is antitumor acetogenin that can be isolated from the bark and seeds of the pawpaw tree, Asimina trilobal Dunal. Asimicin inhibits mitochondrial respiration through the inhibition of complex I. Asimicin shows toxicity to Aphis gossypii, mosquito larvae and mammalian.
  • HY-109015S
    Tucidinostat-d4

    Chidamide-d4; HBI-8000-d4; CS 055-d4

    		 HDAC Cancer
    Tucidinostat-d4 is the deuterium labeled Tucidinostat. Tucidinostat is a potent and orally bioavailable HDAC enzymes class I (HDAC1/2/3) and class IIb (HDAC10) inhibitor, with IC50s of 95, 160, 67 and 78 nM, respectively[1].
  • HY-100371
    (RS)-MCPG

    alpha-MCPG

    		 mGluR Neurological Disease
    (RS)-MCPG (alpha-MCPG) is a competitive and selective group I/group II metabotropic glutamate receptor (mGluR) antagonist. (RS)-MCPG blocks theta-burst stimulation (TBS)-induced shifts in both juvenile and neonatal rat hippocampal neurons.
  • HY-145929
    MC-Val-Cit-PAB-Exatecan

    MC-Val-Cit-PAB-DX8951

    		 Drug-Linker Conjugates for ADC Cancer
    MC-Val-Cit-PAB-Exatecan (MC-Val-Cit-PAB-DX8951) is a agent-linker conjugate for ADC. MC-Val-Cit-PAB-Exatecan is composed of a DNA topoisomerase I DX-8951 (HY-13631) and a cathepsin cleavable ADC linker.
  • HY-101954
    Inarigivir

    ORI-9020; SB-9000

    		 HBV Infection
    Inarigivir (ORI-9020) is a dinucleotide antiviral drug that can significantly reduce liver HBV DNA in transgenic mice expressing hepatitis B virus. Inarigivir (ORI-9020) act as a RIG-I agonist to activate cellular innate immune responses.
  • HY-100530D
    Rp-cAMPS sodium salt

    		PKA Neurological Disease
    Rp-cAMPS sodium salt, a cAMP analog, is a potent, competitive cAMP-induced activation of cAMP-dependent PKA I and II (Kis of 12.5 µM and 4.5 µM, respectively) antagonist. Rp-cAMPS sodium salt is resistant to hydrolysis by phosphodiesterases.
  • HY-133114
    Ezetimibe ketone

    EZM-K

    		 Keap1-Nrf2 Autophagy Cancer Cardiovascular Disease
    Ezetimibe ketone (EZM-K) is a phase-I metabolite of Ezetimibe. Ezetimibe is a Niemann-Pick C1-like1 (NPC1L1) inhibitor, and is a potent Nrf2 activator. Ezetimibe is a potent cholesterol absorption inhibitor.
  • HY-112062
    POL1-IN-1

    		DNA/RNA Synthesis Cancer
    POL1-IN-1 is a RNA polymerase 1 (POL1, also known as Pol I) inhibitor with an IC50 of less than 0.5 uM. POL1-IN-1 inhibits ribosome biogenesis by inhibiting POL1 transcription.
  • HY-100530A
    Rp-cAMPS

    		PKA Neurological Disease
    Rp-cAMPS, a cAMP analog, is a potent, competitive cAMP-induced activation of cAMP-dependent PKA I and II (Kis of 12.5 µM and 4.5 µM, respectively) antagonist. Rp-cAMPS is resistant to hydrolysis by phosphodiesterases.
  • HY-15778A
    AVE 0991 sodium salt

    		Angiotensin Receptor Cardiovascular Disease Endocrinology
    AVE 0991 sodium salt is a nonpeptide and orally active Ang-(1-7) receptor Mas agonist. AVE 0991 competes for high-affinity binding of [ 125I]-Ang-(1-7) to bovine aortic endothelial cell membranes with IC50 of 21 nM.
  • HY-13687
    IKK 16

    		IKK LRRK2 Inflammation/Immunology
    IKK 16 is a selective IκB kinase (IKK) inhibitor for IKK2, IKK complex and IKK1 with IC50s of 40 nM, 70 nM and 200 nM, respectively. IKK16 also inhibits leucine-rich repeat kinase-2 (LRRK2) with an IC50 of 50 nM.
  • HY-A0210
    Cerulenin

    		Fatty Acid Synthase (FASN) Fungal Apoptosis Antibiotic Infection Metabolic Disease
    Cerulenin, a potent, natural inhibitor of fatty acid synthase (FASN), is an epoxide produced by the fungus Cephalosporium caeruleus. Cerulenin inhibits topoisomerase I catalytic activity and augments SN-38-induced apoptosis. Cerulenin has antifungal and antitumor activies.
  • HY-N2306
    Aclacinomycin A

    Aclarubicin

    		 Topoisomerase DNA/RNA Synthesis Proteasome Antibiotic Cancer
    Aclacinomycin A (Aclarubicin) is an orally active and potent anthracycline antitumor antibiotic. Aclacinomycin A is an inhibitor of topoisomerase I and II. Aclacinomycin A inhibits synthesis of nucleic acid, especially RNA. Aclacinomycin A might inhibit the 26S protease complex as well as the ubiquitin-ATP-dependent proteolysis.
  • HY-P2093A
    S961 TFA

    		Insulin Receptor Metabolic Disease
    S961 TFA is an high-affinity and selective insulin receptor (IR) antagonist with IC50s of 0.048, 0.027, and 630 nM for HIR-A, HIR-B, and human insulin-like growth factor I receptor (HIGF-IR) in SPA-assay, respectively.
  • HY-146979
    hA2A/hCA XII modulator 1

    		Adenosine Receptor Carbonic Anhydrase Cancer
    hA2A/hCA XII modulator 1 (compound 14), a triazolopirazine, is a potent hA2A adenosine receptor (hA2AAR) antagonist with Kis of 6.4 nM, 4.819 μM, >30 μM for hA2AAR, hA1AR, hA3AR, respectively. hA2A/hCA XII modulator 1 is a potent human carbonic anhydrase XII (hCA XII) inhibitor with Kis of 6.2 nM, 46 nM, 466 nM, 8.351 μM for hCA XII, hCA II, hCA IX and hCA I, respectively. hA2A/hCA XII modulator 1 has the potential for cancer research.
  • HY-146201
    PDE4B/7A-IN-1

    		Phosphodiesterase (PDE) Others
    1 a /5-hydroxynitrile rubber 7 receptor antagonist (5-HT1 a k i = 8 nm, kb= 0.04 nm; 5-nitrile rubber 7K I = 451 nm, kb= 460 nm) has pde4b/pde7a inhibitory activity (PDE4B ic50= 80.4 μ M; Pde7a chip 50= 151.3 μ M）。 Compound 22 has a very good ability of passive penetration of biofilm and high metabolic stability in vitro. In addition, 22's pharmacological evaluation showed its pre cognitive and antidepressant properties in rat behavioral tests.
  • HY-W010452S
    3-Hydroxybutyric acid-d2 sodium

    β-Hydroxybutyric acid-d2 sodium

    		 Endogenous Metabolite Metabolic Disease
    3-Hydroxybutyric acid-d2 (sodium) is the deuterium labeled 3-Hydroxybutyric acid sodium[1]. 3-Hydroxybutyric acid sodium (β-Hydroxybutyric acid sodium) is a metabolite that is elevated in type I diabetes. 3-Hydroxybutyric acid sodium can modulate the properties of membrane lipids[2].
  • HY-107759
    Butabindide oxalate

    UCL-1397 oxalate

    		 Others Neurological Disease
    Butabindide (UCL-1397) oxalate is a potent, selective tripeptidvl peptidase II (TPP II) inhibitor with Ki values of 7 nM and 10 μM for TPP II and TPP I, respectively. Butabindide oxalate inhibits TPP II to protect CCK-8 against inactivation.
  • HY-109191A
    Sovesudil hydrochloride

    PHP-201 hydrochloride; AMA0076 hydrochloride

    		 ROCK Neurological Disease
    Sovesudil (PHP-201) hydrochloride is a potent, ATP-competitive, locally acting Rho kinase (ROCK) inhibitor with IC50s of 3.7 and 2.3 nM for ROCK-I and ROCK-II, respectively. Sovesudil hydrochloride lowers intraocular pressure (IOP) without inducing hyperemia.
  • HY-13955S1
    Telmisartan-d4

    		Angiotensin Receptor Autophagy Cardiovascular Disease Endocrinology
    Telmisartan-d4 is the deuterium labeled Telmisartan. Telmisartan is a potent, long lasting antagonist of angiotensin II type 1 receptor (AT1), selectively inhibiting the binding of 125I-AngII to AT1 receptors with IC50 of 9.2 nM[1][2].
  • HY-10195
    Ruboxistaurin

    LY333531

    		 PKC Metabolic Disease
    Ruboxistaurin (LY333531) is an orally active, selective PKC beta inhibitor (Ki=2 nM). Ruboxistaurin exhibits ATP dependent competitive inhibition of PKC beta I with an IC50 of 4.7 nM. Ruboxistaurin inhibits PKC beta II with an IC50 of 5.9 nM.
  • HY-152257
    HPK1-IN-31

    		MAP4K Cancer Inflammation/Immunology
    HPK1-IN-31 (compound 5i) is an orally active hematopoietic progenitor kinase 1 (HPK1) inhibitor with an IC50 value of 0.8 nM. HPK1-IN-31 has anti-tumour activity and has great potential for immunoresearch.
  • HY-13026
    Idelalisib

    CAL-101; GS-1101

    		 PI3K Autophagy Cancer
    Idelalisib (CAL-101; GS-1101) is a highly selective and orally bioavailable p110δ inhibitor with an IC50 of 2.5 nM, showing 40- to 300-fold selectivity for p110δ over other PI3K class I enzymes.
  • HY-109191
    Sovesudil

    PHP-201; AMA0076

    		 ROCK Others
    Sovesudil (PHP-201) is a potent, ATP-competitive, locally acting Rho kinase (ROCK) inhibitor with IC50s of 3.7 and 2.3 nM for ROCK-I and ROCK-II, respectively. Sovesudil lowers intraocular pressure (IOP) without inducing hyperemia.
  • HY-10195B
    Ruboxistaurin hydrochloride

    LY333531 hydrochloride

    		 PKC Metabolic Disease
    Ruboxistaurin (LY333531) hydrochloride is an orally active, selective PKC beta inhibitor (Ki=2 nM). Ruboxistaurin hydrochloride exhibits ATP dependent competitive inhibition of PKC beta I with an IC50 of 4.7 nM. Ruboxistaurin hydrochloride inhibits PKC beta II with an IC50 of 5.9 nM.
  • HY-B0109S
    Dorzolamide-d5

    		Carbonic Anhydrase Cancer
    Dorzolamide-d5 is the deuterium labeled Dorzolamide. Dorzolamide (L671152) is a potent carbonic anhydrase II inhibitor, with IC50 values of 0.18 nM and 600 nM for red blood cell CA-II and CA-I respectively. Dorzolamide possesses anti-tumor activity[1][2].
  • HY-139983
    SDH-IN-1

    		Fungal Infection
    SDH-IN-1 (compound 4i) is a succinate dehydrogenase (SDH) inhibitor with an IC50 of 4.53 μM. SDH-IN-1 has potent antifungal activities. SDH-IN-1 displays potent activity against S. sclerotiorum (EC50 of 0.14 mg/L).
  • HY-N1956
    Rubiadin-1-methyl ether

    		NF-κB Metabolic Disease
    Rubiadin-1-methyl ether is a natural anthraquinone isolated from Morinda officinalis How, and inhibits osteoclastic bone resorption via inhibition on the phosphorylation of NF-κB p65 and the degradation of IκBα as well as decrease in the nuclear translocation of p65.
  • HY-126359
    1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine

    		Endogenous Metabolite Metabolic Disease
    1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine can be chosen as a model used to investigate the volatile compounds from oxidised phosphatidylcholine molecular species. This method is applied to a real food sample, i.e. soy lecithin.
  • HY-13323A
    CX-5461 dihydrochloride

    		DNA/RNA Synthesis Cancer
    CX-5461 dihydrochloride is a potent and orally bioavailable inhibitor of Pol I-mediated rRNA synthesis, with IC50s of 142 nM in HCT-116, 113 nM in A375, and 54 nM in MIA PaCa-2 cells, and shows little or no effect on Pol II (IC50 ≥25 μM).
  • HY-13955S
    Telmisartan-d3

    		Angiotensin Receptor Autophagy Cardiovascular Disease Endocrinology
    Telmisartan-d3 is the deuterium labeled Telmisartan. Telmisartan is a potent, long lasting antagonist of angiotensin II type 1 receptor (AT1), selectively inhibiting the binding of 125I-AngII to AT1 receptors with IC50 of 9.2 nM[1][2].
  • HY-19615B
    MS023 dihydrochloride

    		Histone Methyltransferase Cancer
    MS023 dihydrochloride is a potent, selective, and cell-active inhibitor of human type I protein arginine methyltransferases (PRMTs) inhibitor, with IC50s of 30, 119, 83, 4 and 5 nM for PRMT1, PRMT3, PRMT4, PRMT6, and PRMT8, respectively.
  • HY-19615
    MS023

    		Histone Methyltransferase Cancer
    MS023 is a potent, selective, and cell-active inhibitor of human type I protein arginine methyltransferases (PRMTs) inhibitor, with IC50s of 30, 119, 83, 4 and 5 nM for PRMT1, PRMT3, PRMT4, PRMT6, and PRMT8, respectively.
  • HY-148034
    Plm IV inhibitor-1

    		Others Infection
    Plm IV inhibitor-1 (compound 6) is a potent plasmepsin IV (Plm IV) inhibitor with IC50s of 4.1, 0.80, 0.25, 0.35 µM for Plm I, Plm II, Plm IV, Cat D, respectively.
  • HY-14776
    Quarfloxin

    CX-3543

    		 DNA/RNA Synthesis Cancer
    Quarfloxin (CX-3543), a fluoroquinolone derivative with antineoplastic activity, targets and inhibits RNA pol I activity, with IC50 values in the nanomolar range in neuroblastoma cells. Quarfloxin disrupts the interaction between the nucleolin protein and a G-quadruplex DNA structure in the ribosomal DNA (rDNA) template.
  • HY-N0613
    Sauchinone

    		NF-κB Inflammation/Immunology
    Sauchinone is a diastereomeric lignan isolated from Saururus chinensis (Saururaceae). Sauchinone inhibits LPS-inducible iNOS, TNF-α and COX-2 expression through suppression of I-κBα phosphorylation and p65 nuclear translocation. Sauchinone has anti-inflammatory and antioxidant activity.
  • HY-15544
    CCR1 antagonist 10

    		CCR Inflammation/Immunology
    CCR1 antagonist 10 (example 1) is a potent and orally active CCR1 antagonist. CCR1 antagonist 10 inhibits 125I-MIP-1α binding to THP-1 cell membranes with an Ki value of 2.3 nM.
  • HY-12071A
    LDN193189 Tetrahydrochloride

    		TGF-β Receptor Cancer
    LDN193189 Tetrahydrochloride is a selective BMP type I receptor inhibitor, which efficiently inhibits ALK2 and ALK3 (IC50=5 nM and 30 nM, respectively), with weaker effects on ALK4, ALK5 and ALK7 (IC50≥500 nM).
  • HY-125331
    DRF-1042

    		Topoisomerase ADC Cytotoxin Cancer
    DRF-1042 is an orally active derivative of Camptothecin. DRF-1042 acts to inhibit DNA topoisomerase I. DRF-1042 shows good anticancer activity against a panel of human cancer cell lines including multi-agent resistance (MDR) phenotype.
  • HY-149035
    PAA4

    		Others Cancer
    PAA4 is a methide carbon-centered polynuclear Au(I) clusters. PAA4 shows antiproliferative activity. PAA4 increases the expression of pH2AX in a time dependent manner. PAA4 shows anti-tumor effect in orthotopic bladder cancer mouse model.
  • HY-110114
    Gue1654

    		Others Others
    Gue1654 is a modulator of OXE-R. Gue1654 inhibits Gβγ but not Gα signaling triggered upon activation of Gα(i)-βγ by the chemoattractant receptor OXE-R. Gue1654 does not interfere nonspecifically with signaling directly at or downstream of Gβγ.
  • HY-100530
    Rp-cAMPS triethylammonium salt

    		PKA Neurological Disease
    Rp-cAMPS triethylammonium salt, a cAMP analog, is a potent, competitive cAMP-induced activation of cAMP-dependent PKA I and II (Kis of 12.5 µM and 4.5 µM, respectively) antagonist. Rp-cAMPS triethylammonium salt is resistant to hydrolysis by phosphodiesterases.
  • HY-119608
    GSK854

    		Others Cardiovascular Disease
    GSK854 is a potent Inhibitor of Troponin I-Interacting Kinase (TNNI3K). GSK854 is a suitable lead for identifying new cardiac medicines and have been employed as in vivo tools in investigational studies aimed at defining the role of TNNI3K within heart failure.
  • HY-N0191
    Andrographolide

    Andrographis

    		 NF-κB SARS-CoV Influenza Virus Autophagy Parasite Cancer Infection Inflammation/Immunology
    Andrographolide is a NF-κB inhibitor, which inhibits NF-κB activation through covalent modification of a cysteine residue on p50 in endothelial cells without affecting IκBα degradation or p50/p65 nuclear translocation. Andrographolide has antiviral effects.
  • HY-W033577
    Tricarbonyldichlororuthenium(II) dimer

    CORM-2

    		 Others Inflammation/Immunology
    Tricarbonyldichlororuthenium(II) dimer is a pharmacological donor of CO releasing. CO releases from Tricarbonyldichlororuthenium(II) dimer prevents gastric mucosal oxidative damage induced by ischemia/reperfusion (I/R) improving gastric blood flow (GBF), decreasing DNA oxidation and inflammatory response on systemic level.
  • HY-A0116S1
    Trandolaprilate-d6

    		Angiotensin-converting Enzyme (ACE) Endogenous Metabolite Cardiovascular Disease
    Trandolaprilate-d6 is the deuterium labeled Trandolaprilate[1]. Trandolaprilate is a potent angiotensin-converting enzyme (ACE) inhibitor. Trandolaprilate partially inhibits angiotensin-I-mediated c-fos induction. Trandolaprilate is main bioactive metabolite of Trandolapril. Trandolaprilate shows high lipophilicity[2][3].
  • HY-13955S2
    Telmisartan-13C,d3

    BIBR 277-13C,d3

    		 Angiotensin Receptor Autophagy Cardiovascular Disease Endocrinology
    Telmisartan- 13C,d3 is the 13C- and deuterium labeled Telmisartan. Telmisartan is a potent, long lasting antagonist of angiotensin II type 1 receptor (AT1), selectively inhibiting the binding of 125I-AngII to AT1 receptors with IC50 of 9.2 nM.
  • HY-114782
    H-Tyr-Tyr-OH

    L-Tyrosyl-L-tyrosine

    		 Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    H-Tyr-Tyr-OH (L-Tyrosyl-L-tyrosine) is an antihypertensive peptide. H-Tyr-Tyr-OH inhibits angiotensin I-converting enzyme (ACE) with an IC50 value of 0.028 mg/mL. H-Tyr-Tyr-OH can be used for the research of high blood pressure.
  • HY-P1110
    AF12198

    		Interleukin Related Inflammation/Immunology
    AF12198 is a potent, selective and specific peptide antagonist for human type I interleukin-1 receptor (IL1-R1) (IC50=8 nM) but not the human type II receptor (IC50=6.7 µM) or the murine type I receptor (IC50>200 µM). AF12198 inhibits IL-1-induced IL-8 production (IC50=25 nM) and IL-1-induced intercellular adhesion molecule-1 (ICAM-1) expression (IC50=9 nM) in vitro. AF12198 has anti-inflammatory activities and blocks responses to IL-1 in vivo.
  • HY-136190
    TRPC6-PAM-C20

    		TRP Channel Neurological Disease
    TRPC6-PAM-C20 is a selective positive allosteric modulator (PAM) of TRPC6 channels. TRPC6-PAM-C20 is a potent enhancer of channel activation, enabling low basal concentrations of DAG to induce activation of the ion channel. TRPC6-PAM-C20 induces increases in intracellular Ca 2+ concentrations ([Ca 2+]i) in TRPC6-expressing HEK293 cells with an EC50 of 2.37 μM. TRPC6-PAM-C20 can be used as a valuable tool to selectively exaggerate TRPC6-dependent signals.
  • HY-143494
    RSV/IAV-IN-3

    		RSV Influenza Virus Infection
    RSV/IAV-IN-3 (compound 14'i) is a dual inhibitor of respiratory syncytial virus (RSV) and influenza A virus (IAV) with EC50 values of 2.92 µM and 1.90 µM,respectively. RSV/IAV-IN-3 has antiviral effect against H1N1 and H3N2 with EC50 values of 3.25 µM and 1.50 µM in MDCK cells, respectively. RSV/IAV-IN-3 significantly inhibits the activity of luciferase in a dose-dependent manner, with an EC50 of 3.89 µM. RSV/IAV-IN-3 inhibits IAV infectivity and RdRp activity. RSV/IAV-IN-3 inhibits IAV and RSV replication at the post-entry stage.
  • HY-P2450
    Leucinostatin A

    Antibiotic P168

    		 Fungal Antibiotic Cancer Infection
    Leucinostatin A (Antibiotic P168) is a nonapeptide exerting a remarkable activity especially against Candida albicans and Cryptococcus neoformans. Leucinostatin A is a hydrophobic nonapeptide antibiotic. Leucinostatin A inhibits prostate cancer growth through reduction of insulin-like growth factor-I expression in prostate stromal cells. Antiprotozoal activies.
  • HY-100620
    RPR121056

    APC

    		 Topoisomerase Cholinesterase (ChE) Cancer
    RPR121056 (APC) is a metabolite of Irinotecan (CPT-11), which is generated by CYP3A4. Irinotecan (CPT-11) is an antineoplastic agent that inhibits topoisomerase type I, causing cell death, and is widely used in the treatment of colorectal cancer. Irinotecan also directly inhibits AChE.
  • HY-101037
    Sarcosine

    N-Methylglycine; Sarcosin

    		 Endogenous Metabolite GlyT Cancer
    Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia.
  • HY-100954
    2,4-Diamino-6-hydroxypyrimidine

    		NO Synthase Inflammation/Immunology
    2,4-Diamino-6-hydroxypyrimidine is a specific GTP cyclohydrolase I inhibitor (the rate-limiting enzyme in de novo pterin synthesis). 2,4-Diamino-6-hydroxypyrimidine blocks Tetrahydrobiopterin (BH4) synthesis and suppresses NO production.
  • HY-101535
    ARP101

    		MMP Cancer
    ARP101 is a potent and selective inhibitor matrix metalloproteinase-2 (MMP-2). ARP101 induces autophagy-associated cell death in cancer cells. ARP101 is effective in inducing the formation of autophagosome and conversion of LC3I into LC3II.
  • HY-121309S
    Doxorubicinone-d3

    Adriamycin aglycone-d3; Adriamycinone-d3

    		 Endogenous Metabolite Cancer
    Doxorubicinone-d3 is the deuterium labeled Doxorubicinone. Doxorubicinone is a metabolite of an anti-cancer chemotherapy agent Doxorubicin[1]. Doxorubicin is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC50s of 0.8 μM and 2.67 μM, respectively.
  • HY-147840
    HDAC-IN-41

    		HDAC Cancer
    HDAC-IN-41 (Compound 7c) is a selective, orally active class I HDAC inhibitor with IC50 values of 0.62, 1.46 and 0.62 μM against HDAC1, HDAC2 and HDAC3, respectively. HDAC-IN-41 shows NO releasing activity.
  • HY-100748
    Zabadinostat

    CXD101

    		 HDAC Cancer
    Zabadinostat (CXD101) is a potent, selective and orally active class I HDAC inhibitor with IC50s of 63 nM, 570 nM and 550 nM for HDAC1, HDAC2 and HDAC3, respectively. Zabadinostat has no activity against HDAC class II. Zabadinostat has antitumor activity.
  • HY-P2977
    N-Acetylneuraminate lyase (CgNal)

    Sialic acid aldolase (CgNal)

    		 Endogenous Metabolite Others
    N-Acetylneuraminate lyase (CgNal) (Sialic acid aldolase (CgNal)) is a class I aldolase, is often used in biochemical studies. N-Acetylneuraminate lyase (CgNal) catalyzes the reversible condensation of pyruvate with N-acetyl-d-mannosamine (ManNAc) to yield the sialic acid N-acetylneuraminic acid (Neu5Ac).
  • HY-149017
    Apoptosis inducer 7

    		Apoptosis Cancer
    Apoptosis inducer 7 (Compound 5I) induces apoptosis in cancer cells. Apoptosis inducer 7 inducrs cleavage of PARP, caspases, down-regulation of anti-apoptotic protein c-Flip and up regulation of pro-apoptotic protein Noxa. Apoptosis inducer 7 exhibits antitumor activity.
  • HY-139909
    CL2E-SN38

    		Drug-Linker Conjugates for ADC Cancer
    CL2E-SN-38, a highly releasable and structurally stable antibody-SN-38-conjugate, is a part of the antibody drug conjugate (ADC). SN-38, the active metabolite of Irinotecan from camptothecins, is an Topoisomerase I inhibitor.
  • HY-146008
    hCAII-IN-3

    		Carbonic Anhydrase Cancer
    hCAII-IN-3 (Compound 16) is a human carbonic anhydrase (hCA) inhibitor with Ki values of 403.8, 5.1, 10.2 and 5.2 nM against hCA I, hCA II, hCA IX and hCA XII, respectively. hCA IX-IN-2 shows anticancer activity.
  • HY-12512
    cGAMP

    Cyclic GMP-AMP; 3',3'-cGAMP

    		 STING Inflammation/Immunology
    cGAMP (Cyclic GMP-AMPP) functions as an endogenous second messenger in metazoans and triggers interferon production in response to cytosolic DNA. cGAMP activates stimulator of interferon genes (STING), which activates a signaling cascade leading to the production of type I interferons and other immune mediators.
  • HY-142690
    HDAC-IN-27

    		HDAC Cancer
    HDAC-IN-27 (Compound 11h) is a potent, selective and orally active HDAC Class I inhibitor, with IC50 values ranging from 0.43 nM to 3.01 nM for HDAC1-3. HDAC-IN-27 shows anti-acute myeloid leukemia (AML) activity.
  • HY-147521
    Antitumor photosensitizer-3

    		Necroptosis Cancer
    Antitumor photosensitizer-3 (Compound I) is a chlorin derivative. Antitumor photosensitizer-3 induces tumor cells apoptosis and necrosis under 650 nm laser irradiation. Antitumor photosensitizer-3 exhibits lower skin photo-toxicity than positive reference m-THPC in vivo.
  • HY-118467
    Benzolamide

    CL11366

    		 Carbonic Anhydrase Neurological Disease
    Benzolamide (CL11366) is a potent carbonic anhydrase (CA) inhibitor, with Kis of 15 nM, 9 nM, 94 nM and 78 nM for hCA I, hCA II, EcoCAγ and VchCAγ, respectively. Benzolamide also inhibits CAS3, with a Ki of 54 nM. Benzolamide can be used for the research of glaucoma and seizures.
  • HY-50847
    ZSTK474

    		PI3K Autophagy Cancer
    ZSTK474 is an ATP-competitive pan-class I PI3K inhibitor with IC50s of 16 nM, 44 nM, 4.6 nM and 49 nM for PΙ3Κα, PI3Kβ, PI3Kδ and PI3Kγ, respectively.
  • HY-114170
    ML604440

    		Proteasome Inflammation/Immunology
    ML604440 is a specific and cell-permeable Proteasome β1i (LMP2) subunit inhibitor. ML604440 can be used in experimental colitis, EAE and autoimmune disease research. ML604440 shows synergistic effects and advantageous when combined with LMP7 inhibitor.
  • HY-146260
    NVP-CLR457

    		PI3K Cancer
    NVP-CLR457 (compound 40) is an orally active, potent and balanced pan-class I PI3K inhibitor. NVP-CLR457 shows a clear dose-dependent PK/PD/efficacy relationship. NVP-CLR457 has antitumor activity.
  • HY-107096
    CH-0793076

    TP3076

    		 Topoisomerase Cancer
    CH-0793076 (TP3076), a hexacyclic camptothecin analog, is active drug and major metabolite of TP300. CH-0793076 inhibits DNA topoisomerase I with an IC50 of 2.3 μM. CH-0793076 is efficacious against cells expressing BCRP (breast cancer resistance protein).
  • HY-18351
    Indotecan

    LMP-400; NSC-724998

    		 Topoisomerase Cancer Infection
    Indotecan (LMP-400), an indenoisoquinoline derivative, is a potent Topoisomerase I inhibitor, with IC50s of 300, 1200, 560 nM for P388, HCT116, MCF-7 cell lines, respectively. Indotecan prevents the relaxation of supercoiled DNA and can be used for the research of visceral leishmaniasis.
  • HY-A0259
    Floctafenine

    		COX Inflammation/Immunology
    Floctafenine, a nonsteroidal anti-inflammatory agent (NSAID), acts as an effective analgesic agent. Floctafenine is an inhibitor of COX-1 and COX-2 activities in vitro,showing a slightly higher potency towards COX-I. Floctafenine is used for the research of short term pain research.
  • HY-16012
    Domatinostat tosylate

    4SC-202

    		 HDAC Apoptosis Cancer
    Domatinostat tosylate (4SC-202) is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. It also displays inhibitory activity against Lysine specific demethylase 1 (LSD1).
  • HY-127026S
    Quinaprilat-d5

    		Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Quinaprilat-d5 is a deuterium-labeled Quinaprilat. Quinaprilat is a nonsulfhydryl ACE inhibitor, the active diacid metabolite of Quinapril. Quinaprilat specifically blocks the conversion of angiotensin I to the vasoconstrictor angiotensin II and inhibits bradykinin degradation. Quinaprilat primarily acts as a vasodilator, decreasing total peripheral and renal vascular resistance[1].
  • HY-A0230
    Spirapril

    SCH 33844

    		 Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Spirapril is a potent and cross the blood-brain barrier angiotensin converting enzyme (ACE) inhibitor with antihypertensive activity. Spirapril competitively binds to ACE and prevents the conversion of angiotensin I to angiotensin II. Spirapril is an orally active proagent of Spiraprilat and can be used for the research of hypertension, congestive heart failure.
  • HY-139909A
    CL2E-SN38 TFA

    		Drug-Linker Conjugates for ADC Cancer
    CL2E-SN-38 TFA, a highly releasable and structurally stable antibody-SN-38-conjugate, is a part of the antibody drug conjugate (ADC). SN-38, the active metabolite of Irinotecan from camptothecins, is an Topoisomerase I inhibitor.
  • HY-152138
    Antituberculosis agent-8

    		Bacterial Fungal Infection
    Antituberculosis agent-8 (Compound 9i) is an antitubercular agent with an MIC of 3.53 μM (1.6 μg/mL) against M. tuberculosis H37Rv. Antituberculosis agent-8 also shows good antifungal activity against A. niger with an MIC of 62.50 μM.
  • HY-147270
    MC-VA-PAB-Exatecan

    		Drug-Linker Conjugates for ADC Cancer
    MC-VA-PAB-Exatecan is a agent-linker conjugate for ADC. MC-VA-PAB-Exatecan contains the ADC linker (peptide MC-VA-PAB) and a DNA topoisomerase I inhibitor Exatecan (HY-13631). MC-VA-PAB-Exatecan synthesized ADC shows good antitumor activity.
  • HY-148029
    Dazostinag disodium

    TAK-676

    		 STING Cancer
    Dazostinag disodium (TAK-676) is an agonist of STING, triggering the activation of STING signaling pathway and type I interferons. Dazostinag disodium is also a modulator of immune system, resulting complete regressions and durable memory T-cell immunity. Dazostinag disodium promotes durable IFN-dependent antitumor immunity.
  • HY-125773
    β-cyano-L-Alanine

    Beta-cyano-l-alanine

    		 Endogenous Metabolite Neurological Disease
    β-cyano-L-Alanine (Beta-cyano-l-alanine), a nitrile of widespread occurrence in higher plants, is enzymatically produced by cyanoalanine synthase from cyanide and cysteine as substrates. β-cyano-L-Alanine abolishes the protective effect of ethanol on cerebral ischemia/reperfusion (I/R) injury.
  • HY-P99843
    Datopotamab

    CDP7657

    		 ADC Antibody Cancer
    Datopotamab (CDP7657) is an antibody targeting to TROP2. Datopotamab can be used to synthesize Datopotamab deruxtecan (HY-141598), TROP2-directed antibody-drug conjugate (ADC). Datopotamab deruxtecan consists of DNA topoisomerase I inhibitor Deruxtecan (HY-13631E) and Datopotamab.
  • HY-W009783
    1-Deoxymannojirimycin hydrochloride

    		HIV Influenza Virus Infection
    1-Deoxymannojirimycin hydrochloride is a selective class I α1,2-mannosidase inhibitor with an IC50 of 20 μM. 1-Deoxymannojirimycin hydrochloride is also a N-linked glycosylation inhibitor and inhibits HIV‐1 strains. 1-Deoxymannojirimycin hydrochloride has antiviral activity.
  • HY-13521
    SB-505124

    		TGF-β Receptor Cancer
    SB-505124 is a selective inhibitor of TGF-β Receptor type I receptors (ALK4, ALK5, ALK7), with IC50s of 129 nM and 47 nM for ALK4, ALK5, respectively, but it does not inhibit ALK1, 2, 3, or 6.
  • HY-122958
    Peucedanocoumarin III

    		α-synuclein Neurological Disease
    Peucedanocoumarin III is an inhibitor of α-synuclein and Huntington protein aggregates that enhances the clearance of nuclear and cytoplasmic β23 aggregates and prevents cytotoxicity induced by disease-associated proteins (i.e., mutant Huntington proteins and α-synuclein). Peucedanocoumarin III may be used in Parkinson's disease research.
  • HY-146541
    FGFR4-IN-10

    		FGFR Cancer
    FGFR4-IN-10 (compound 5a) is a potent and selective FGFR4 inhibitor with an IC50 value of 70.7 nM. FGFR4-IN-10 shows no inhibition against other FGFR family members, i.e. FGFR1, FGFR2 and FGFR3.
  • HY-146007
    hCAIX-IN-17

    		Carbonic Anhydrase Cancer
    hCA IX-IN-1 (Compound 6f) is a human carbonic anhydrase (hCA) inhibitor with Ki values of 331.4, 28.4, 9.4 and 17.8 nM against hCA I, hCA II, hCA IX and hCA XII, respectively. hCA IX-IN-1 shows anticancer activity.
  • HY-148035
    Plm IV inhibitor-2

    		Parasite Infection
    Plm IV inhibitor-2 (compound 3) is a potent digestive vacuole plasmepsins IV (Plm IV) inhibitor with IC50 values of 24 nM, 70 nM and 0.3 μM for Plm IV, II and I, respectively. Plm IV inhibitor-2 can be used to research malaria caused by Plasmodium parasites.
  • HY-13982
    JSH-23

    		NF-κB Cancer Metabolic Disease Inflammation/Immunology
    JSH-23 is an NF-κB inhibitor which inhibits NF-κB transcriptional activity with an IC50 of 7.1 μM in lipopolysaccharide (LPS)-stimulated macrophages RAW 264.7. JSH-23 inhibits nuclear translocation of NF-κB p65 without affecting IκBα degradation.
  • HY-120234
    Z-LLNle-CHO

    Z-Leu-Leu-Nle-CHO; GSII

    		 γ-secretase Proteasome Apoptosis Cancer
    Z-LLNle-CHO (Z-Leu-Leu-Nle-CHO) is a γ-secretase inhibitor I. Z-LLNle-CHO induces caspase and ROS-dependent apoptosis by blocking the Akt-mediated pro-survival pathway. Z-LLNle-CHO can be used in cancer research, such as breast cancer and leukaemia.
  • HY-14852
    Tafamidis

    		Transthyretin (TTR) Neurological Disease
    Tafamidis is a potent and selective transthyretin (TTR) stabilizer, shows comparable potency and efficacy to the mutumant homotetramers V30M-TTR, V122I-TTR and wild type WT-TTR, with EC50s of 2.7-3.2 μM. Tafamidis inhibits amyloidogenesis.
  • HY-110385
    cGAMP disodium

    Cyclic GMP-AMP disodium; 3',3'-cGAMP disodium

    		 STING Endogenous Metabolite Inflammation/Immunology
    cGAMP (Cyclic GMP-AMPP) disodium functions as an endogenous second messenger in metazoans and triggers interferon production in response to cytosolic DNA. cGAMP diammonium activates stimulator of interferon genes (STING), which activates a signaling cascade leading to the production of type I interferons and other immune mediators.
  • HY-B1471
    Fluorometholone acetate

    		Carbonic Anhydrase Inflammation/Immunology
    Fluorometholone acetate is a synthetic glucocorticoid corticosteroid and a corticosteroid ester. Fluorometholone acetate potently inhibits carbonic anhydrase (CA) with IC50s of 2.18 μM and 17.5 μM for hCA-I and hCA-II, respectively. Fluorometholone acetate has anti-inflammatory effect and has the potential for external ocular inflammation research.
  • HY-13687A
    IKK 16 hydrochloride

    		IKK LRRK2 Inflammation/Immunology
    IKK 16 hydrochloride is a selective IκB kinase (IKK) inhibitor for IKK2, IKK complex and IKK1 with IC50s of 40 nM, 70 nM and 200 nM, respectively. IKK16 also inhibits leucine-rich repeat kinase-2 (LRRK2) with an IC50 of 50 nM.
  • HY-16100
    BI 99179

    		Fatty Acid Synthase (FASN) Cancer Metabolic Disease
    BI 99179 is a potent and selective type I fatty acid synthase (FAS) inhibitor with an IC50 of 79 nM. BI 99179 is a tool compound suitable for the in vivo validation of FAS as a target for lipid metabolism related diseases. BI 99179 exhibits significant exposure (both peripheral and central) upon oral administration in rats.
  • HY-110385A
    cGAMP diammonium

    Cyclic GMP-AMP diammonium; 3',3'-cGAMP diammonium

    		 STING Endogenous Metabolite Inflammation/Immunology
    cGAMP (Cyclic GMP-AMPP) diammonium functions as an endogenous second messenger in metazoans and triggers interferon production in response to cytosolic DNA. cGAMP diammonium activates stimulator of interferon genes (STING), which activates a signaling cascade leading to the production of type I interferons and other immune mediators.
  • HY-117066
    CL075

    3M002

    		 Toll-like Receptor (TLR) Inflammation/Immunology
    CL075 (3M002) is a selective TLR8 agonist with immunomodulating properties. CL075 triggers a MyD88-dependent signaling pathway to elicit production of inflammatory cytokines and type I interferons (IFNs) via activation of NF-κB and IRF7, respectively.
  • HY-101647
    Intoplicine

    RP 60475

    		 Topoisomerase Cancer
    Intoplicine (RP 60475), an antitumor derivative in the 7H-benzo[e]pyrido[4,3-b]indole series, is a DNA topoisomerase I and II inhibitor. Intoplicine strongly binds DNA (KA = 2 x 10 5 /M) and thereby increases the length of linear DNA.
  • HY-106218
    Flurocitabine

    5-Fluorocyclocytidine; 5'-Fluorocyclocytidine

    		 Nucleoside Antimetabolite/Analog Cancer
    Flurocitabine (5-Fluorocyclocytidine) is a fluorinated anlydride analog of cytosine arabinoside, partially hydrolysecl in vivo into two active antitumor substances (arabinosyl-tluorocytosine (ara-FC) and arabinosyl-fluorouracil (ara-FU)). Flurocitabine (5-Fluorocyclocytidine) has antitumor activity during phase I studies in acute leukemia and solid tumors.
  • HY-129421
    PA-9

    		Others Inflammation/Immunology Neurological Disease
    PA-9 is a pituitary adenylate cyclase-activating polypeptide (PACAP) type I (PAC1) receptor antagonist. PA-9 dose dependently inhibits PACAP-induced cAMP elevation with an IC50 of 5.6 nM. PA-9 can be used for the research of neuropathic and/or inflammatory pain.
  • HY-P4109
    vMIP-II (1-21)

    NT21MP; V1 peptide

    		 CXCR Cancer Inflammation/Immunology
    vMIP-II (1-21) is a CXCR4 antagonist. vMIP-II has broad-spectrum interaction with CC and CXC chemokine receptors. vMIP-II (1-21) binds with CXCR4 with an IC50 value of 190 nM for competing with CXCR4 binding of 125I-SDF-1R.
  • HY-13521A
    SB-505124 hydrochloride

    		TGF-β Receptor Cancer
    SB-505124 hydrochloride is a selective inhibitor of TGF-β Receptor type I receptor (ALK4, ALK5, ALK7), with IC50s of 129 nM and 47 nM for ALK4, ALK5, respectively, but it does not inhibit ALK1, 2, 3, or 6.
  • HY-16012A
    Domatinostat

    4SC-202 free base

    		 HDAC Apoptosis Cancer
    Domatinostat (4SC-202 free base) is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. It also displays inhibitory activity against Lysine specific demethylase 1 (LSD1).
  • HY-16952A
    Bepridil hydrochloride hydrate

    (±)-Bepridil hydrochloride hydrate; Org 5730 hydrochloride hydrate

    		 Calcium Channel Cardiovascular Disease
    Bepridil hydrochloride hydrate ((±)-Bepridil hydrochloride hydrate) is a non-selective, long-acting Ca + channel antagonist and Na +, K + channel inhibitor, with antianginal and type I antiarrhythmic effects. Bepridil hydrochloride hydrate also acts as a cardiac Na +/Ca2 + exchange (NCX1) inhibitor. Bepridil hydrochloride hydrate can be used for the research of cardiovascular disorders.
  • HY-B1099
    Hycanthone

    		DNA/RNA Synthesis Topoisomerase Parasite Infection
    Hycanthone is a thioxanthenone DNA intercalator and inhibits RNA synthesis as well as the DNA topoisomerases I and II. Hycanthone inhibits nucleic acid biosynthesis and inhibits apurinic endonuclease-1 (APE1) by direct protein binding with a KD of 10 nM. Hycanthone is a bioactive metabolite of Lucanthone (HY-B2098) and has anti-schistosomal agent.
  • HY-135780A
    3'-Deoxyuridine-5'-triphosphate trisodium

    3'-dUTP trisodium

    		 Nucleoside Antimetabolite/Analog DNA/RNA Synthesis Endogenous Metabolite Metabolic Disease
    3'-Deoxyuridine-5'-triphosphate trisodium (3'-dUTP trisodium) is a nucleotide analogue that inhibits DNA-dependent RNA polymerases I and II. 3'-Deoxyuridine-5'-triphosphate trisodium strongly and competitively inhibits the incorporations of UTP into RNA with a Ki value of 2.0 μM.
  • HY-W111226
    Fmoc-His(3-Me)-OH

    		Amino Acid Derivatives Amyloid-β Cardiovascular Disease
    Fmoc-His(3-Me)OH derives Histidine-associating compounds with biological activity. Fmoc-His(3-Me)OH, with Fmoc-citrulline-OH, Fmoc-His(1-Me)-OH together, forms tri-peptides and shows vasodilating effect with EC50s of 2.7-4.7 mM in 1.0 mM Phenylephrine (PE)-contracted aorta rings. Fmoc-His(3-Me)OH (resin) also makes Methyl-His-Gly-Lys (His(3-Me)-Gly-Lys), thus acts as an [Ca 2+]i inhibitor. Fmoc-His(3-Me)OH methylates NAHIS02, making it unable to block the Alzheimer's Aβ channel.
  • HY-10195BS
    Ruboxistaurin-d6 hydrochloride

    		PKC Metabolic Disease
    Ruboxistaurin-d6 (hydrochloride) is the deuterium labeled Ruboxistaurin hydrochloride. Ruboxistaurin (LY333531) hydrochloride is an orally active, selective PKC beta inhibitor (Ki=2 nM). Ruboxistaurin hydrochloride exhibits ATP dependent competitive inhibition of PKC beta I with an IC50 of 4.7 nM. Ruboxistaurin hydrochloride inhibits PKC beta II with an IC50 of 5.9 nM[1][2].
  • HY-134723
    DBCO-PEG4-GGFG-Exatecan

    DBCO-PEG4-GGFG-DX8951

    		 Drug-Linker Conjugates for ADC Cancer
    DBCO-PEG4-GGFG-Exatecan (DBCO-PEG4-GGFG-DX8951) is a agent-linker conjugate for ADC with potent antitumor activity by using DX8951 (a DNA topoisomerase I inhibitor), linked via the cleavable ADC linker DBCO-PEG4-GGFG.
  • HY-147307
    MC-Gly-Gly-Phe-Gly-Cyclobutanecarboxylic-Exatecan

    		Drug-Linker Conjugates for ADC Cancer
    MC-Gly-Gly-Phe-Gly-Cyclobutanecarboxylic-Exatecan is a agent-linker conjugate for ADC, contains the ADC linker (MC-Gly-Gly-Phe-Gly-Cyclobutanecarboxylic acid) and a DNA topoisomerase I inhibitor Exatecan (HY-13631). MC-Gly-Gly-Phe-Gly-Cyclobutanecarboxylic-Exatecan synthesized ADC can be used in study of cancer.
  • HY-114233
    MC-GGFG-Exatecan

    MC-GGFG-DX8951

    		 Drug-Linker Conjugates for ADC Cancer
    MC-GGFG-Exatecan (MC-GGFG-DX8951) is a agent-linker conjugate for ADC. MC-GGFG-Exatecan is a DX8951 (a DNA topoisomerase I inhibitor) derivative with protease cleavable MC-GGFG linker. MC-GGFG-Exatecan shows antitumor activity and can be used to prepare DX8951 antibody conjugate (ADC).
  • HY-10964
    Vadimezan

    DMXAA; ASA-404

    		 STING IFNAR Influenza Virus Cancer Infection
    Vadimezan (DMXAA; ASA-404), the tumor vascular disrupting agent (tumor-VDA), is a murine agonist of the stimulator of interferon genes (STING) and also a potent inducer of type I IFNs and other cytokines. Vadimezan has anti-influenza virus H1N1-PR8 activities.
  • HY-120994A
    Rp-8-CPT-cAMPS

    		PKA Inflammation/Immunology Neurological Disease
    Rp-8-CPT-cAMPS, a cAMP analog, is a potent and competitive antagonist of cAMP-induced activation of cAMP-dependent PKA I and II. Rp-8-CPT-cAMPS preferentially selects site A of RI compares to site A of RII and site B of RII compares to site B of RI.
  • HY-147970
    Antifungal agent 34

    		Fungal Infection
    Antifungal agent 34 (compound 6i) is a potent antifungal agent. Antifungal agent 34 shows a potent antifungal activity against Candida albicans, with a MIC of 4 µg/mL. Antifungal agent 34 shows significant inhibition on Candida albicans hyphae and biofilm development. Antifungal agent 34 exhibits no cytotoxicity to mammalian cells.
  • HY-N4104
    Agaric acid

    Agaricinic Acid

    		 Mitochondrial Metabolism Metabolic Disease
    Agaric acid (Agaricinic Acid) is obtained from various plants of the fungous tribe, i.e. Polyporus officinalis and Polyporus igniarius. Agaric acid induces mitochondrial permeability transition through its interaction with the adenine nucleotide translocase. Agaric acid promotes efflux of accumulated Ca 2+, collapse of transmembrane potential, and mitochondrial swelling. Agaric acid is used to regulate lipid metabolism.
  • HY-152158
    α-Glucosidase-IN-22

    		Glucosidase Metabolic Disease
    α-Glucosidase-IN-22 (compound 7i), a benzimidazole, is a potent α-glucosidase inhibitor with an IC50 of 0.64 μM. α-Glucosidase-IN-22 is a potent anti-diabetic agent and has the potential for type 2 diabetes mellitus (T2DM) research.
  • HY-145909
    BRD4 Inhibitor-17

    		Epigenetic Reader Domain Cancer
    BRD4 Inhibitor-17 (Compound 5i) is a potent inhibitor of BRD4 with an IC50 of 0.33 μM. BRD4 Inhibitor-17 plays crucial role in regulating transcription of inflammatory, proliferation and cell cycle genes. BRD4 Inhibitor-17 serves as potential antidotes for arsenicals.
  • HY-A0236A
    Aprindine hydrochloride

    		Potassium Channel Cardiovascular Disease
    Aprindine hydrochloride is a class I-b anti-arrhythmic agent and a?hERG channel blocker with an IC50 of 0.23 μM. Aprindine hydrochloride has inhibitory effects on Na +/Ca 2+ exchanger currents, which is partly responsible for their antiarrhythmic and cardioprotective effects. Aprindine hydrochloride is widely used for trial and ventricular tachyarrhythmias research research.
  • HY-D0162
    Malachite green oxalate

    		IKK NF-κB Apoptosis Cancer
    Malachite green oxalate is a triphenylmethane dye which can be used to detect the release of phosphate in enzymatic reactions. Malachite green oxalate is also a potent and selective inhibitor of IKBKE, and inhibits its downstream targets such as IκBα, p65 and IRF3. Malachite green oxalate exhibits antitumor activity in vitro and in vivo.
  • HY-P2918
    Glucose 6-phosphate isomerase

    GPI; Phosphoglucose Isomerase

    		 Endogenous Metabolite Others
    Glucose 6-phosphate isomeras (GPI), i.e., phosphoglucose isomerase/phosphoglucoisomerase (PGI) or phosphohexose isomerase (PHI), is often used in biochemical studies. Glucose 6-phosphate isomeras is a highly conserved glycolytic and dimeric enzyme. Glucose 6-phosphate isomeras catalyzes the reversible isomerization of glucose-6-phosphate to fructose-6-phosphate.
  • HY-120118
    Metarrestin

    ML246

    		 DNA/RNA Synthesis Cancer
    Metarrestin (ML246) is an orally active, first-in-class and specific perinucleolar compartment inhibitor. Metarrestin disrupts the nucleolar structure and inhibits RNA polymerase (Pol) I transcription, at least in part by interacting with the translation elongation factor eEF1A2. Metarrestin blocks metastatic development and extends survival in mouse cancer models.
  • HY-126307
    Urolithin B

    		NF-κB JNK ERK Akt AMPK Endogenous Metabolite Inflammation/Immunology
    Urolithin B is one of the gut microbial metabolites of ellagitannins, and has anti-inflammatory and antioxidant effects. Urolithin B inhibits NF-κB activity by reducing the phosphorylation and degradation of IκBα, and suppresses the phosphorylation of JNK, ERK, and Akt, and enhances the phosphorylation of AMPK. Urolithin B is also a regulator of skeletal muscle mass.
  • HY-P1256C
    JMV 449 acetate

    		Neurotensin Receptor Neurological Disease
    JMV 449 acetate is a potent neurotensin receptor agonist. JMV 449 acetate shows an IC50 of 0.15 nM for inhibition of 125I-neurotensin binding to neonatal mouse brain and an EC50 of 1.9 nM in contracting the guinea-pig ileum. JMV 449 acetate has highly potent and long-lasting hypothermic and analgesic effects in the mouse.
  • HY-B0615AS
    Moricizine-d8(Hydrochloride)

    EN 313-d8; Ethmosine-d8; Ethmozin-d8

    		 Isotope-Labeled Compounds Cardiovascular Disease
    Moricizine-d8 (Hydrochloride) is the deuterium labeled Moricizine Hydrochloride (HY-B0615A). Moricizine Hydrochloride is an orally active Class I antiarrhythmic agent. Moricizine Hydrochloride decreases the maximum rate of phase 0 depolarization; increases rates of phase 2 and 3 repolarization, decreases action potential duration, and decreases effective refractory period[1][2].
  • HY-15180
    Buparlisib Hydrochloride

    BKM120 Hydrochloride; NVP-BKM120 Hydrochloride

    		 PI3K Apoptosis Cancer
    Buparlisib Hydrochloride (BKM120 Hydrochloride) is a pan-class I PI3K inhibitor, with IC50 of 52 nM/166 nM/116 nM/262 nM for p110α/p110β/p110δ/p110γ, respectively.
  • HY-P1985A
    Notch 1 TFA

    		Notch Cancer Cardiovascular Disease
    Notch 1 TFA (Notch homolog 1, translocation-associated) can encode a member of the NOTCH family of proteins. Members of this Type I transmembrane protein family share structural characteristics including an extracellular domain consisting of multiple epidermal growth factor-like (EGF) repeats, and an intracellular domain consisting of multiple different domain types.
  • HY-16526
    Pilaralisib

    XL-147; SAR245408

    		 PI3K Cancer
    Pilaralisib (XL147; SAR245408) is a potent and highly selective class I PI3Ks inhibitor with IC50s of 39 nM, 383 nM, 23 nM and 36 nM for PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ.
  • HY-118091
    LY191704

    		5 alpha Reductase Endocrinology
    LY191704, as a benzoquinolinone, is a potent, nonsteroidal, noncompetitive and selective human type I 5α-reductase inhibitor. LY191704 is a racemic mixture of the compounds LY300502 and LY300503. LY191704 may be useful in the research of human endocrine disorders associated with overproduction of dihydrotestosterone (DHT) by 5α-reductase type 1.
  • HY-107096B
    CH-0793076 TFA

    TP3076 TFA

    		 Topoisomerase Cancer
    CH-0793076 (TP3076) TFA, a hexacyclic camptothecin analog, is active drug and major metabolite of TP300. CH-0793076 TFA inhibits DNA topoisomerase I with an IC50 of 2.3 μM. CH-0793076 TFA is efficacious against cells expressing BCRP (breast cancer resistance protein).
  • HY-101647A
    Intoplicine dimesylate

    RP 60475 dimesylate

    		 Topoisomerase Cancer
    Intoplicine (RP 60475) dimesylate, an antitumor derivative in the 7H-benzo[e]pyrido[4,3-b]indole series, is a DNA topoisomerase I and II inhibitor. Intoplicine dimesylate strongly binds DNA (KA = 2 x 10 5 /M) and thereby increases the length of linear DNA.
  • HY-12278
    K02288

    		TGF-β Receptor Others
    K02288 is a potent bone morphogenetic protein (BMP) type I receptor inhibitor with IC50s of 1.8, 1.1, 6.4 nM for ALK1, ALK2 and ALK6, respectively. K02288 shows slightly weaker inhibition against ALK3 and ALK6 with IC50s of of 5-34 nM.
  • HY-142922
    BCR-ABL-IN-4

    		Bcr-Abl Cancer
    BCR-ABL-IN-4 is a BCR-ABL inhibitor with anticancer effects. BCR-ABL-IN-4 inhibits the cancer cell growth with IC50 values of 0.67 nM and 16 nM for K562 cells and BCR-ABL T315I transfected Ba/F3 cells, respectively (WO2021143927A1; compound 11).
  • HY-P1256
    JMV 449

    		Neurotensin Receptor Neurological Disease
    JMV 449 is a potent neurotensin receptor agonist. JMV 449 shows an IC50 of 0.15 nM for inhibition of [ 125I]-neurotensin binding to neonatal mouse brain and an EC50 of 1.9 nM in contracting the guinea-pig ileum. JMV 449 has highly potent and long-lasting hypothermic and analgesic effects in the mouse.
  • HY-15666
    Olverembatinib

    GZD824; HQP1351

    		 Bcr-Abl Cancer
    Olverembatinib (GZD824) is a potent and orally active pan-Bcr-Abl inhibitor. Olverembatinib potently inhibits a broad spectrum of Bcr-Abl mutants. Olverembatinib strongly inhibits native Bcr-Abl and Bcr-Abl T315I with IC50s of 0.34 nM and 0.68 nM, respectively. Olverembatinib has antitumor activity.
  • HY-120994
    Rp-8-CPT-cAMPS sodium

    		PKA Inflammation/Immunology Neurological Disease
    Rp-8-CPT-cAMPS sodium, a cAMP analog, is a potent and competitive antagonist of cAMP-induced activation of cAMP-dependent PKA I and II. Rp-8-CPT-cAMPS sodium preferentially selects site A of RI compares to site A of RII and site B of RII compares to site B of RI.
  • HY-146780
    TGFβRI-IN-4

    		TGF-β Receptor Cancer
    TGFβRI-IN-4 is a highly potent and orally active TGFβ receptor type I (TGFβRI) inhibitor, with IC50s of 44 nM and 42.5 nM for ALK5 and NIH3T3. TGFβRI-IN-4 can suppress tumor growth and tumor weight in tumor xenograft model.
  • HY-50514
    AT9283

    		JAK Aurora Kinase Bcr-Abl FLT3 Apoptosis Autophagy Cancer
    AT9283 is a multi-targeted kinase inhibitor with potent activity against Aurora A/B, JAK2/3, Abl (T315I) and Flt3 (IC50s ranging from 1 to 30 nM). AT9283 inhibits growth and survival of multiple solid tumors in vitro and in vivo.
  • HY-147836
    Akt/NF-κB/JNK-IN-1

    		Akt NF-κB JNK TNF Receptor COX Inflammation/Immunology
    Akt/NF-κB/JNK-IN-1 (Compound 2i) is an inhibitor of Akt, NF-κB and JNK signaling pathways. Akt/NF-κB/JNK-IN-1 inhibits nitric oxide production with an IC50 of 3.15 μM. Akt/NF-κB/JNK-IN-1 shows anti-inflammatory activities.
  • HY-P4580
    Suc-Ala-Ala-Pro-Phe-SBzl

    		Proteasome Others
    Suc-Ala-Ala-Pro-Phe-SBzl can be used as the substrate of rat intestinal mast cell protease (RMCP I), rat skeletal muscle mast cell protease (RMCP II) and Chymotrypsin (HY-108910). Suc-Ala-Ala-Pro-Phe-SBzl can be hydrolyzed by glycine (R208G).
  • HY-50101A
    Mavorixafor trihydrochloride

    AMD-070 trihydrochloride

    		 CXCR HIV Infection Endocrinology Cancer
    Mavorixafor trihydrochloride (AMD-070 trihydrochloride) is a potent, selective and orally available CXCR4 antagonist, with an IC50 value of 13 nM against CXCR4 125I-SDF binding, and also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC50 of 1 and 9 nM, respectively.
  • HY-P3678
    Neuropeptide Y (18-36) (porcine)

    		Neuropeptide Y Receptor Neurological Disease Cardiovascular Disease
    Neuropeptide Y (18-36) (porcine) is a competitive neuropeptide Y (NPY) cardiac receptor antagonist. Neuropeptide Y (18-36) (porcine) inhibits the binding of I-NPY to cardiac ventricular membranes in a concentration-dependent manner with an IC50 value of 158 nM and an Ki value of 140 nM. Neuropeptide Y (18-36) (porcine) can be used for the research of congestive heart failure.
  • HY-116451
    PF-04859989 hydrochloride

    		Others Neurological Disease
    PF-04859989 hydrochloride is a brain-penetrant, irreversible kynurenine aminotransferase (KAT) II inhibitor with IC50s of 23 and 263 nM for hKAT II and rKAT II. PF-04859989 hydrochloride is selective for KAT II over human KAT I, KAT III, and KAT IV (IC50s of 22, 11, and >50 μM, respectively).
  • HY-P99813
    Patritumab deruxtecan

    HER3-DXd; U3-1287

    		 Antibody-Drug Conjugates (ADCs) Cancer
    Patritumab deruxtecan (HER3-DXd) is an antibody-drug conjugate (ADC) consisting of a fully human anti-HER3 IgG1 monoclonal antibody Patritumab (HY-P99275) attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. Patritumab deruxtecan shows anticancer activity.
  • HY-A0166S
    Cilastatin-15N,d3

    MK0791-15N,d3

    		 Bacterial Antibiotic Infection
    Cilastatin- 15N,d3 is a 15N-labeled and deuterium labeled Cilastatin. Cilastatin (MK0791) is a reversible, competitive renal dehydropeptidase I inhibitor with an IC50 of 0.1 μM. Cilastatin inhibits the bacterial metallob-lactamase enzyme CphA with an IC50 of 178 μM. Cilastatin is an antibacterial adjunct[1][2][3].
  • HY-13024
    Rebastinib

    DCC-2036

    		 Bcr-Abl FLT3 Src Apoptosis Cancer
    Rebastinib (DCC-2036) is an orally active, non-ATP-competitive Bcr-Abl inhibitor for Abl1 WT and Abl1 T315I with IC50s of 0.8 nM and 4 nM, respectively. Rebastinib also inhibits SRC, KDR, FLT3, and Tie-2, and has low activity to seen towards c-Kit.
  • HY-144264
    hCAII-IN-6

    		Carbonic Anhydrase Endocrinology
    hCAII-IN-6 (Compound S-13) is a potent human carbonic anhydrase II (hCA II) inhibitor with a Ki of 4.4 nM. hCAII-IN-6 also inhibits other hCAs isoforms I, IV and IX, with Ki values of 9.2 nM, 480.2 nM and 14.7 nM, respectively. hCAII-IN-6 can be used for glaucoma research.
  • HY-147698
    ZLHQ-5f

    		CDK Topoisomerase Apoptosis Cancer
    ZLHQ-5f is a dual CDK2 and Topo I inhibitor with an IC50 of 0.145 μM against CDK2/CycA2. ZLHQ-5f arrests the cell cycle in S-phase, triggers apoptosis in HCT116 cells, and has a good safety profile.
  • HY-I0096S
    Indole-2-carboxylic acid-13C

    		Endogenous Metabolite iGluR Neurological Disease
    Indole-2-carboxylic acid- 13C is the 13C-labeled Indole-2-carboxylic acid. Indole-2-carboxylic acid is a strong inhibitor of lipid peroxidation. Indole-2-carboxylic acid (I2CA) specifically and competitively inhibits the potentiation by glycine of NMDA-gated current[1][2].
  • HY-12598A
    DHPG

    (RS)-3,5-DHPG

    		 mGluR Neurological Disease
    DHPG ((RS)-3,5-DHPG) is an amino acid, which acts as a selective and potent agonist of group I mGluR (mGluR 1 and mGluR 5), shows no effect on Group II or Group III mGluRs. DHPG ((RS)-3,5-DHPG) is also an effective antagonist of mGluRs linked to phospholipase D.
  • HY-B1451
    Imidapril hydrochloride

    TA-6366

    		 Angiotensin-converting Enzyme (ACE) MMP Metabolic Disease Cardiovascular Disease
    Imidapril hydrochloride (TA-6366) is an orally active angiotensin-converting enzyme (ACE) and MMP-9 inhibitor. Imidapril hydrochloride suppresses the conversion of angiotensin I to angiotensin II and thereby reduces total peripheral resistance and systemic blood pressure. Imidapril hydrochloride can be used for hypertension, type 1 diabetic, nephropathy and chronic heart failure research.
  • HY-100446
    NTU281

    		Glutaminase Apoptosis Metabolic Disease Inflammation/Immunology
    NTU281 is a potent transglutaminase-2 inhibitor. NTU281 can reduce the increases in serum creatinine and albuminuria in diabetic rats. NTU281 can also reduce glomerular collagen I accumulation, Hic-5 and α-SMA expression, and apoptosis. NTU281 can be used for researching glomerulosclerosis caused by diabetes.
  • HY-115739
    RTIL 13

    		Ras Cancer Neurological Disease
    RTIL 13 is a potent inhibitor of dynamin GTPase, with an IC50 of 2.3 µM for dynamin I GTPase. RTIL 13 also targets pleckstrin homology lipid binding domain. RTIL 13 can inhibit receptor-mediated and synaptic vesicle endocytosis, with IC50s of 9.3 μM and 7.1 μM, respectively.
  • HY-101037S1
    Sarcosine-d3

    N-Methylglycine-d3; Sarcosin-d3

    		 Endogenous Metabolite GlyT Cancer
    Sarcosine-d3 is the deuterium labeled Sarcosine. Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia[1][2].
  • HY-108355
    R59949

    		PKC Cancer
    R59949 is a pan diacylglycerol kinase (DGK) inhibitor with an IC50 of 300 nM. R59949 strongly inhibits the activity of type I DGK α and γ and moderately attenuates the activity of type II DGK θ and κ. R59949 activates protein kinase C (PKC) by enhancing the levels of the endogenous ligand diacyl glycerol.
  • HY-143274
    DENV-IN-5

    		HIV DNA/RNA Synthesis Infection
    DENV-IN-5 (Compound 4b) is a dengue virus (DENV) inhibitor with EC50s of 1.47, 9.23, 7.08 and 8.91 μM against DENV-I ∼ IV replication, respectively. DENV-IN-5 also inhibits HIV-1IIIB strain with an EC50 of 0.1512 μM.
  • HY-50101
    Mavorixafor

    AMD-070

    		 CXCR HIV Infection Endocrinology Cancer
    Mavorixafor (AMD-070) is a potent, selective and orally available CXCR4 antagonist, with an IC50 value of 13 nM against CXCR4 125I-SDF binding, and also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC50 of 1 and 9 nM, respectively.
  • HY-136170
    MC-SN38

    		Drug-Linker Conjugates for ADC Cancer
    MC-SN38 is a agent-linker conjugate composed of a potent microtubule-disrupting agent SN38 and a non-cleavable MC linker to make antibody agent conjugate (ADC). SN-38, an active metabolite of the Topoisomerase I inhibitor Irinotecan, inhibits DNA synthesis and causes frequent DNA single-strand breaks.
  • HY-118530
    Bucillamine

    SA96; Thiobutarit

    		 VEGFR Inflammation/Immunology Cardiovascular Disease
    Bucillamine (SA96) is an orally active and potent sulfhydryl donor and antioxidant. Bucillamine is also an antirheumatic agent with antiangiogenic properties. Bucillamine can protect against Ischemia/reperfusion (I/R) injury in high-risk organ transplants. Bucillamine inhibits the production of VEGF. Bucillamine can be used for the research of choroidal neovascularization (CNV) and rheumatoid arthritis (RA).
  • HY-145818
    JPS035

    		HDAC PROTACs Cancer
    JPS035 is a benzamide-based Von Hippel-Lindau (VHL) E3-ligase proteolysis targeting chimeras (PROTAC). JPS035 degrades class I histone deacetylase (HDAC). JPS035 is potent HDAC1/2 degrader correlated with greater total differentially expressed genes and enhanced apoptosis in HCT116 cells.
  • HY-120994B
    Sp-8-CPT-cAMPS

    		PKA Inflammation/Immunology Neurological Disease
    Sp-8-CPT-cAMPS, a cAMP analog, is a potent and selective activator of the cAMP-dependent protein kinas A (PKA I and PKA II). Sp-8-CPT-cAMPS selects site A of RI compares to site A of RII by 153-fold and site B of RII compares to site B of RI by 59-fold.
  • HY-145816
    JPS016

    		HDAC PROTACs Cancer
    JPS016 is a benzamide-based Von Hippel-Lindau (VHL) E3-ligase proteolysis targeting chimeras (PROTAC). JPS016 degrades class I histone deacetylase (HDAC). JPS016 is potent HDAC1/2 degrader correlated with greater total differentially expressed genes and enhanced apoptosis in HCT116 cells.
  • HY-101985
    BV02

    		Bcr-Abl Cancer
    BV02 is a potent 4-3-3 PPI (14-3-3 protein–protein interaction) inhibitor. BV02 shows cytotoxicity for hematopoietic cells expressing the IM (imatinib mesylate)-sensitive wild type Bcr-Abl and the IM-resistant T315I mutation. BV02 has the potential for the research of chronic myeloid leukemia.
  • HY-145819
    JPS036

    		HDAC PROTACs Cancer
    JPS036 is a benzamide-based Von Hippel-Lindau (VHL) E3-ligase proteolysis targeting chimeras (PROTAC). JPS036 degrades class I histone deacetylase (HDAC). JPS036 is potent HDAC1/2 degrader correlated with greater total differentially expressed genes and enhanced apoptosis in HCT116 cells.
  • HY-101333
    CPPG

    (RS)-CPPG

    		 mGluR Neurological Disease
    CPPG ((RS)-CPPG) is a potent group II/III mGlu receptors antagonist. CPPG exhibits some selectivity (approximately 20 fold) for group III (IC50=2.2 nM) over group II (IC50=46.2 nM) mGlu receptors in the rat cerebral cortex. CPPG has weak effects at group I mGlu receptors.
  • HY-13704S1
    SN-38-d5

    NK012-d5

    		 Topoisomerase ADC Cytotoxin Autophagy Cancer
    SN-38-d5 is deuterium labeled SN-38. SN-38 (NK012) is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 (NK012) inhibits DNA and RNA synthesis with IC50s of 0.077 and 1.3 μM, respectively[1][2][3][4].
  • HY-109068A
    Parsaclisib hydrochloride

    INCB050465 hydrochloride; IBI-376 hydrochloride

    		 PI3K Cancer
    Parsaclisib hydrochloride (INCB050465 hydrochloride) is a potent, selective and orally active inhibitor of PI3Kδ, with an IC50 of 1 nM at 1 mM ATP. Parsaclisib hydrochloride shows approximately 20000-fold selectivity over other PI3K class I isoforms. Parsaclisib hydrochloride can be used for the research of relapsed or refractory B-cell malignancies.
  • HY-128943
    MAC glucuronide phenol-linked SN-38

    		Drug-Linker Conjugates for ADC Cancer
    MAC glucuronide phenol-linked SN-38 is a pH-susceptible lactone MAC glucuronide phenol-linked SN-38 (DNA topoisomerase I inhibitor) agent linker. MAC glucuronide phenol-linked SN-38 is cytotoxic across L540cy cells and Ramos cells with IC50 values of 113 and 67 ng/mL, respectively.
  • HY-15142
    Doxorubicin hydrochloride

    Hydroxydaunorubicin hydrochloride; Hydroxydaunorubicin Hydrochloride

    		 Topoisomerase ADC Cytotoxin AMPK Autophagy Apoptosis HIV HBV Mitophagy Antibiotic Bacterial Cancer Infection
    Doxorubicin (Hydroxydaunorubicin) hydrochloride, a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin hydrochloride is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC50s of 0.8 μM and 2.67 μM, respectively. Doxorubicin hydrochloride reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin hydrochloride induces apoptosis and autophagy.
  • HY-143321
    STING agonist-13

    		STING Cancer
    STING agonist-13 is a stimulator of interferon genes (STING) agonist, for cancer immunity via STING-mediated immune activation. STING agonist-13 can stimulate STING downstream signaling and promoting type I interferon immune responses. STING agonist-13 significantly decreases tumor volume and shows immunological memory-derived cancer inhibition.
  • HY-109068
    Parsaclisib

    INCB050465; IBI-376

    		 PI3K Cancer
    Parsaclisib (INCB050465) is a potent, selective and orally active inhibitor of PI3Kδ, with an IC50 of 1 nM at 1 mM ATP. Parsaclisib shows approximately 20000-fold selectivity over other PI3K class I isoforms. Parsaclisib can be used for the research of relapsed or refractory B-cell malignancies.
  • HY-12164
    Mocetinostat

    MGCD0103

    		 HDAC Autophagy Apoptosis Cancer
    Mocetinostat (MGCD0103) is a potent, orally active and isotype-selective HDAC (Class I/IV) inhibitor with IC50s of 0.15, 0.29, 1.66 and 0.59 μM for HDAC1, HDAC2, HDAC3 and HDAC11, respectively. Mocetinostat shows no inhibition on HDAC4, HDAC5, HDAC6, HDAC7, or HDAC8.
  • HY-14852A
    Tafamidis meglumine

    Fx-1006A

    		 Transthyretin (TTR) Neurological Disease
    Tafamidis meglumine (Fx-1006A) is a potent and selective transthyretin (TTR) stabilizer, shows comparable potency and efficacy to the mutumant homotetramers V30M-TTR, V122I-TTR and wild type WT-TTR, with EC50s of 2.7-3.2 μM. Tafamidis meglumine inhibits amyloidogenesis.
  • HY-106961
    ONO 1301

    ONO-AP 500-02

    		 Pros